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SYNOPSIS 
 
Phenomenal rise in prevalence of obesity and its complications has made it 
imperative to tackle the issue on a war footing, especially given the failure of current 
life style and medical approaches. Clearly, alternate means of treating obesity need 
to be explored. In contrast to white adipose tissue (WAT), which stores excess 
energy, brown adipose tissue (BAT) dissipates chemical energy in the form of heat 
by uncoupling oxidative phosphorylation from electron transport chain, to maintain 
body temperature homeostasis. Recent revelation of functionality of BAT in adult 
humans provides an excellent opportunity of stimulating it to increase energy 
expenditure, in turn causing weight loss alongside improving lipid and glucose 
homeostasis. This thesis sought to investigate the physiological nature of brown fat, 
by exploring the environmental, biophysical and behavioural factors that can activate 
BAT.  
 
18Fluoro-labelled-2-deoxyglucose Positron Emission Tomography (18F-FDG PET) is 
currently the gold standard and the most sensitive method to study BAT and its 
function. These studies concluded that younger-age, lower body mass index, female 
sex and cooler outdoor temperatures are strong determinant factors of BAT 
prevalence, activity and mass. Interestingly, modest elevation of thyroid hormones in 
a sustained iatrogenically created thyrotoxic state did not influence any of the BAT 
indices, contrary to conventional wisdom of strong stimulation, thus highlighting the 
complexity of BAT metabolism. Arguably, BAT has a role in diet-induced 
thermogenesis. Manipulation of diet-induced thermogenesis by prolonging meal 
duration to 40 minutes resulted in excess postprandial energy expenditure loss than 
shorter meal duration of 10 minutes. However, prolonged meal duration had weakly 
! XXIII!
positive effect on metabolic biochemical markers and no influence on pancreatic and 
gut hormones relevant to appetite. These studies advocate life style and behavioural 
public health messages of lowering thermostat in living spaces and chewing the food 
adequately in order to obtain potential metabolic benefits. As a follow-up of 
exploring BAT’s physiology, a successful attempt at characterising BAT’s anatomy 
was made through novel imaging technique of Iterative Decomposition of Echo 
Asymmetry and Least Squares Estimation (IDEAL) Magnetic Resonance Imaging. 
The first ever non-PET imaging demonstration of adult human BAT using IDEAL 
MRI was achieved with immunohistochemical confirmation, and provided proof of 
concept for developing MR as a safe, non-radiation exposure imaging biomarker of 
BAT.  
 
In summary, this thesis provided useful insights into environmental, 
anthropometrical, behavioural, and hormonal factors regulating BAT, whilst also 
providing a proof of principle of an imaging tool to visualise full extent of both 
metabolically active and inactive BAT, aiding future pursuits of BAT therapeutics to 
combat the global obesity epidemic. 
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1.1 Obesity 
 
1.1.1 Epidemiology of Obesity 
 
According to the World Health Organization (WHO) report, worldwide obesity rates 
have more than doubled since 1980. Global figures from 2008 showed that 1.46 
billion adults were overweight and that obesity affected 200 million men and 300 
million women, with the numbers expected to rise exponentially (World Health 
Organization, Obesity and overweight, Fact sheet No 311 Updated March 20131). As 
per the New International Association for the Study of Obesity/International Obesity 
Taskforce analysis (IASO/IOTF) 2010, it is estimated that approximately 1 billion 
overweight adults (Body Mass Index [BMI] 25-29.9 kg/m²), and a further 475 
million adults are obese  (BMI 30 kg/m2 or over). With an Asian-specific definition 
of obesity (BMI >28 kg/m2), global obesity prevalence in adults is estimated at >600 
million (International Association for the Study of Obesity/ International Obesity 
Taskforce analysis 20102). The prevalence of clinical obesity in United Kingdom is 
highest in Europe and is expected to rise to more than 1 in every 2 adults by 2050 
(Foresight 20073). Almost a quarter of adults (24% of men and 25% of women aged 
16 or over) in England are classified as obese, and the prevalence increased from 
14.9% to 24.9% between 1993 and 2013 (Health Survey England 20104, National 
Obesity Observatory 20135).  
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1.1.2    Complications of Obesity 
 
Obesity is associated with increased risk of number of chronic conditions including 
type 2 diabetes mellitus (T2DM), coronary heart disease, heart failure, stroke, 
hypertension, dyslipidaemia, reproductive and gastrointestinal cancers, fatty liver 
disease, osteoarthritis and obstructive sleep apnoea (Padwal, R et al Cochrane review 
20046), resulting in overall increase of mortality rates (Calle et al 19997). Sims and 
colleagues in 1970’s aptly coined the term ‘diabesity’ as around 90% of T2DM 
patients have a BMI of more than 23 kg/m2 and the risk increases further with family 
history of diabetes, gestational diabetes and early weight gain especially in 
childhood (Wannamethee, S, G et al8). The number one cause of mortality remains 
cardiovascular disease (CVD), and obesity is a key factor in increased rates of CVD 
associated morbidity and mortality (Flegal et al 20079, Kenchaiah et al 200210). 
Obesity is a significant determinant for increased rates of cancer (Guh et al 200911, 
Basen-Engquist et al 201112), obstructive sleep apnoea, asthma, gall bladder disease 
and osteoarthritis (Anandam et al 201313, Gami et al 200314, Guh et al 200911). It is 
also associated with significant psychological morbidity, including depression 
(Hryhorczuk et al 201315). 
 
1.1.3     Economic Burden of Obesity 
 
The medical costs of obesity represent the monetary value of health-care resources 
devoted to managing obesity-related disorders, including the costs incurred by 
excess use of ambulatory care, hospitalization, drugs, radiological or laboratory tests, 
and long-term care including that of nursing homes (Wang et al 201116). A 
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systematic review of worldwide economic burden of direct health-care costs of 
obesity reveals that it accounts for 0.7–2.8% of a country’s total health-care costs, 
and that obese individuals had 30% higher medical costs than those with normal 
weight (Withrow et al 201117). Compared with normal-weight individuals, obese 
patients incur 46% increased inpatient costs, 27% more physician visits and 
outpatient costs, and 80% increased spending on prescription drugs (Finkelstein et al 
200918). Loss of productivity accounting for the indirect costs, further adds to this 
financial burden. The direct cost of treating overweight and obesity in England has 
risen from £479.3 million to £4.2 billion in 2007, and estimates of indirect costs 
ranges from £2.6 to £15.8 billion (Economic Burden of Obesity, National Obesity 
Observatory, October 20104, Foresight 20073). It is expected to rise to £9.7 billion in 
direct costs, and £49.9 billion in indirect costs (Foresight 20073). 
 
1.1.4     Measurement of Obesity 
 
There are various ways in which to measure different aspects of obesity. They 
include BMI, skin fold thickness, waist circumference, waist-to-hip ratio, bio-
impedance and radiological methods. The most widely used method of measuring 
obesity is BMI due to the ease of measurement; established cut-offs and existing 
published statistics. BMI is calculated as weight in kilograms divided by height in 
metres squared (BMI= weight [kg]/ height [m2]). WHO classification of weight 
categories based on BMI is shown in Table 1.1.4. BMI is a good predictor of health 
risk, such as CVD mortality, in white Caucasian populations - as described in two 
separate meta-analyses (Whitlock et al, Prospective Studies Collaboration 200919, 
Berrington de Gonzalez et al 201019-21). Both these studies demonstrated an overall 
! 5!
increased mortality risk in both overweight and obese populations, with an estimated 
loss of 2-4 years of life for BMI 30-35 kg/m2, and 8-10 years for BMI 40-45 kg/m2 
compared to an optimum BMI of 22.5-25 kg/m2. However, BMI is only a proxy 
indicator of body fatness; factors such as fitness (muscle mass), ethnic origin and 
puberty can alter the relationship between BMI and body fatness whilst also 
underestimating mortality risk (WHO Expert Consultation 200422). Abdominal or 
centripetal obesity is shown to be a better predictor of health risk than BMI alone 
(National Obesity Observatory23, Pischon et al 200824, Koster et al 200825). Waist 
circumference or waist-to-hip ratio is shown to be more strongly associated with the 
risk of myocardial infarction than BMI (Yusuf S et al 200526), and also seem to be 
better predictors of risk of insulin resistance and future risk of T2DM than BMI 
alone (Langenberg et al 201227). 
 
Bioelectrical impedance measures body fat percentage, by recording the impedance 
or opposition to the flow of a very small electric current as it passes through the 
body. As lean mass is made up of 73% water and fat has no water content, this 
method estimates lean tissue mass (which acts as a conductor) and fat mass (which 
acts as an insulator), through changes in voltage (Pietilainen et al 201328). More 
accurate measurement of body fat percentage is by underwater weighing and air 
displacement plethysmography, but inherits practical limitations for general 
population assessment (Ginde et al 200529, Koda et al 200030).  
                                                         
Radiological methods such as Computed Tomography (CT), Dual Energy X-ray 
Absorption (DEXA) or Magnetic Resonance Imaging (MRI) assess adiposity and 
obesity more accurately, but are expensive and cumbersome, and therefore used for 
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research purposes only (Seidell et al 198831, Kaul et al 201232, Pietilainen et al 
201328). 
 
Table 1.1.4 Classification of Weight Categories Based on BMI  
 
 White Europeans Asians 
Classification BMI (Kg/m2) BMI (Kg/m2) 
Normal weight 18.5-24.9 
18.5-22.9 
23-24.9 
Pre-obese 25-29.9 
25-27.4 
27.5-29.9 
Class I Obesity 30-34.9 
30.0-32.4 
32.5-34.9 
Class II Obesity 35-39.9 
35.0-37.4 
37.5-39.9 
Class III Obesity >40.0 >40.0 
 
For Asian populations, classifications remain the same as the international 
classification, but the public action points are set at 23, 27.5, 32.5 and 37.5 kg/m2 for 
intervention purposes33. Source: International Diabetes Federation (IDF) position 
statement on bariatric surgery 201134, as adapted from World Health Organization 
(WHO) 200435. 
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1.1.5     Management of Obesity 
 
The multi-pronged management approach of obesity includes lifestyle changes, 
pharmacological interventions, and in extreme obesity, surgical approaches are 
warranted. The management of obesity through changes to lifestyle is notoriously 
difficult and the resulting effects on weight are variable and often transient. Weight 
regain following weight loss is common and results from a number of mechanisms 
that redress any loss of energy storage capacity (Geldszus et al 199636, Cummings et 
al 200237, Chearskul et al 200838). Current therapeutic options for obesity 
management are very limited following the recent withdrawal of sibutramine and 
rimonabant amid safety concerns. Orlistat, which is the only licensed medication in 
UK, faces problems relating to the supply, unacceptable side-effect profile and long-
term efficacy (Padwal et al 20046). Bariatric surgery is the only effective treatment 
modality that appears to have sustained weight loss maintenance, but is reserved for 
selected population with morbid obesity, and does not represent a practical solution 
to the global obesity epidemic (Buchwald et al 200439, Sjöström et al40, Pontiroli et 
al 201141, O’Brien et al 201342). Given the limitations of current therapeutic 
approaches to obesity, and the current global obesity epidemic and escalating 
incidence of obesity-related deaths, it is imperative to identify novel and effective 
therapeutic options. Adipose tissue, a multifarious endocrine organ with multiple 
signalling capabilities to both central and peripheral systems, is currently targeted for 
research-based solutions for the obesity epidemic. 
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1.2 Insulin Resistance 
 
1.2.1 Physiology of Insulin Resistance 
 
Insulin is produced by β beta cells of pancreas in response to increased circulating 
levels of glucose and amino acids after a meal. The major sites of action of insulin 
are liver, skeletal muscle and adipose tissue. In liver, insulin increases glycogen 
synthesis, inhibits gluconeogenesis and promotes de novo lipogenesis. In skeletal 
muscle, insulin promotes glucose uptake and glycogen synthesis. In adipose tissue, it 
promotes lipogenesis and inhibits lipolysis. The opposite happens in the fasted state 
when insulin level is reduced.  Insulin resistance is a state of subnormal response of 
target tissues to normal concentrations of insulin hormone. The pathophysiology of 
insulin resistance is depicted in Figure 1.2.1 (Eckel et al 200543). Abundant free fatty 
acids (FFA) released from expanded adipose tissue mass, acts on liver to cause 
increased production of glucose, triglycerides and secretion of Very Low Density 
Lipoprotein (VLDL). This results in low High Density Lipoprotein (HDL) and high 
Low Density Lipoprotein (LDL). FFA also reduce insulin sensitivity in muscle by 
inhibiting insulin mediated glucose uptake, reduced glycogen synthesis and 
increased triglyceride accumulation (Eckel et al 200543). Increase in glucose and 
increase in FFA stimulates excess insulin secretion from pancreas causing 
hyperinsulinaemia, which in turn simultaneously contributes to hypertension from 
sodium reabsorption and increase sympathetic nervous system activity caused by 
hyperinsulinaemia. Increased lipogenesis action of hyperinsulinaemia causes fat 
deposition in liver resulting in Non-Alcoholic Fatty Liver Disease (NAFLD), where 
as poor glucose uptake over long duration causes β-cell fatigue, resulting in Impaired 
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fasting Glycaemia (IFG), Impaired Glucose Tolerance (IGT) and T2DM (Stumvoll 
et al 200544). Autocrine and paracrine effect of proinflammatory cytokines, such as 
Tumour Necrosis Factor- α (TNF-α) and Interleukin- 6 may enhance hepatic glucose 
production, hepatic VLDL production and skeletal muscle insulin resistance. 
Increased circulating adipocytokines and FFA may also contribute to prothrombotic 
state as shown in the Figure 1.2.1.  
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Figure 1.2.1 Pathophysiology of insulin resistance (Eckel et al 200543) 
Abbreviations- HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, 
VLDL: Very Low Density Lipoprotein, FFA: Free Fatty Acids, PAI-1: Plasminogen 
Activator Inhibitor-1, TNF-α: Tumour Necrosis Factor- α 
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1.2.2      Measures of Insulin Resistance 
 
Although there are various methods to measure insulin resistance, there are no 
validated methods currently to undertake in a clinical setting for widespread usage. 
Hyperinsulinaemic euglycaemic clamp is a type of dynamic test, considered as the 
gold-standard for measurement of insulin resistance (DeFronzo et al 197945, Borai et 
al 201146). Other dynamic tests include Intravenous Glucose Tolerance Test 
(IVGTT) and Insulin Tolerance Test (ITT) (Buchanan et al 201047, Bergman et al 
198548). Insulin sensitivity index (ISI), homeostasis model assessment insulin 
resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) 
(Matthews et al 198549, Katz et al 200050, Wallace et al 200451) are few of the most 
commonly used indices. Although HOMA-IR and QUICKI are well-validated 
simple and practical fasting blood test assessments, which can be used in large 
population studies in clinical settings, they are considered a reflection of hepatic 
insulin resistance than peripheral insulin resistance (Hoffman et al 200852). Also, 
they are not well validated in conditions where insulin reserve is reduced, such as in 
patients with uncontrolled T2DM or Type 1 Diabetes Mellitus (T1DM). Serum 
insulin levels, intact and total pro-insulin levels are also used a surrogate markers of 
insulin resistance, but are not well validated  (Pfützner et al 200853). Matsuda index 
is another index derived from Oral Glucose Tolerance Test (OGTT) (Matsuda et al 
199954) which is found to correlate well with euglycaemic clamp, especially in south 
Asian population (Trikudanathan et al 201355).  
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1.2.3      Risk factors for Insulin Resistance 
 
Insulin resistance, which is the main cause of metabolic syndrome co-exists with 
obesity or may be a significant aetiological factor for obesity. Diet and life style 
along with genetic predisposition are established causes of obesity and insulin 
resistance. Family history of T2DM and presence of Polycystic Ovarian Syndrome 
(PCOS) can increase the risk of developing insulin resistance. Insulin resistance may 
be physiological as noted in puberty, pregnancy and ageing population (DeFronzo et 
al 1979, Buchanan et al 1990, Moran et al 199956-60). Incidence of insulin resistance 
is high in South Asians, Hispanics and Afro-Carribbean ethnic groups (Farooqi et al 
199461, Kramer et al 201362). Extreme form of insulin resistance is found in inherited 
disorders like leptin receptor defects, SH2B1 and LAMIN-A mutations leading to 
lipodystrophic states (Patricia et al 201263, Duan et al 200464, Farooqi et al 199965). 
 
Certain medications, such as corticosteroids, anti-retro viral drugs used in treatment 
of Human Immunodeficiency Virus (HIV) have shown to cause insulin resistance as 
a side effect (Yasuda et al 198266, Tebas et al 200867). 
 
1.2.4     Metabolic Syndrome 
 
The metabolic syndrome is also known as Syndrome X (Reaven et al 198868), the 
insulin resistance syndrome (DeFronzo et al 199169), and the deadly quartet (Kaplan 
et al 198970). The constellation of metabolic abnormalities includes glucose 
intolerance (T2DM, impaired glucose tolerance, impaired fasting glycaemia), insulin 
resistance, central obesity, dyslipidaemia, and hypertension, all well recognized risk 
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factors for CVD (Eckel et al 200543). The central component is obesity which is 
included as the main parameter in majority of accepted definitions of metabolic 
syndrome: WHO (Alberti et al 199871), European Group for the Study of Insulin 
Resistance (Balkau et al 199972), National Cholesterol Education Program’s Adult 
Treatment Panel III  (NCEP: ATP III) (JAMA 200173) and International Diabetes 
Federation  (IDF) (Alberti et al 200574). The most currently accepted and clinically 
easy to use definition is that of IDF’s which is shown in Table 1.2.4. 
 
Insulin resistance remains to be the vital factor leading to insulin resistant states such 
as T2DM and Gestational Diabetes Mellitus (GDM). More than 90% of diabetes 
patients are of T2DM variety and are at increased risk of macro-vascular (Stroke, 
CVD, Peripheral Vascular Disease) and micro-vascular complications (Retinopathy, 
Nephropathy, Peripheral neuropathy, and Autonomic neuropathy) (Turner et al 
199875, UKPDS 199876).  
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Table 1.2.4.1 International Diabetes Federation (IDF) Criteria for Diagnosis of 
Metabolic Syndrome 
1. Central obesity (waist circumference of ≥94 cm for European men and ≥80 cm 
for European women, with ethnicity specific values for other groups) 
In addition to any two of the following four factors 
2. Raised triglyceride level (TG): (≥150 mg/dL or 1.7 mmol/L) 
Or specific treatment for this lipid abnormality 
3. Reduced high density lipoprotein (HDL): (<40 mg/dL or 1.03 mmol/L in 
males) and (<50 mg/dL or 1.29 mmol/L in females) 
Or specific treatment for this lipid abnormality 
4. Raised blood pressure: (systolic BP ≥130 or diastolic BP ≥85 mm Hg 
Or treatment of previously diagnosed hypertension 
5. Raised fasting plasma glucose, FPG: (≥100 mg/dL or 5.6 mmol/L 
Or previously diagnosed type 2 diabetes 
 
Table 1.2.4.2 Ethnic specific values for waist circumference 
Country/Ethnic group Sex Waist circumference 
 
Europeans 
In USA, the ATPIII values (102 cm 
♂;88 cm ♀) are to continue 
Male ≥94 
Female ≥80 
 
South Asians 
Based on the Chinese, Malay and 
Asian-Indian population  
Male ≥90 
Female ≥80 
 
Chinese 
Male ≥90 
Female ≥80 
 
Japanese 
Male ≥90 
Female ≥80 
 
Ethnic South and Central 
Americans 
 
Use South Asian recommendations until 
more specific data are available 
 
Sub-Saharan Africans 
 
Use European data until more specific data 
are available 
 
Eastern Mediterranean and Middle 
East (Arab) populations 
 
Use European data until more specific data 
are available 
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1.2.5     Insulin Resistant States 
 
T2DM is an insulin resistant state in the presence of relative insulin deficiency 
resulting in hyperglycaemia. More than 90% of diabetes patients are of T2DM 
variety and are at increased risk of macro-vascular (Stroke, CVD, Peripheral 
Vascular Disease) and micro-vascular complications (Retinopathy, Nephropathy, 
Peripheral neuropathy, and Autonomic neuropathy), the risks of which can be 
substantially reduced on optimal glycaemic management (Turner et al 199875, 
UKPDS 199876).       
 
GDM is defined as glucose intolerance noted during pregnancy and the aetiology is 
not similar to that of T2DM (American Diabetes Association 200477). It is generally 
accepted that glucose lowering, in combination with life style changes has better 
pregnancy outcomes (Crowther et al 200578 Metzger et al 200879, Rowan et al 
200880, Lautatzis et al 201381). 
 
PCOS is another insulin resistant metabolic disorder comprising menstrual 
irregularities, hyperandrogenism and multiple cysts in ovaries. On satisfying any 2 of 
the 3 following components of Rotterdam 2003 criteria, remains the most acceptable 
diagnosis of PCOS: oligo- or anovulation, clinical or biochemical signs of 
hyperandrogenism, and sonographic visualisation of multiple cysts in ovaries 
(Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group 200482). 
Approximately 40 to 85% of PCOS women are overweight or obese compared to age 
matched controls and carry increased CV risk (Randeva et al 201283).   
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1.3      Dietary Patterns and Obesity 
  
To mitigate the adverse impact of obesity on global health and health-care 
economies, a multi-faceted approach is required. Such an approach should 
incorporate the development of novel pharmacological strategies, re-design of our 
living spaces for enhanced energy expenditure, governmental approaches to improve 
our diet and obesogenic environment and cultural and lifestyle changes. Diet is a 
major determinant of fat mass, and an obvious target for the prevention and 
management of obesity (Forget et al 201384). It is well known that dietary behaviour 
patterns is closely linked with obesity/insulin resistance, in turn results in increased 
CV risk. The evidence for effects of meal quality, meal size, meal frequency and 
meal duration over obesity and human metabolism is discussed below. 
 
Meal quality, particularly constituting high fat diet results in dyslipidaemic profile: 
elevated serum cholesterol, elevated LDL, elevated triglycerides (TG), HDL 
resulting in increasing CV risk, reversing the same substantially reduces the risk (4S-
Study Group 199485, LIPID-Study-Group 199886). Dietary cholesterol, trans fatty 
acids and saturated fatty acids increase atherogenic lipoproteins and are 
recommended to reduce intake to lower CV risk (Kris-Etherton et al 200187). The 
UK dietary reference value for total recommended fat intake is less than 35% of total 
energy required (Dietary reference values for energy, Scientific Advisory Committee 
of Nutrition 201188). It is shown that nutritional factors inherent to fast food, such as 
low levels of dietary fibre, high palatability, high energy density, high fat content, 
high glycaemic load, and high content of sugar in liquid form promote excess energy 
intake (Ebbeling et al 200789). 
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Meal quantity in excess over prolonged period, even in recommended proportions, is 
fundamental to weight gain and the development of obesity (Mayer et al 196790). 
However methodological constraints may appear in proving this concept due to 
under-reporting of dietary exposures (Rennie et al 200591). In a series of studies, it is 
shown that larger meal size increases energy intake and aids more deposition of fat 
(Kral et al 200492, Rolls et al 199893, Rolls et al 200094). 
 
Meal frequency is linked with weight and metabolic diseases, as suggested by Fabry 
et al in 1960’s. The authors inferred that men eating 3 or fewer meals per day were 
heavier, had higher incidence of hypercholesterolaemia and glucose intolerance, 
compared to men eating 5 or more meals a day (Fabry et al 1964). Contrarily, rodent 
studies (Anson et al 200395, Mattson et al 200596) and human studies (Harvie et al 
201197, Harvie et al 201398) have shown intermittent fasting with fewer meal 
frequency have beneficial metabolic profile and lesser weight gain. So evidence for 
higher or lower meal frequency is conflicting (Summerbell et al 199699, Crawley et 
al 1997100, Dreon et al 1998101, Cameron et al 2010102, La Bounty et al 2011103). 
However, erratic meal patterns are shown to be detrimental than regular meal pattern 
(6 meals per day), in healthy lean and obese women (Farshchi et al 2004104, Farshchi 
et al 2005105).  
 
Meal duration and its effect on weight, appetite, food ingestion and metabolism 
remain to be fully clarified. Faster eating rate is shown to increase energy intake, 
(Andrade et al 2008106, Martin et al 2007107, Zandian et al 2009108) lower satiating 
efficiency index, and is associated with increased BMI (Hill et al 1984109, Otsuka et 
al 2006110, Maruyama et al 2008111). Subsequent study did not back up the same 
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finding, as longer meal duration did not alter the energy intake in lone diners 
(Brindal et al 2011112). Appetite is mediated by a variety of neural and endocrine 
signals including several pancreatic and gut hormones such as insulin, Glucagon-like 
peptide-1 (GLP-1), peptide-YY (PYY), pancreatic polypeptide (PP) and ghrelin 
(Cummings et al 2007113). The effect of meal duration/eating rate on energy intake 
and on the pancreatic and gut hormones that influence energy intake and appetite are 
undetermined. The role of brown adipose tissue on diet-activated energy expenditure 
is discussed in section 1.7.2. There is a need for well-designed studies to assess gut 
hormone responses to meal duration, in conjunction with energy expenditure 
assessment to evaluate any beneficial metabolic effects. 
 
1.4       Adipose Tissue 
 
1.4.1   Adipose Tissue: A cause of Insulin Resistance 
 
An unwanted by product of contemporary human behaviour related to eating and 
physical activity is excess adipose tissue accumulation in comparison to lean body 
mass (Guilherme et al 2008114). It is well established that lipid overload and 
lipotoxicity promotes obesity by perturbing insulin signalling pathways resulting in 
disturbed homeostasis of glucose, lipids and lipoprotein pathways (Unger et al 
1995115). Insulin resistance develops because of the effects of inflammatory and 
hormonal factors, endoplasmic reticulum (ER) stress, and accumulation of by-
products of nutritional ‘overload’ in insulin-sensing tissues (Muoio et al 2008116), 
such as in skeletal muscle as depicted in Figure 1.4.1. Adipose tissue, a crucial site 
of inflammation produces preferential anti-inflammatory adipocytokines in lean 
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individuals, such as Transformation Growth Factor-β (TGF β), Interleukin-10 (IL-
10), Interleukin-4 (IL-4), Interleukin-13 (IL-13), and Apelin; whilst producing pro-
inflammatory adipocytokines in obese individuals, such as tumour necrosis factor-α 
(TNFα), Interleukin-6 (IL-6), leptin, visfatin, resistin, angiotensin-II, Plasminogen 
Activator Inhibitor-1 (PAI-1), in addition to several interleukins (Ouchi et al 
2011117). Furthermore, the above adipocytokines directly modulate insulin resistance 
by affecting insulin signalling pathways, or indirectly, via stimulating inflammatory 
pathways. The inter-organ communication between liver, skeletal muscle adipose 
tissue and other insulin sensitive organs occur through combined effect of adipokines 
and inflammatory mediators. This results in insulin resistance via activation of I-
Kappa B Kinase catalytic subunit- β (IKKβ)/Nuclear Factor Kappa B (NFκB) and c-
Jun N-terminal Kinases (JNK) pathways (Harte et al 2013118, Pirola et al 2004119, 
Tilg et al 2008120, Kalupahana et al 2012121). 
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Figure 1.4.1 Guilherme et al 2008114 Nature reviews  
Chronic inflammation in adipose tissue triggers insulin resistance in skeletal muscle. 
a) In the lean state, small adipocytes efficiently store fatty acids as triglyceride (TG 
input, arrow), which can be mobilized and used to generate ATP through the 
mitochondrial β-oxidation pathway in muscle during periods of caloric need. Insulin-
stimulated glucose uptake under these conditions is normal. b) Excess caloric intake 
leads to metabolic overload, increased TG input and adipocyte enlargement. 
Nonetheless, in non-diabetic overweight individuals, TG storage by adipose cells 
and β-oxidation in muscle is maintained to prevent insulin resistance. c) On further 
overloading with TG, hypertrophy of adipocytes and increased secretion of 
macrophage chemoattractants occurs, including the secretion of monocyte 
chemoattractant protein-1 (MCP1; arrows), which recruits additional macrophages. 
d) Macrophage recruitment in turn results in a pro-inflammatory state in obese 
adipose tissue. Infiltrating macrophages secrete large amounts of TNFα, which 
results in a chronic inflammatory state with impaired TG deposition and increased 
lipolysis (arrow and plus signal). The excess of circulating TG and free fatty acids 
results in the accumulation of activated lipids in the muscle (yellow dots), disrupting 
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functions such as mitochondrial oxidative phosphorylation and insulin-stimulated 
glucose transport, thus triggering insulin resistance. 
 
1.4.2   Types of Adipose Tissue 
 
Although excess adipose tissue as observed in obesity, is a recognized site of 
inflammation and adipokine dysregulation, leading to chronic subclinical 
inflammation and in turn resulting in insulin resistance (Shoelson et al 2006122), the 
location of the tissue also determines the degree of inflammation.   
 
Central fat distribution (apple-shaped, android, abdominal) is considered more 
inflammatory and confers considerable metabolic risks, compared to peripheral fat 
distribution (pear-shaped, gynoid, gluteo-femoral), which may even be protective 
(Vega et al 2006123, Snijder et al 2005124, Fox et al 2007125, Azuma et al 2007126, 
Koster et al 200825, St-Pierre et al 2007127). Thus, better identification of 
abdominally obese subjects at risk of developing metabolic diseases is measurement 
of waist and hip circumferences and calculating waist-to-hip ratio (WHR). Waist 
circumferences greater than 94 cm in European men and 80 cm in European women, 
and WHR greater than 1.0 in men and 0.8 in women define those at increased risk 
(Alberti et al 2009128). Waist circumference cut-offs of respective ethnicities are 
illustrated in Table 1.2.4.2. 
 
Adipose tissue can also be grossly divided into subcutaneous adipose tissue and 
visceral adipose tissue based on the location. Subcutaneous deposits include 
abdomen, thigh, mammary and gluteo-femoral regions. Visceral depots are located 
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around internal organs, such as stomach (omental), intestine (mesenteric), peri-renal 
(kidney) and heart (epicardial). Computed tomography (CT) or Magnetic Resonance 
(MR) images taken at L2-3 and/or L4-5 to distinguish visceral and abdominal 
subcutaneous depots indicate strong negative effects of visceral fat mass that are 
independent of total body fat on metabolic risks (Despres and Lemieux, 2006129). 
Sex differences in metabolic risk can also partially attributed to the higher visceral 
fat mass in men compared to women (Despres and Lemieux, 2006129). Ethnic 
minority populations such as in South Asians have tendency of central obesity, 
which explains the higher CV risk than compared to Caucasians of similar BMI 
(WHO-Expert-Consultation 200422, Bellary et al 2008130). Abdominal subcutaneous 
adipose tissue appears to be more active than it was previously thought, secreting 
multiple pro-inflammatory adipocytokines. (Mcternan et al 2002131, McTernan et al 
2003132, Fischer et al 2002133, Harte et al 2003134).  
 
Another classification of adipose tissue based on the histology and function is: White 
Adipose Tissue (WAT) and Brown Adipose Tissue (BAT). WAT stores energy in 
the form of triglycerides and BAT expends energy due to presence of a specialised 
protein Uncoupling Protein-1 (UCP1), in its mitochondria, which uncouples 
respiration dissipating energy in the form of heat (Hull et al 1966135, Nicholls et al 
1984136, Feldman et al 2009137).  
 
Traditionally, it was thought that BAT was present only in infants. The advent of 
Positron Emission Tomography (PET), demonstrated metabolically active BAT in 
human adults as evident by physiological uptake of 18-Fluoro-labelled -2-deoxy-
glucose (18FDG) dye, as shown in Figure 1.4.2 (Hany et al 2002138, Nedergaard et al 
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2007139, Virtanen et al 2009140, Cypess et al 2009141, van Marken Lichtenbelt et al 
2009142, Saito et al 2009143,144, Zingaretti et al 2009144). This led to renewed interest 
in BAT, as it is currently considered as a potential anti-obesity therapeutic target due 
to its energy expending properties. 
 
         
 
Figure 1.4.2: Amount and activity of brown adipose tissue as shown in PET (left), 
CT (centre) and combined PET-CT (right). Cypess et al 2009141 
 
1.4.3       White, Brown and Beige Adipose Tissue  
 
There are two main types of adipose tissue: WAT and BAT that have evolved for 
completely different purposes: to survive famine and prevent hypothermia 
respectively. WAT and BAT, as energy storage and thermogenic tissues 
respectively, therefore evolved to protect mammalian organisms from important 
environmental threats including lack of food and exposure to cold climates 
(Enerback et al 2010145). Humans are therefore evolutionarily maladapted to our 
modern obesogenic and thermo-regulated environment, with abundance of food and 
adoption of sedentary lifestyles resulting in WAT excess. This is likely to be an 
important explanation for the current obesity epidemic.  
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In addition to WAT and BAT, a third intermediate-type of adipose tissue termed 
‘beige’ or ‘brite’ is identified (Wu et al 2012146), referred in text as Beige Adipose 
Tissue (BeAT). Adipocytes from BeAT depots resemble white adipocytes but 
possess the classical properties of brown adipocytes (Wu et al 2012146). The 
histological and morphological properties of each of the types of adipose tissue are 
further elaborated in section 1.5.2. 
 
1.5       Brown adipose tissue 
 
1.5.1    Evolution of Brown adipose tissue 
 
Konrad von Gesner first identified brown fat in 1551 in European marmots Muris 
alpines, but it was not until the 1960’s and 70’s that the importance of BAT as a 
thermoregulatory organ was appreciated (Prusiner et al 1968147, Cannon et al 
1978148, Cannon et al 2004149). BAT seen in human neonates and small mammals on 
several necropsy studies, was thought to be absent in human adults. Juliet Heaton in 
1972 demonstrated its presence in humans through autopsy studies of over 50 
corpses and concluded that BAT incidence is high in neonates and declines with age 
but can still be present even in the eighth decade Heaton et al 1972150,151). Later in 
1979, Rothwell & Stock alluded to its presence in humans through infrared 
thermography following ephedrine administration (although the increase in surface 
temperature may have resulted from the effect of ephedrine on cutaneous blood 
flow) (Rothwell et al 1979152). The timeline and summary of major developments in 
BAT research are depicted in Table 1.5.1 modified from Lee et al 2013153.  
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Table 1.5.1: Timeline of major developments in BAT research: Lee et al 2013153  
 
Year Authors Findings 
1902 Hatai et al154 Similarity between cervical fat of human neonate and 
interscapular BAT in hibernating mammals 
1908 Bonnot et al155 Detailed description of the interscapular gland in an 
adult human 
1922 Rasmussen et 
al156 
Morphological similarity between paediatric peri-renal 
and animal BAT 
1964 Silverman et al157 Maintenance of warm temperature in nape of infants 
during cold exposure, providing first evidence of BAT 
function in humans 
1965 Dawkins and 
Scopes et al158 
Demonstration of non-shivering thermogenesis in 
infants, indicating BAT as thermogenic organ 
1972 Heaton et al 150 Histological evidence that BAT is present in humans 
throughout adult life 
1983 Bouillaud et al159  Discovery of UCP1 in human BAT 
1984 Astrup et al160  No evidence in human that interscapular fat is 
thermogenic or functional 
2002 Hany et al161 FDG uptake in cervical/supraclavicular region of PET-
CT scan may be BAT 
2004 Garcia et al162  FDG uptake in BAT during PET-CT is influenced by 
ambient temperature 
2006 Chiba et al163 Inverse relationships between BAT activity and BMI, 
suggesting metabolic significance of BAT 
2009 Saito et al143 High incidence of metabolically active BAT in adult 
humans 
2009 Cypess et al141 Higher prevalence of BAT in women than men and 
during winter; inverse relationships between BAT 
activity, age, and BMI 
2009 Van Marken Lich 
-tenbelt et al142 
Quantification of BAT activation in adult humans 
during cold exposure 
2009 Virtanen et al140 Signature genes of FDG-avid BAT in human 
2011 Lee et al164 Universal presence of BAT from supraclavicular fat in 
humans regardless of PET imaging status 
2011 Lee et al165 Inducible brown adipogenesis of human supraclavicular 
BAT in vitro 
2012 Ouellet et al166 Contribution of BAT oxidative metabolism to energy 
expenditure 
2012 Wu et al146 and 
Sharp et al167 
Identification of beige adipocytes; evidence supporting 
developmental origin of human BAT from this lineage 
2013 Orava et al 168 Insulin-stimulated glucose uptake rate and cold-induced 
glucose uptake rate are attenuated in obese humans 
2013 Chen et al169 A slight decrease in ambient temperature (19 ºC) is 
sufficient to activate BAT with a significant energy 
consuming impact in healthy males and females 
2013 Van der Lans et 
al170 
A 10-day, 6-hour daily cold exposure at 15–16 °C 
increases BAT SUV and volume in healthy lean adults 
2014 Blondin et al171 A 4-week, 2-hour daily cold exposure at 10 °C results 
in 45% increase in BAT volume of activity and 2.2-fold 
increase in cold-induced BAT oxidative metabolism. 
 
PET- Positron Emission tomography; SUV- Standard uptake value 
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1.5.2    Anatomy of Brown adipose tissue 
 
The presence of BAT in human adults is now incontrovertible following recent 
radiological and histological confirmation of BAT depots in the axillary, 
paravertebral, supraclavicular and cervical regions (Nedergaard et al 2007139, Cypess 
et al 2009141, van Marken Lichtenbelt et al 2009142, Virtanen et al 2009140, Saito et al 
2009143, Zingaretti et al 2009144). Adult human BAT is composed of brown 
adipocytes with a matrix rich in blood vessels and nerves, in keeping with its 
primary function of supplying heat to the body in response to sympathetic nervous 
activity (Cinti et al 2000172). Although brown adipocytes contain enzymes required 
for synthesis and storage of triglycerides, lipids within brown adipocytes are usually 
stored in multiple (multilocular) small fat droplets, in contrast to white adipocytes 
that contain one large (unilocular) droplet of triglyceride (Cinti et al 2000172). Brown 
adipocytes are comparatively smaller (15-60µm in diameter) than white adipocytes 
(25-200µm) (Cinti et al 2000172). In contrast to white adipocytes which have few 
mitochondria, brown adipocytes contain abundant mitochondria that are crucial for 
heat generation (Napolitano et al173). Abundant mitochondria with iron as cofactor in 
their respiratory chain cytochrome enzymes, along with vasculature within BAT 
impart a dark red (brown) discolouration to the tissue and is therefore responsible for 
its name, compared to pale hue colour of WAT (Cinti et al 2000172). Adipocytes 
from beige adipose tissue (BeAT) depots resemble white adipocytes but possess the 
classical properties of brown adipocytes (Wu et al146). The characteristic features of 
WAT, BAT and BeAT are illustrated in Table 1.5.2, and histological differences 
between WAT and BAT are depicted in Figure 1.5.2. 
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Table 1.5.2: Morphological features of BAT, WAT and BeAT 
 
 WAT 
 
BAT BeAT 
Cell shape Variable, but 
classically 
spherical 
Polygonal Resembles 
WAT 
Cell size Variable, but large 
(25-200µm) 
Comparatively small 
(15-60µm) 
Variable 
Nucleus Peripheral, 
flattened 
Central, round or 
oval in shape 
Not studied 
Cytoplasm Thin, peripheral 
rim 
Large volume 
evenly distributed 
throughout 
Not studied 
Lipid content Single large 
droplet occupying 
90% cell volume 
Multiple small lipid 
droplets 
 
Not studied 
Mitochondria Few Abundant Intermediate 
Endoplasmic 
reticulum (ER) 
 
Little, but 
recognizable as 
rough and smooth 
ER 
Present, but poorly 
developed 
 
Not studied 
Tissue 
organisation 
Small lobules of 
densely packed 
cells 
Lobular, gland-like  Not studied 
Cell content Multiple cell 
types present 
Few other cell types 
present 
Not studied 
Vascularity Adequate Highly vascularised Not studied 
Gene 
expression 
 
PPAR-gamma, 
aP2, Adiponectin, 
adipsin, perilipin 
UCP-1, PGC-
1alpha, β-3 adreno 
receptor (ARB3), 
PRDM16, 
Iodothyronine type 
II (D2) 
Low UCP1, 
but activated 
by cAMP 
stimulation  
Cell markers CD34, ABCG2, 
ALDH 
EVA1, EBF3, 
FBXO31 
CD137, 
TMEM26, 
TBX1 
 
 
BAT- Brown adipose tissue; WAT- White adipose tissue; BeAT- Beige adipose 
tissue; ER- Endoplasmic reticulum 
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Figure 1.5.2: Virtanen et al NEJM 2009140: a) Haematoxylin and Eosin staining 
preparations of adipose tissues on 3 subjects demonstrating multilocular and 
intracellular lipid droplets in brown adipose tissue, absent in WAT; b) 
Immunohistochemistry demonstrating high UCP-1 uptake in BAT for UCP-1 anti-
specific sera, which is absent in WAT.  
 
1.5.3    Function of Brown adipose tissue  
 
The presence of the 32 kDa UCP-1 in BAT mitochondria enables the inward 
translocation of protons across the mitochondrial inner membrane. This process 
enables uncoupling of oxidative phosphorylation from the electron transport chain, 
resulting in dissipation of heat rather than the generation of adenosine tri-phosphate 
(ATP) (Nicholls et al 1984136), as depicted in Figure 1.5.3. The generation of heat 
!!!!!!!a!!!!!!!!!!!!!!!!!!!!b!
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from uncoupled oxidative phosphorylation, termed adaptive thermogenesis, has been 
demonstrated in rodent studies to be essential for the homeostasis of body 
temperature (Enerback et al 1997174). Adaptive thermogenesis refers to production of 
heat in responses to environmental temperature changes (cold induced temperature 
[CIT]175) and diet (diet induced thermogenesis[DIT]), and BAT is implicated in both 
CIT (Orava et al 2011176) and DIT (Vrieze et al 2012177). Adaptive thermogenesis 
may also play a role in the control of body weight through enhancement of energy 
expenditure and may therefore also protect against the development of obesity, 
although such a role would presumably not have been particularly important for 
survival and reproduction during our famine-prone and food-deprived evolutionary 
past (Guerra et al 1998178, Feldmann et al 2009137). It seems likely therefore that 
manipulating BAT activity and BAT volume may offer solution to combat obesity 
through regulating adaptive thermogenesis. 
   
                   a                                     b 
Figure 1.5.3: Cannon et al 2004149: a) Food, cold and high body energy reserves 
stimulate ventromedial nucleus in hypothalamus triggering nor-epinephrine release 
via sympathetic nervous system, which initiates triglyceride breakdown in brown 
adipocytes, predominantly through β3 adrenergic receptors. This releases free fatty 
acids, which are substrate of thermogenesis and regulators of uncoupling protein-1 
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activity; b) Intracellular signalling following nor-epinephrine stimulation in brown 
adipocyte, resulting in release of free fatty acids, which in turn transferred on to 
respiratory chain resulting in pumping out of protons. This leads to formation of 
proton-motive force that drives back the protons back into mitochondrial matrix 
through UCP-1. The energy stored in proton motive force is then released as heat. 
  
1.5.4    Prevalence of Brown adipose tissue 
 
BAT was originally thought to be present in between 3.5 and 60% of adult humans 
(Cypess et al 2009141, Saito et al 2009143). More recent studies have demonstrated the 
presence of BAT in 96% of adult humans following cold-induced activation (van 
Marken Lichtenbelt et al142). PET-CT currently remains the gold standard technique 
for detection of BAT, but is associated with exposure to ionizing radiation, and 
images are dependent on factors such as environmental temperature resulting in 
intra-individual variability over time (Cypess et al 2009141 and van Marken 
Lichtenbelt et al142). It would therefore be desirable for safer and more reliable 
imaging modalities for BAT to be developed. One important unanswered question is 
the extent to which BAT occurs in adult humans (regardless of its activity). To date, 
we do not have a reliable means of imaging inactive BAT, and it remains possible 
that in the majority of adult humans with no apparent BAT activity on PET-CT 
imaging, inactive BAT is still present. Having an estimate for the proportion of the 
population with inactive BAT depots present would clearly have important 
implications for and inform the direction of future therapeutic developments to 
manipulate human BAT as a weight-loss strategy: strategies to enhance existing 
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BAT activity versus those to stimulate the formation of new BAT from other fat 
depots for example. 
 
1.5.5    Origin of Brown adipose tissue 
 
Adipose tissue develops from the mesoderm along with bone, cartilage and skeletal 
muscle (Gossler et al 1998179). It was proposed that WAT and BAT develop from 
common progenitors and then diverge along their own lineages (Gossler et al 
1998179). More recent studies have challenged the notion of a common progenitor for 
white and brown adipocytes (Atit et al 2006180). Gene profiling has identified a 
myogenic gene signature within brown fat preadipocytes suggesting that brown fat 
and skeletal muscle share a common progenitor (Timmons et al 2007181). 
Furthermore, it has been shown that brown fat bundles originate from progenitors 
within the central dermatomyotome (derived from paraxial mesoderm) that express 
engrailed-1 (En1), while others have suggested that brown adipocytes originate from 
progenitors expressing myogenic regulating factor-5 (Myf5) (Atit et al 2006180, Seale 
et al 2008182). 
 
An alternative origin of brown adipocytes is trans-differentiation from WAT. WAT-
derived brown adipocytes tend to be BeAT, and do not seem to arise from Myf5+ 
progenitors, but rather develop through re-programming of white progenitors (Seale 
et al 2008182). BeAT resemble white fat cells in having low UCP1, but respond to 
cAMP stimulation with high UCP1 expression like classical brown fat (Wu et al 
2012183). The functional characteristics of BeAT and how these relate to those of 
brown fat should be a focus for further research. The origin of adipocytes appears to 
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be influenced by location: brown adipocytes that are present in classical locations 
such as perirenal or interscapular regions are derived from Myf5+ cells (Seale et al 
2008182).  Conversely, the origin of white adipocytes is linked to mural cells 
(pericytes) of the vasculature of WAT, but not the vasculature of other tissues (Tang 
et al 2008184), whilst white adipocytes in the cephalic region derive their origin from 
the cranial neural crest (Billon et al 2007185). Whilst both WAT and BAT express 
high levels of Peroxisome Proliferator-Activated receptor Gamma Alpha (PPAR-γ) 
(Farmer et al 2006186), BAT expresses UCP-1 (Heaton et al 1978150), Peroxisome 
Proliferator-Activated receptor Gamma Coactivator 1 alpha (PGC1α) (Puigserver et 
al 1998187), type 2 deiodinase (D2) (Silva et al 1983188), PR domain containing 16  
(PRDM16) (Seale et al 2008182) and β3 adrenergic receptor (Arch et al 1989175) 
(ADRB3), the presence of which are now also confirmed in human BAT (Virtanen 
et al 2009140). The origin of brown adipocyte is depicted in Figure 1.5.5. 
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Figure 1.5.5: Multipotent mesenchymal stem cells commit to brown adipocyte 
lineage following developmental triggers such as bone morphogenic proteins (BMP) 
and fibroblast growth factors (FGFs) leading on to cascade resulting in a fully 
developed brown adipocyte. Distinct progenitors give rise to preformed versus 
systemic brown adipocytes. Myf5-expressing progenitors give rise to skeletal muscle 
and brown adipocytes in traditional sites such as interscapular area. Myf5-negative 
progenitors are common precursors for both white adipocyte and recruitable brown 
adipocyte or beige adipocyte. Beige adipocyte is formed from either the trans-
differentiation from white adipose tissue in response to cues such as Irisin or from 
recruitable brown preadipocyte. 
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1.6       Imaging of Brown adipose tissue 
 
1.6.1   Positron Emission-Tomography-Computed Tomography (PET-CT) 
Imaging of Brown Adipose Tissue 
 
PET-CT is a non-invasive molecular imaging used for whole body scanning and 
functional assessment. PET imaging was introduced in 1980’s for the diagnosis and 
staging of cancers, and hybridized CT was combined for better anatomical 
definition. It is based on the principle, that tumours have high metabolic rates, and 
increased glycolytic activity will result in avid uptake of glucose tagged 
radiolabelled tracers such as 18FDG. This will aid to differentiate tissues of high 
activity (cancers) from that of lesser or no activity (non-cancerous tissues). 
Serendipitously, low-density tissues of higher metabolic activity were noted in 
supraclavicular area which were subsequently confirmed to be of BAT, providing 
renewed evidence of BAT presence in adult life (Hany et al 2002161, Nedergaard et 
al 2007139). PET detected BAT is seen in cervical, supraclavicular, paravertebral, 
axillary, mediastinal, pericardial, perirenal/adrenal, trachea-oesophageal, intercostal 
and mesenteric areas, correlating well with previous post-mortem studies (Heaton et 
al 1972151, Cypess et al 2009141). FDG avid uptake BAT areas are depicted in Figure 
1.6. 1.  
 
! 35!
                  
 
Figure 1.6.1: Coronal image of a 25-year old female following curative surgery for 
neck malignancy resection demonstrating avid 18FDG uptake in supraclavicular, 
cervical, mediastinal and axillary region.  
 
BAT prevalence in humans in large cohort PET studies in ambient temperature range 
from 2% to 7% (Yeung et al 2003189, Au-Young et al 2009190, Pfannenberg et al 
2010191, Ouellet et al 2011166, Turong et al 2004192, Kim et al 2008193, Williams et al 
2008194, Stefan et al 2009195), and 36% to 96% in cold activated PET studies (van 
Marken Lichtenbelt et al 2009142, Saito et al 2009143, Yoneshiro et al 2011196, 
Yoneshiro et al 2011197, Orava et al 2011176). A comparison of prevalence rate of 
BAT detection in retrospective PET studies is shown in Table 1.6.1. BAT prevalence 
! 36!
correlates positively to young age, female sex, low BMI and cooler outdoor 
temperature (Cypess et al 2009141, Ouellet et al 2011166). 
 
Table 1.6.1: Comparison of prevalence rate of BAT detection in retrospective 
PET studies 
 
Year Authors Location No of 
BAT+ve 
subjects 
No of 
BAT-ve 
subjects 
Prevale
nce 
 
2002 Hany et al161 Zurich, 
Switzerland 
17 638 2.5% 
2003 Cohade et al198 Baltimore, USA 68 107 6.7% 
2004 Truong et al192 Houston, USA 15 845 1.8% 
2009 Au-Yong et al190 Nottingham, UK 167 3614 4.6% 
2009 Cypess et al141 Boston, USA 106 1972 5.4% 
2009 Cheng et al199 Beijing, China 41 1080 3.8% 
2010 Jacene et al200 Baltimore, USA 56 908 6.2% 
2011 Pace et al201 Naples, Italy 73 848 8.6% 
2011 Ouellet et al166 Sherbrooke, 
Canada 
328 4842 6.8% 
2012 Cronin et al202 Boston, USA 298 6867 4.3% 
 
                  PET- Positron Emission tomography; BAT- Brown adipose tissue 
 
 
Limitations of PET in assessment of BAT include: It is a useful tool to detect BAT 
activity, but is not yet shown to reliably quantify human BAT volume/mass. Images 
derived from PET are influenced heavily by environmental temperature, given the 
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temperature-dependence of BAT activity (which increases in cold conditions) 
(Ouellet et al 2011166, Zukotynski et al 2009203) Furthermore, PET involves exposure 
to potentially harmful ionizing radiation, and is an expensive technique for imaging 
BAT in humans (Ouellet et al 2011166). A safe alternative to PET as an imaging 
modality for human BAT, and one that can potentially overcome the obstacles 
outlined above is Magnetic Resonance (MR) imaging. 
 
1.6.2     Magnetic Resonance Imaging of Brown Adipose Tissue 
 
Magnetic Resonance Imaging (MRI), also called as Nuclear Magnetic Resonance, 
Magnetic Resonance Topography, is a technique that uses a magnetic field and radio 
waves to create detailed images of organs and tissues. This technique has had 
enormous influence in radiology field and has generated more than one Nobel Prize. 
From the first development of MRI awarded to Felix Bloch (Bloch, 1946) and 
Edward Mills Purcell (Bloembergen, 1948) in the 1952 Physics prize, to the latest 
recognition of Paul C. Lauterbur (Lauterbur,1986) and Sir Peter Mansfield 
(Mansfield and Maudsley, 1977) in the 2003 prize for Physiology or Medicine. The 
advantages of MRI over PET are: non-invasive, less cumbersome, no radiation 
involved, less expensive, and finally it detects both metabolically inactive and active 
tissue.  
 
Several attempts to differentiate BAT from WAT in rodents using techniques such as 
magnetic resonance (MR) spectroscopy and chemical shift MR are proven successful 
(Hamilton et al 2011204). However, the delineation of BAT and WAT in human 
adults has so far remained elusive.  
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BAT and WAT differ in their water:fat ratios due to the different functions of these 
two tissue types. Whilst BAT contains abundant mitochondria, WAT consists mainly 
of triglyceride (Cinti et al 2005205). Therefore, BAT contains proportionately more 
water and less fat than WAT. This important difference provides a rationale for 
exploring MR as a potential imaging modality to discern BAT from WAT. MR 
technique of iterative decomposition of water and fat with echo asymmetry and 
least-squares estimation (IDEAL) has been used successfully in rats to clearly 
delineate BAT from WAT (Hu et al 2010206). The lower signal intensity of BAT 
compared to WAT has been exploited to obtain IDEAL fat-water imaging in rats. 
With reconstructed fat-fraction images, a broad fat-fraction range was observed for 
BAT (37-70%), in contrast to a higher and smaller range for WAT (90-93%), in both 
excised tissue samples and in situ (Hu et al 2010206). The excised adipose samples 
from rats and their mean fat-fractions are depicted in Figure 1.6.2. 
              
Figure 1.6.2: Hu et al 2010206 IDEAL results from excised tissues imaged placing 
in water filled petri dish. a) Macroscopic brown and white adipose tissue (BAT, 
WAT) in vials; b) water; c) fat, and d) fat-fraction map. Mean fat-fraction map for 
the 4 samples (from left to right) 92%, 51%, 93%, and 62%.  
 
Intermediate signal intensity in comparison with hypointense subcutaneous fat and 
hyperintense muscle was noted on T2- weighted MR images of presumed BAT in 
supraclavicular and axillary region of a 13-day old neonate (Carter et al 2008207). 
Recently, using water-fat imaging in 11 healthy human volunteers, a paired 
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difference in fat fraction of 16.3% (4.9%) was noted between BAT and WAT, and 
on dynamic T2* imaging, cold stimulation revealed signal fluctuations that were 
sensitive to BAT activation (van Rooijen et al 2012208). But histological 
confirmation was not adopted to conclusively confirm BAT presence.   
 
In summary, an MRI-based methodology to identify and also quantify BAT is highly 
desirable step in addressing the role of BAT in obesity related disorders. MRI studies 
conducted so far have not conclusively confirmed BAT presence in living human 
adults based on both histological and imaging parameters. 
 
1.7       Brown Adipose Tissue and Energy Expenditure 
 
1.7.1    Energy Expenditure 
 
Obesity is as a result of chronic imbalance between energy intake and energy 
expenditure. The human body’s energy balance between energy intake (food) and 
energy expenditure (heat and work) is a complex phenomenon. It is estimated that 4-
8% of the ingested energy is lost in digestion (faeces), and another 3-5% is lost in 
urine and via skin, leaving approximately 90% of metabolizable ingested energy. A 
large part of this metabolizable energy is expended in the form of heat (Blaxter et al 
1989209).  
 
Heat production plus external work account for the average daily metabolic rate or 
total energy expenditure (TEE). TEE can be classically divided into resting 
metabolic rate (RMR; normally 55–65% of TEE), activity related energy expenditure 
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(AEE; normally 25–35% of TEE), and DIT (about 10% of TEE) (van Marken 
Lichtenbelt et al 2011210, Westerterp et al 1999211).  
 
RMR is the energy spent when a person is awake in a fasting rested state (Ravussin 
et al 1982212, Prentice et al 1986213, Ravussin et al 1986214, Riggs et al 2007215). 
Sleeping metabolic rate (SMR) is 3 consecutive hours of resting energy expenditure 
measured when asleep (Schoffelen et al 2008216). Although it is generally considered 
that SMR is equal to RMR (FAO/WHO/UNO 1985. Report of a joint expert 
consultation, Energy and protein requirement WHO technical report series no 724 . 
WHO:Geneva217), the rate of SMR was noted to be higher than RMR at the 
beginning of sleeping period, and lower than RMR in early morning hours. 
Furthermore, average SMR is noted to be lower than RMR in obese subjects, and 
higher than average RMR in non-obese subjects (Zhang et al 2002218). 
 
AEE is a composite of planned physical exercise, and that related to daily activities 
such as fidgeting and pacing (Rumpler et al 1990219). AEE accounts for 
approximately 30% of TEE and is the most modifiable part of TEE (Rumpler et al 
1990219). Hence exercise and physical activity escalation is a standard 
recommendation for any weight loss programme.  
 
DIT is the increase in heat production by the body after eating. It is due to both the 
metabolic energy cost of digestion (the secretion of digestive enzymes, active 
transport of nutrients from the gut, and gut motility) and the energy cost of forming 
tissue reserves of fat, glycogen, and protein (Marino et al 2002220). DIT is highest for 
alcohol and protein, followed by carbohydrates and then fat (Westerterp et al 
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1999211, Westerterp et al 2004221). Although DIT constitutes only 10% of TEE, some 
studies suggest that bigger meal size and increased meal frequency result in higher 
DIT (Kinabo et al 1990222, Tai et al 1991223).  
 
Alternative classification is obligatory energy expenditure, which includes RMR, 
involuntary AEE and obligatory part of DIT, and facultative thermogenesis, which 
includes voluntary AEE, cold-induced non-shivering thermogenesis (NST), cold-
induced shivering thermogenesis, and facultative part of DIT (van Marken 
Lichtenbelt et al 2011210). 
 
Table 1.7.1  Components of Human Energy Expenditure  
 
Total Energy        Resting Metabolic       Activity Energy           Diet Induced 
Expenditure    =             Rate             +       Expenditure      +    Thermogenesis     
(TEE)                          (RMR)                       (AEE)                      (DIT) 
100%                            55-65%                      25-35%                      10% 
 
Obligatory Energy Expenditure Facultative Energy Expenditure 
Resting Metabolic Rate  Cold Induced Thermogenesis or Non-shivering Thermogenesis 
Involuntary Activity related energy 
expenditure 
Voluntary Activity related energy 
expenditure 
Obligatory part of Diet Induced 
Thermogenesis  
Facultative part of Diet Induced 
Thermogenesis  
 
Table depicting components of human energy expenditure, as adapted from 
van Marken Lichtenbelt et al 2011210.  
 
There are various ways of measuring energy expenditure, and the most accurate way 
is by whole room indirect calorimetry (Schoffelen et al 1997224, Westerterp et al 
1999211, Bonomi et al 2013225, Westerterp et al 2013226) and is measured in Kilo 
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calories (Kcal) per 24 hours. Indirect calorimetry is the method by which energy 
expenditure is calculated on the basis of total oxygen consumed (VO2) is converted 
into carbon dioxide (VCO2) and water. Technological advances have yielded more 
accurate measurements of oxygen and carbon dioxide, whilst preventing ambient air 
mixing with the gases that are being measured. Room calorimeters are airtight to 
prevent leakages of air, with large fans to enable adequate mixing of air, as it is 
measured when exiting the room. 
 
1.7.2 Role of Brown Adipose Tissue in Cold and Diet Induced Thermogenesis  
 
As stated in chapter 1.5.3, studies in animals have established that cold exposure 
acutely elevates UCP1 mRNA expression (Jacobsson et al 1994227, Griggio et al 
1999228), whereas prolonged exposure induces BAT hypertrophy and hyperplasia 
(Mory et al 1980229, Mineo et al 2012230). Cold exposure also induces UCP-1 
immunoreactive BAT emergence in WAT (Barbatelli et al 2012231). BAT is shown 
to have a role in adaptive thermogenesis through CIT and DIT by a common 
regulation of sympathetic nervous system (Feldmann et al 2009137, van Marken 
Lichtenbelt et al 2009142, Marino et al 2002220). Recent human PET-CT studies using 
radio-labelled tracers have further confirmed BAT’s role in CIT (also called non-
shivering thermogenesis) through mitochondrial uncoupling property of UCP-1 
(Ouellet et al 2012232, Muzik et al 2012233).  
 
In mice, nutrient ingestion acutely raises energy expenditure by 20%, along with 
doubling of blood flow in BAT, in absence of enhanced blood flow to other 
metabolic tissues (Glick et al 1984234, Glick et al 1984235). In humans, insulin 
! 43!
mediated 5-fold increase in FDG uptake in BAT indirectly suggests that BAT has a 
role in postprandial energy metabolism (Orava et al 2011176). More recently, PET 
studies following high-calorie meal in lean men have shown increased FDG uptake 
in brown fat, implicating BAT in DIT (Vosselman et al 2013236). 
 
1.7.3      Metabolic significance of Brown Adipose Tissue in Humans     
 
BAT provides persuasive evidence for a metabolic role of potential significance, 
given the recent evidence that BAT is present in most humans, if not all, and at least 
in a small proportion. (Lee et al 2011237, van Marken Lichtenbelt et al 2009142). 
BAT’s contribution to energy expenditure (CIT and DIT), a chief determinant of 
energy balance, offers a possible anti-obesity strategy through cellular bio-energetic 
route.   
 
Some of the mice studies claim the thermogenic potential of BAT when maximally 
activated is 300 W/kg (Cannon et al 2004149, Rothwell et al 1983238). On this basis, 
Rothwell and Stock extrapolated that 40-50 g of BAT in humans can account to 20% 
of energy expenditure (Rothwell and Stock et al152). Human studies by Virtanen and 
colleagues estimated 4.1 kg of weight loss over one year through maximally 
activating 63 g of BAT (Virtanen et al 2009140). BAT can potentially be activated for 
prolonged periods based on rodent studies demonstrating sustained CIT 
(Golozoubova et al 2001239). Two independent but congruent human PET studies 
estimated an energy expenditure of 200-400 kcal/day, a 10 to 20% rise in daily basal 
metabolic rate through BAT activation (Yoneshiro et al 2011196, Muzik et al 
2012240). Therefore, the glucose disposal (Orava et al 2011241) and triglyceride 
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clearance properties of BAT Bartelt et al 2011242), when fully utilized may act as an 
energy sink. Further evidence of BAT’s contribution to TEE is provided in Table 
1.7.3. BAT prevalence is higher in leaner subjects and is inversely correlated to BMI 
in multiple retrospective PET studies (Cypess et al 2009141, Ouellet et al 2011166). In 
summary, these studies provide strong evidence that BAT’s contribution to TEE, 
although small in proportion, is significant and sufficient to contribute to weight loss 
over time. There are three ways of enhanced energy expenditure through 
manipulation of BAT could be theoretically achieved: i) maximal and continual 
activation of BAT; ii) trans-differentiation of WAT to BAT (to form BeAT), and; iii) 
transplantation of BAT stem cells. 
 
Table 1.7.3: Metabolic significance of BAT in Adult Humans, Lee et al 2013153 
Author Year Extrapolated 
parameter 
Magnitude Contributi-
on of BAT 
to TEE  
Virtanen et 
al140 
2009 Glucose uptake into 
cold stimulated BAT 
12.2µmol/ 
100 g/min  
7% 
Yoneshiro et 
al196 
2011 Difference in cold-
stimulated EE in BAT 
positive and negative 
individuals 
368 kcal/d 25% 
Orava et al176  2011 Increase in glucose 
uptake into BAT after 
cold stimulation 
 
Difference in cold-
stimulated EE between 
BAT positive and 
negative individuals 
8µmol/ 
100 g/min 
 
 
 
286 kcal/d  
5% 
 
 
 
 
22% 
Ouellet et 
al232  
2012 Glucose uptake into 
cold-stimulated BAT  
 
Difference in EE in 
BAT positive 
individuals in cold and 
warm environments 
10.8µmol/ 
100 g/min 
 
2001 kcal/d 
6.7% 
 
 
77% 
 
              BAT- Brown adipose tissue; TEE- Total energy expenditure 
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1.8       Regulators of Brown Adipose Tissue   
 
1.8.1    Environmental Temperature and Brown Adipose Tissue   
 
To capitalize BAT as an anti-obesity target, it is vital to know the factors, which 
stimulate and increase BAT activity/volume and/or aid transcription of WAT to 
beige. There are several regulatory factors identified over years, but most studied 
ones are environmental temperature and sympathetic nervous system. 
 
Cold is classically known to stimulate rodent BAT activity, BAT hypertrophy, BAT 
hyperplasia whilst causing morphological transformation of WAT to beige 
(Jacobsson et al 1994227, Griggio et al 1982228, Mory et al 1980229, Mineo et al 
2012230, Barbatelli et al 2010231). Several cooling protocols in human PET 
examinations involving a temperature range from 16°C to 20°C, have increased the 
PET detection rate up to 100%, and increased FDG uptake by 15 fold (Feldmann et 
al 2009137, van Marken Lichtenbelt et al 2009142, Marino et al 2002220, Ouellet et al 
2012232, Muzik et al 2012233). Studies using 11C-Acetate (Ouellet et al 2012232) and 
15O2 tracers (Muzik et al 2012233) to measure oxidative metabolism and oxygen 
extraction in human PET studies, unequivocally prove cold exposure stimulate BAT 
activity. Contrarily, inverse correlation is noted that PET detected BAT prevalence is 
lesser in summer and on increasing room temperature (Cypess et al 2009141).  
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1.8.2    Sympathetic Nervous System and Brown Adipose Tissue   
 
Sympathetic nerves richly innervate BAT. Cold exposure increases sympathetic 
drive and doubles plasma noradrenaline levels (Celi et al243). Lateral hypothalamus 
area is shown to influence sympathetic nerves in BAT and BAT induced 
thermogenesis, hypothesized through central melanocortin signalling (Cerri et al 
2005244, Fan et al 2007245). Contrarily, central nervous depressants such as isoflurane 
(Fueger et al 2006246), halothane (and diazepam suppress BAT detection (and hence 
activation) in PET imaging. 
 
Epinephrine causes vasodilatation and enhances glucose and oxygen consumption in 
skeletal muscle (Simonsen et al 1992247) whilst also enhancing thermogenesis in 
humans (Simonsen et al 1993248). BAT is also activated in patients with 
phaeochromocytoma, with increased UCP1 expression similar to levels in cold-
exposed rodents (Ricquier et al 1982249, Lean et al250). BAT activity is greater in 
patients with phaeochromocytoma (English et al 1973251, Melicow et al 2002252) due 
to over-activity of the SNS and elevated levels of circulating catecholamines, that in 
turn stimulate β3 adrenergic receptors, thereby activating UCP1 expression via 
cyclic adenosine monophosphate (cAMP) and protein kinase-A (PKA) pathways 
(Bouillaud et al253). Hadi et al. demonstrated active BAT to be present in 27% 
(26/96) of phaeochromocytoma patients undergoing FDG PET/CT scans (Hadi et al 
2007254), indicating higher detection rates compared to 5.37% (106/1972) of all 
cause PET/CT studies reported by Cypess and colleagues (Cypess et al 2009141). 
Recent human observational studies demonstrate a correlation between plasma 
metanephrine levels and BAT activity (Wang et al 2011255). 
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 1.8.3    Thyroid hormones and Brown Adipose Tissue   
 
We have known for over a century that thyroid hormone (TH) increases metabolic 
rate and thermogenesis in homeothermic species, and hence is an important 
physiological modulator of energy homeostasis (Klitgaard et al 1952256, Klieverik et 
al 2009257). TH not only stimulates both obligatory and facultative thermogenesis 
(Silva et al 2006258), but also enhances oxidative phosphorylation through induction 
of mitochondrial biogenesis and modulation of the expression of genes implicated in 
the regulation of the mitochondrial respiratory chain (Sheehan et al 2004259). The 
weight gain and decreased cold tolerance observed in individuals with 
hypothyroidism, and the weight loss and sweating/heat intolerance observed in 
patients with hyperthyroidism, are predictable clinical manifestations of alterations 
in BAT activity (Lopez et al 2010260). It follows therefore that differences in BAT 
quantity and/or activity between individuals may also influence the clinical 
manifestations of hypo- or hyperthyroid states. This may also explain the inter-
individual variability of weight changes and heterogeneity of other clinical 
manifestations of dysthyroid states. Type 2 deiodinase (D2) is present abundantly in 
BAT, and plays an essential role in mediating the full thermogenic response of BAT 
to adrenergic stimulation via increased thyroxine (T4) to thyronine (T3) conversion 
within this tissue (Bianco et al 1988261). A thyroid hormone analogue, GC-1 
compound, a selective Thyroid Receptor Beta (TRβ) agonist, induces UCP1 gene 
expression in rats (Rebeiro et al 2001262), improves glucose homeostasis (Bryzgalova 
2008263), increases energy expenditure and reduces fat mass and plasma cholesterol 
(Grover 2004264).  
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Promising data from human studies implicate thyroid hormones of having important 
effects on BAT activity. T3 treatment of differentiated human multipotent adipose-
derived stem cells in vitro induces UCP1 expression and mitochondrial biogenesis 
through effects on TRβ (Lee et al 2011265). Following thyroidectomy and subsequent 
treatment with thyroxine replacement therapy in a patient with papillary carcinoma, 
BAT activity was enhanced with concurrent weight-loss and remission of T2DM 
(Skarulis et al 2010266). Thyroxine may cause ‘brownification’ of WAT (Lee et al 
2011265), although this remains a hypothesis.  
 
1.8.4   Transcriptional Regulation   
 
Given that adult humans have BAT, it is important to explore BAT manipulation as a 
means of promoting weight-loss through enhanced energy expenditure via BAT 
manipulation. In addition to augmentation of BAT content and/or enhancement of 
BAT activity, other approaches include trans-differentiation of non-BAT progenitors 
into BAT pre-adipocytes, and surgical implantation of BAT. Development of novel 
BAT-related therapies will require a complete understanding of the embryological 
and transcriptional mechanisms of BAT specification and development in human 
models. We also need to characterize and confirm the physical and genetic attributes 
of BAT including anatomical and histological distributions of human BAT. Further 
challenges will be to develop a sustained long-term BAT stimulating or recruiting 
molecular circuit with adequate knowledge of counter-regulatory mechanisms for an 
acceptable safety profile, and to identify a reliable and safe imaging modality to 
monitor the effects of such therapies on BAT once developed and administered. 
 
! 49!
Several transcriptional regulators of brown adipocyte differentiation are described in 
rodents, with some revealing promising effects even in human models. Irisin is a 
112-amino-acid polypeptide hormone, and is a cleaved and secreted fragment of 
fibronectin type III domain containing 5 (FNDC5) membrane protein, in turn 
released by muscle through increased PGC-1α expression following exercise in both 
rodents and humans (Bostrom et al 2012267). Irisin showed a powerful browning 
effect on certain white adipose tissues in mice, both in culture and in vivo (Bostrom 
et al 2012267). Human irisin is believed to be identical to mouse irisin, and in healthy 
adult subjects showed a 2-fold increase in plasma levels following 10 weeks of 
supervised endurance exercise training, as compared to the non-exercised state 
(Bostrom et al 2012267). This PGC-1α dependent myokine alludes to the super-added 
beneficial effects of exercise via BAT, which need to be further explored.  
 
The PRDM16-C/EBP-β transcriptional complex acts in Myf5-positive myoblastic 
precursors or pre-adipocytes to drive the thermogenic program with co-activation of 
PPAR-γ and PGC-1α (Seale et al 2008182, Kajimura et al 2009268). The cAMP-
dependent thermogenic program is potentiated by Forkhead box C2 (FOXC2) 
(Cederberg et al 2001269) and PRDM16 and repressed by Receptor-Interacting 
Protein 140 (RIP140) (Hallberg et al 2008270). Other transcriptional regulators of 
Bone Morphogenic Protein-7 (BMP7) (Tseng et al 2008271), Fibroblast Derived 
Growth Factor-21 (FGF-21) (Beenken et al 2009272), PPAR-γ ligands (Wilson-Fritch 
et al 2004273) and Atrial Natriuretic Peptide (ANP) (Bordicchia et al 2012274), have 
been described in rodents. Successful transcription of WAT through these various 
regulators result in BeAT, as opposed to classical BAT and success of these 
compounds depend upon extrapolating the gains in human studies. The cellular 
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mechanisms of some of these endocrine factors are shown in Figure 1.8.3. 
 
           
Figure 1.8.3: Harms et al 2013275- Illustration of origin and cellular receptor 
pathways of some of the secreted endocrine regulators, which recruit brown and/or 
beige adipocytes. 
 
1.9    Neurohormonal Adiposity Signals 
 
1.9.1   Central regulation of body weight 
 
The regulation of feeding, energy intake and expenditure, and body weight is a 
homeostatic process (Wilding 2002276). Neurohormonal signals and adipokines from 
the gut and adipose tissue respectively converge and integrate in hypothalamus, 
resulting in energy intake and expenditure regulation (Wren et al 2007277). Two 
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neuronal populations in arcuate nucleus (ARC) of hypothalamus, possessing 
opposite effects on energy balance forms the basis of central integration of 
peripheral adiposity signals. Medial arcuate nucleus consists of neurons that express 
Neuropeptide Y (NPY) and Agouti-Related Peptide (AgRP), which act to stimulate 
food intake and weight gain. In contrast, lateral arcuate nucleus contains pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript co-
expressing neurons that inhibit food intake and promote weight loss (Williams et al 
2001278, Cone et al 2001279, Wren et al 2007277). In response to peripheral adiposity 
signals, relative activity of these appetite stimulating and appetite suppressing 
hypothalamic neurons results in release of respective neuropeptides, which in turn 
regulate feeding behaviour and body weight regulation (Williams et al 2001278, Cone 
et al 2001279, Wren et al 2007277).  
 
1.9.2    Leptin 
 
Leptin is a long-term adiposity signal and was the first discovered adipokine in 1994 
(Zhang et al280). Secreted by WAT, circulating level of leptin is proportional to fat 
mass. Mice lacking leptin develop hyperphagia, obesity, insulin resistance and 
hypogonadism (Friedman et al 1998). Regular central or peripheral administration of 
leptin or leptin agonists in ob/ob mice induces weight loss by satiety suppression and 
increase in energy expenditure, whilst recovering euglycaemia and reproductive 
function (Halaas et al 1995281, Campfield et al 1995282, Pelleymounter et al 1995283). 
In humans, leptin is shown to inhibit orexigenic NPY/AgRP co-expressing neurons, 
and to stimulate anorexigenic POMC-expressing neurons of the hypothalamic 
arcuate nucleus (Sahu et al 2003284). Obesity caused by congenital leptin deficiency, 
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which alleviates on treatment with recombinant leptin, is very rare (Farooqi et al 
1999285). On the contrary, leptin levels are found to be higher in obese individuals, 
probably as a result of insulin resistance and recombinant leptin use in such 
individuals are unfavourable (Maffei et al 1995286, Moon et al 2011287, Vatier et al 
2012288). It proportionally correlates with BMI and has been implicated in multiple 
cardiovascular pathologies including myocardial infarction, stroke, hypertension and 
atherosclerosis, where it is said to act synergistically with other inflammatory 
mediators (Gualillo et al 2007289, Lawlor et al 2007290, Sattar et al 2009291). Overall, 
leptin acts as ‘adipostat’ and regulates food intake and energy expenditure through 
its actions on hypothalamus. 
 
1.9.3    Adiponectin 
 
Adiponectin, most abundant protein secreted by adipose tissue (Scherer et al 
1995292), unlike many other adipokines, is known to increase insulin sensitivity and 
vascular function, thus possessing both anti-diabetic and anti-atherogenic (Trujillo et 
al 2003293, Ouchi et al 1999294) properties. Administration of recombinant 
adiponectin in rodent models increases insulin sensitivity (Yamauchi et al 2001295), 
and adiponectin transgenic mice showed partial amelioration of insulin resistance 
(Yamauchi et al 2003296). In contrast, adiponectin deficient mice displayed glucose 
intolerance and insulin resistance (Kubota et al 2002297). Low levels of plasma 
adiponectin in humans correlate to CVD (Von Enyatten et al 2008298) and metabolic 
syndrome (Salmenniemi et al 2004299). High adiponectin levels are protective 
towards atherosclerosis because of anti-inflammatory properties (Gualillo et al 
2007289). It is hypothesized that adiponectin acts as a starvation signal, increases in 
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fasting state and stimulates appetite, having an opposite to leptin’s satiety action, 
thus indicating a role in energy homeostasis (Kubota et al 2007 300). However, a 
definitive role of adiponectin in energy homeostasis is yet to be fully determined. 
 
1.9.4    Ghrelin 
 
Ghrelin, a 28-amino acid peptide produced primarily in gastric fundus and proximal 
small intestine, is the only orexigenic hormone identified till date, that powerfully 
triggers hunger in a diverse of species including humans (Kojima et al 1999301, 
Tschop et al 2000302, Wren et al 2001303). Ghrelin is an endogenous ligand for 
growth hormone secretagogue receptor and hence releases growth hormone (Wren et 
al 2001303). Although the precise mechanisms are unclear, it is speculated to act on 
hypothalamic medial arcuate nucleus and triggers NPY/AgRP co-expressing neurons 
to stimulate food intake and is known as a meal initiator (Wren et al 2001304). 
Ghrelin is implicated in meal-time hunger and meal initiation in both lean and obese 
individuals (Druce et al 2005305), and on intravenous infusion is noted to increase 
dietary intake by 30% in human volunteers (Murphy et al 2004306). Circulating 
plasma ghrelin levels surge before meals and suppress on ingestion of nutrients 
(carbohydrates, protein and fats in order of effectiveness of suppression) (Weigle et 
al 2003307, Mohlig et al 2002308). The typically expected post-prandial suppression of 
ghrelin is attenuated or absent in obese individuals (English et al 2002309). Ghrelin 
status following gastric bypass surgery remains to be determined, as studies report 
levels to be increased (Cummings et al 2002310), same (Karamanakos et al 2008311, 
Couce et al 2006312) or reduced (Garcia-Fuentes et al 2008313). However, ghrelin 
blockade studies show promise both in rodent models (Wortley et al 2005314, Zigman 
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et al 2005315) and in humans (Foster-Schubert et al 2006316), convincing us the role 
of ghrelin in energy homeostasis. The most promising strategy for an anti-obesity 
agent through ghrelin pathway would be to attempt pre-prandial receptor blockade. 
 
1.9.5   Peptide YY 
 
PYY, is secreted in full-length 36-amino acid form from L-cells of distal gastro-
intestinal tract (primarily colon), circulates in 34-amino acid active PYY3-36 form. It 
acts via Y2 receptor (G-protein coupled receptor family) in hypothalamus, inhibiting 
the release of NPY, the most potent CNS stimulant of appetite (Batterham et al 
2002317). Circulating levels of PYY3-36 become elevated 1 hour post-meal, and are 
influenced by diet composition and calorie content (Adrian et al 1985318). 
Endogenous fasting and post-prandial concentrations were lower in obese than in 
lean subjects, and fasting level negatively correlated with BMI (Batterham et al 
2003319). Increased level of PYY3-36 is noted following gastric bypass surgery 
indicating to long-term success of these procedures in causing weight loss in humans 
(Korner et al 2005320). Intravenous infusion of exogenous PYY3-36 induced lower 24-
hour food intake by 30% and suppress satiety in humans (Batterham et al 2002317, 
Batterham et al 2003319). Intranasal PYY3-36 administration thrice daily results in 
modest weight loss in humans (Gantz et al 2007321). Limitations of PYY3-36 or Y2 
receptor agonists use are severe nausea and vomiting noted in these studies 
(Halatchev et al 2005322). More work is needed before using PYY3-36 as biomarker of 
satiety. A combined approach of other novel agents along with PYY3-36 may usher in 
an anti-obesity drug.  
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1.9.6     Glucagon Like Peptide-1 
 
GLP-1 is a cleaved product from proglucagon, produced by L-cells primarily in 
distal small intestine and colon, where it colocalizes with oxyntomodulin and PYY 
(Verdich et al 2001323). Other proglucagon products include glucagon (a counter 
regulatory hormone), Glucagon like peptide-2 (GLP-2)(an intestinal growth factor), 
glicentin (a gastric acid inhibitor), and oxyntomodulin (Verdich et al 2001323). 
Several of these products are implicated in satiation, but the strongest of these are 
GLP-1 and oxyntomodulin (Herrmann et al 1995324). Two equipotent bioactive 
forms of GLP-17-36 and GLP-17-37, are inactivated by Dipeptidyl dipeptidase -IV 
(DPP-IV), rendering the half-life of GLP-1 to 5 minutes (Kieffer et al 1995325). 
Ingestion of nutrients triggers GLP-1 release from L cells, which applies ‘ileal brake’ 
by reducing gastric and intestinal motility. In addition to delaying gastric emptying, 
GLP-1 accentuates glucose dependent insulin release, inhibits glucagon release, 
stimulates β-cell growth (Tourell et al 2001326) and suppresses satiety through 
central pathways (Turton et al 1996327). Both centrally and peripherally administered 
GLP-1 and GLP-1 receptor agonists exert profound anorexigenic effects in several 
species (John Eng et al 1992328) including normal-weight (Gutzwiller et al 1996329) 
obese (Naslund et al 1999330) and diabetic humans (Toft-Nielsen et al 1999331). 
Anorectic effects are mediated specifically by GLP1R, as they are absent in GLP1R-
deficient mice and are reversed with selective GLP1R antagonists (Baggio et al 
2004332). GLP-1 levels are increased following gastric bypass (le Roux et al 
2007333). The GLP-1 analog, exendin-4, discovered from the venom of the Gila 
monster, Heloderma suspectum, is an established anti-diabetic agent (Eng et al 
1992328). It is also currently being investigated as an anti-obesity agent in non-
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diabetic humans. DPP-IV inhibition is a beneficial approach in treatment of T2DM 
(Ahren et al 2007334). Overall, evidence suggests that plasma GLP-1 level is a useful 
marker for satiation, and use of GLP-1 receptor agonists alleviates glucose 
intolerance and induces weight loss in humans (Verdich et al 2001323).  
 
1.9.7     Pancreatic Polypeptide 
 
Pancreatic polypeptide (PP) is a 36-amino acid anorexigenic peptide, primarily 
synthesized and released from the endocrine pancreas, to a lesser extent from colon 
and rectum (Chaudhri et al 2008335). Levels are low during the fasting state and rise 
in proportion to nutrient load (Track et al 1980336). PP acts predominantly via Y4 
receptor (Lin et al 2009)337. Peripheral administration of PP causes reduced food 
intake and weight loss in rodents (Malaisse-Lagae et al 1977338) and humans 
(Batterham et al 2003339). Although the hypothalamically-regulated anorexigenic 
effects of PP remain to be fully characterized, a product with the capacity to increase 
endogenous PP production while avoiding degradation in the circulation, or to 
increase Y4-mediated signalling, would certainly hold promise as a future anti-
obesity tool (Perry et al 2012340). 
 
1.9.8    Non-esterified Fatty Acids 
 
Non-esterified fatty acids (NEFAs) are adipocyte-derived products, secreted 
primarily during fasting as a nutrient source for the rest of the body. NEFAs 
constitute the primary energy fuel for most tissues during starvation. Their release 
into circulation is partly through hydrolysis of triacylglycerol-rich lipids by 
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activation of lipoprotein lipase, and the rest from tissue triacylglycerol depots, which 
are under the influence of hormone sensitive lipase. NEFA removal is dependent on 
tissue uptake or esterification (Ferrannini et al 1997341). Insulin is a potent regulator 
of NEFA and causes profound suppression through its stimulatory effect on 
lipoprotein lipase and inhibitory effect of hormone sensitive lipase, besides also 
providing α-glycerophosphate, the substrate for NEFA re-esterification (Campbell et 
al 1992342). This action of insulin marks the switch over of energy production from 
dominant fat oxidation to prevalent glucose utilization. Elevated fasting NEFA levels 
are noted in T2DM subjects (Golay et al 1986343), as impaired insulin activity is 
noted, and also in non-diabetic obese subjects despite normal levels of insulin (Golay 
et al 1986343, Frayn et al 1996344). NEFAs effect glucose homeostasis by reducing 
adipocyte and skeletal muscle glucose uptake, and promoting hepatic glucose output  
(Rosen et al 2006345) as shown in Figure 1.9.8. Because lipolysis in adipocytes is 
repressed by insulin, and insulin resistance from any cause can lead to chronic 
NEFA elevation, which in turn results in lipotoxicity of β-cells (McGarry et al 
1999346), reduced glucose dependent insulin excretion (Sako et al 1990347, Zhou et al 
1995348, Mason et al 1999349), impaired insulin gene expression (Gremlich et al 
1997350), and increased β-cell apoptosis (Milburn et al 1995351, Shimabukuro et al 
1998352, Randle et al 1963353). In summary, acute effect of NEFA is to release 
insulin, but chronic effect of NEFA is to reduce insulin secretion as shown in Figure 
1.9.8. 
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Figure 1.9.8: Rosen et al 2006345- NEFA release from adipocytes causes reduced 
glucose uptake in adipocyte and skeletal muscle; acutely, NEFA causes insulin 
release, but chronic exposure causes insulin resistance. 
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1.10      General Aims of the Study 
 
The aims of this thesis are: 
 
1. To develop IDEAL MRI as a novel imaging tool for characterization of BAT 
in humans. This innovation would enable to detect BAT irrespective of its activity, 
and without radiation exposure or interference from external factors such as 
environmental temperature, which would represent a significant advantage over 18F-
FDG PET/CT as a means of imaging human BAT. 
 
2. To explore the effect of various determinants such as age, sex, BMI, fasting 
glucose, outdoor temperature etc., on BAT prevalence and volume in sequential 18F-
FDG PET/CT examinations. 
 
3. To investigate the impact of meal duration (eating rate) on BAT implicated 
diet-induced thermogenesis, and on pancreatic and gut hormones. 
 
The combination of these aims will seek to accurately detect human BAT using safe 
radiological means, whilst exploring various factors of BAT activity and its impact 
on energy expenditure, providing new insights and understanding of BAT on human 
physiology for an ultimate aim to manipulate BAT as an anti-obesity measure.   
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Chapter 2 
 
 
 
METHODS AND MATERIALS 
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2.1 Methods and Materials  
 
This chapter details the methods and materials used for the individual chapters of 
this thesis. Each appropriate chapter has further information outlining specific 
methods for each study. 
 
2.1.1 Positron Emission Tomography (PET) detected Brown Adipose Tissue 
(BAT) study 
 
Retrospective analyses of 3295 consecutive PET-CT scans at the PET centre in 
University Hospitals Coventry and Warwickshire (UHCW) National Health Service 
(NHS) Trust, was undertaken. PET scans were ordered for various diagnostic 
reasons and were largely conducted for clinical evaluation of different 
malignancies. The data collection period was between June 2007 and August 
2012. Substantial physiologic 18F-FDG uptake at recognized BAT areas were 
considered to be putative BAT. The influence of outdoor temperature, sex, age, 
body mass index (BMI), fasting plasma glucose level and thyroid status on the 
prevalence, volume and activity of BAT was investigated. UHCW Human 
Metabolism and Research Unit (HMRU) ethics approved by the Black County 
Research Ethics Committee (Rec No. 11/H1206/3) was applied for the study, and the 
requirement for consent was waived under exempt review, given the retrospective 
observational nature of the study. 
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2.1.2 Basic principles of PET imaging 
 
Positron emission tomography (PET) is a non-invasive functional nuclear imaging 
technique that captures functional, physiological and molecular processes of the 
body tissue (tumour), by producing a three-dimensional picture.  
 
To acquire a PET scan, a positron-emitting radionuclide tracer (e.g., F-18) is tagged 
on a biologically active molecule (e.g., Deoxyglucose) and is intravenously injected 
into the body. Following a waiting period, the tracer thus concentrated in the tissues 
of interest emits gamma photons, which are detected by sensors to construct a three-
dimensional image by computer analysis.  
 
Radionuclides are unstable compounds due to the unsuitable composition of 
neutrons and protons or excess energy. Therefore, they decay by emitting radiations 
such as α particles, β− particles, β+ particles, electron capture, and isomeric transition. 
 
A range of radioactive nuclei of positron-emitting radionuclide tracers, also called as 
PET radiopharmaceuticals (11C, 13N, 15O, 18F, 68Ga and 82Rb), emit positively 
charged electrons (positrons), referred as β+. This process is also called as ‘Positron 
Emission Decay’ or ‘Beta Emission Decay’. A positron is an antiparticle of an 
electron with opposite charge (Basu et al 2011354).  
 
Usually the radiotracers have a short half-life. The most common PET tracer used is 
a radiolabelled glucose analog, 2-deoxy-2- [18F] Fluoro-D-Glucose (18F-FDG). 18F-
FDG has a relatively long half-life of 110 minutes, and provides a waiting period of 
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approximately one-hour for clinical purposes of PET imaging. The waiting period is 
for the active molecule to be concentrated in the tissues of interest. Like glucose, 
18F-FDG is phosphorylated by hexokinase as part of the glycolysis, and therefore is 
taken up by mitochondria of all metabolically active tissues (tumour, heart, brain, 
liver, BAT etc.). Unlike glucose, 18F-FDG is intracellularly trapped as it lacks the 
requisite hydroxyl group at position 2’, therefore not undergoing further glycolysis 
by phosphohexokinase isomerase (Basu et al 2011354).  
 
A positron thus emitted travels to certain distance in the tissue and loses energy by 
interaction with an electron of an absorber atom and comes to rest by a process 
called ‘Annihilation’. Both particles (β+ and e-) are annihilated as a result of matter-
antimatter encounter to produce two Photons of 511 keV, which are emitted in 
opposite directions (approximately 180o), and this forms the basic molecular process 
of PET as shown in Figure 2.1.2. 
                       
Figure 2.1.2 Saha et al, Basics of PET imaging 2nd edition, 2010355: A schematic 
illustration of the annihilation of a positron and an electron in the medium. Two 511-
keV photons are produced and emitted in opposite directions (180o).  
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2.1.3 Image reconstruction from PET 
 
The released Gamma photons (also termed as Gamma rays) are detected by 
scintillation counter to form light photons. The common detectors in PET system are 
bismuth germinate (BGO), lutetium oxyorthosilicate (LSO) and lutetium yttrium 
oxyorthosilicate (LYSO). A true coincidence occurs when two Gamma Photons of 
511-keV from a single annihilation, are sensed simultaneously by a pair of 
diametrically opposite detectors along a Line of Response (LOR), as shown in 
Figure 2.1.3. The light photons are converted to electrical impulse by a 
photomultiplier tube, which contains a photocathode. The anode end of the 
photocathode, which is made of alloy of cesium and antimony, absorbs the light 
photons and emits electrons. The pulse height analyzer (PHA) further discriminates 
the signals, such that only selected energy photons are permitted which is in turn 
computer-processed and stored as a PET image (Saha et al 2010355). 
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Figure 2.1.3 Illustration showing two photons from a single annihilation event 
interacting simultaneously with opposing scintillation crystals along a single Line of 
Response (LOR). The light photons are converted into electrical impulses by a 
photomultiplier tube and are computer processed to produce a PET image. Image 
downloaded from http://en.wikipedia.org/wiki/File: PET-schema.png 
 
The image thus produced however, is a functional image with no anatomical 
reference and low spatial resolution. This is circumvented with integration with 
Computed tomography (CT).  
 
2.1.4 Principles of Computed tomography (CT) 
 
The fact that CT was one of the greatest innovations in the field of radiology since 
the discovery of X-rays in 1895, was duly acknowledged by awarding Nobel prizes 
in medicine to Sir Godfrey Hounsfield and Alan McLeod Cormack in 1979 (Ghonge 
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et al 2013356).  
 
CT is a medical imaging procedure that utilizes computer-processed X-rays to 
produce tomographic images or ‘slices’ of specific regions of interest of the body. 
‘Tomography’ is derived from Greek words tomos  (to slice) and graphien (to write). 
CT is based on the basic principle that the density of the tissue passed by the X-ray 
beam can be measured from calculation of the attenuation co-efficient.  
 
CT is composed of a moving x-ray tube mounted on a rotating gantry and a ring of 
thousands of detectors. The detectors are made of ceramics, gadolinium oxysulfide 
and gemstone, etc. A high voltage is applied to the cathode filament of the x-ray 
tube. These electrons from the cathode impinge to the rotating anode made of 
tungsten, rhenium or molybdenum, producing X-rays. X-ray tube rotates around the 
subject and transmits X-ray beams through the subject’s body (Goldman et al 
2007357) as illustrated in Figure 2.1.4.1. 
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Figure 2.1.4.1 Goldman et al 2007357: Illustration of a CT arrangement. Axial slice 
through patient is swept out by narrow (pencil-width) x-ray beam as linked x-ray 
tube–detector apparatus scans across patient in linear translation. Translations are 
repeated at many angles. Thickness of narrow beam is equivalent to slice thickness. 
 
The detectors measure the transmission of a thin beam (1-10mm) of X-rays through 
a full scan of the body, unlike an X-ray radiography where an image is produced 
directly following the transmission of X-rays. The light signals then are computer-
processed by the photodiode and stored in the form a CT image. Since there are 
distinct atomic masses within the subject, the x-rays will have differential 
attenuation through the subject. The image of the section of the object irradiated by 
the X-ray, is reconstructed from a large number of measurements of attenuation 
coefficient of various tissues obtained (Ghonge et al 2013356, Saha et al 2010355). The 
average attenuation values of various tissues are called ‘Hounsfield units’ named 
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after CT pioneer Sir Godfrey Hounsfield. 
 
Table 2.1.4.2: Range of CT attenuation values for various tissues 
 
Tissue Range of CT numbers 
(Hounsfield units) 
Bone 500-1500 
Muscle 40-60 
Brain 35-45 
Water 0 
Adipose tissue -60 to -150 
Lung -300 to -800 
Air -1000 
                          
2.1.5 Integration of PET with CT 
 
Even though the PET method was developed in the 50’s, and the first commercial 
tomographs were available in the 80’s, the real breakthrough of technology occurred 
in late 90’s with integration of PET with Computed tomography (CT) (Beyer et al 
2000358, Wagner et al 1998359). This gave an ideal platform of integrating functional 
with anatomical imaging, resulting in wide clinical use of PET-CTs since 2001 
(Beyer et al 2000358).  
 
The scanning table goes through the front CT scanner and back PET scanner in a 
common support and gantry. To ensure the images of PET and CT scans can be 
fused together, the subject is kept in the same position throughout the scan, as 
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demonstrated in Figure 2.1.5. 
             
Figure 2.1.5: Schematic representation of dual PET-CT scanner with respective 
positions in a common gantry. 
 
Combining CT with PET not only provides anatomical information, it also provides 
attenuation correction for the reconstructed PET images, adding value to PET 
interpretation. The attenuation correction factor bases on the photon energy of CT X-
ray and PET photon. The CT 70keV X-rays are scaled to match the PET 511keV 
photons by applying a scaling factor which is mass attenuation coefficient ratio in a 
given tissue of 511keV photons to that of 70keV X-rays (Saha et al 2010355). This 
reduces CT scan time to few seconds and thereby reducing the overall PET-CT 
imaging time. This increases the diagnostic accuracy to 84% sensitivity and 88% 
specificity for any cancer evaluation (Saha et al 2010355). In summary, PET-CT is a 
standard imaging modality in cancer evaluation and is the preferred method to detect 
metastases. 
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2.1.6 PET-CT imaging protocol 
 
Scanning was performed on a combined GE Discovery STE PET/CT scanner 
(General Electric Medical Systems, Milwaukee, USA) at UHCW PET centre 
Patients were fasted for at least 6 hours prior to scanning in accordance with 
standard administration and acquisition protocol. After administration of the 18F-
FDG isotope, patients rested for 60 minutes in the waiting room within the PET/CT 
suite, where ambient temperature was maintained at 24°C. Prior to administration of 
the 18F-FDG dye, capillary blood glucose was checked, and 2 to 5 IU of insulin 
administered subcutaneously in cases of hyperglycaemia. 18F-FDG was administered 
intravenously one hour prior to the scan (mean injected dose 362.1 MBq, standard 
deviation 33.2 MBq; range 103 – 505 MBq). Static emission data were obtained 
from the skull base to mid thigh with the arms elevated whenever possible. In cases 
of head and neck cancer a second set of emission data were obtained of the head and 
neck with the arms by the patients’ side. Emission data were obtained for 3 minutes 
in each bed position (each covering between 10 and 20 cm) with 2-dimensional 
acquisition. PET images were reconstructed using the computerised tomography 
(CT) data for attenuation correction. Unenhanced spiral CT scans were acquired 
from the skull base to the mid-thighs using 3.3 mm slice thickness. All oncology 
patients with the exception of those being scanned for the purposes of head and neck 
cancer were given water-soluble iodinated contrast media (Gastrografin®, Bayer plc, 
Newbury, UK) for bowel opacification. Images were reconstructed using the filtered 
back-protection algorithm.  
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2.1.7    Patient Records Data collection 
 
3295 consecutive 18F-FDG-PET/CT whole-body scans were performed on 2685 
patients (1497 males, 1188 females) for various diagnostic reasons between June 
2007 and August 2012, at UHCW NHS Trust PET centre. Data on age, sex, BMI, 
fasting glucose level, scan date and scan timing were obtained for all patients. BMI 
was categorised based on WHO (as illustrated in Chapter 1.1.4) and National 
Institute of Health criteria into 4 groups (Underweight ≤18.5; Normal=18.6-24.9; 
Overweight=25-29.9;Obese≥30, The Evidence Report, National Institutes of Heath 
1998360). Glycaemic group was categorised based on American Diabetes 
Association’s criteria (Normoglycaemia<5.5 mmol/L; Impaired Fasting 
Glycaemia≥5.5-6.9 mmol/L; Diabetes Mellitus≥7.0 mmol/L). 
 
Lean body weight (LBW) was calculated using the following validated formulas 
(Ouellet et al 2011166):  
 
LBW (Males) =[1.10 x Weight (kgs)] - [128 x (Weight [kgs]/Height [cm])2] 
 
LBW (Females) =[1.07 x weight (kilograms)] - [148 x (weight [kilograms]/height 
[centimeters])2.  
 
Basal Metabolic Rate was calculated using revised Harris Benedict equation (Roza et 
al 1984361): 
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BMR (Males) = 88.362 + (13.397 x Weight in kg) + (4.799 x Height in cm)- (5.677 
x Age in years) 
 
BMR (Females) = 447.593 + (9.247 x weight in kg) + (3.098 x height in cm) - 
(4.330 x age in years) 
 
Outdoor temperature in Coventry for the day of the scan was obtained from United 
Kingdom Meteorological Society. PET/CT reports and medical records were 
reviewed for cancer diagnosis. If the diagnosis was not available, it was classified as 
non-cancerous diagnosis.  
 
For the 151 patients who were detected to have putative BAT, electronic and 
medical records were reviewed for other relevant past medical history, drug history, 
smoking status, fasting lipid profile, and biochemical thyroid profile. 
 
Post-thyroidectomy patients in thyroid cancer are iatrogenically rendered mildly 
thyrotoxic by thyroxine replacement therapy (Levothyroxine and Liothyronine) to 
suppress TSH, in order to prevent reactivation of thyroid malignancy.    
 
Out of 229 patients who were treated for thyroid cancer in UHCW during the same 
period, 34 patients underwent PET scans, whose notes and electronic records were 
reviewed irrespective of their BAT status. This small group was further classified 
into Thyrotoxic and Euthyroid subgroups, depending upon patients’ biochemical 
thyroid status (Thyrotoxic: TSH < 0.35 mU/L, Euthyroid: 0.035 – 6.0 mU/L) at the 
time of PET scan. The thyroid profiles were collected only if they were within 6 
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weeks range from the date of PET scan. The summary of this methodology is 
discussed further in Chapter 3.2.1. 
 
2.1.8   Image analyses  
 
All PET/CT scans were initially reported by a Consultant Radiologist with expertise 
in nuclear imaging as part of the patients’ routine clinical care using a Centricity 
PACS workstation (GE Healthcare, USA), and 18F-FDG BAT recorded in the report 
if present. For the purposes of this study each PET/CT scan was re-evaluated by 
second radiologist using a GE ADW Advantage Workstation 4.3 (GE Healthcare, 
USA) to confirm the presence of 18F-FDG BAT. 18F-FDG BAT was considered 
present when there was avid 18F-FDG uptake at a greater-than background level (i.e. 
Standardised Uptake Value [SUV] > 2.5 g/ml) in areas corresponding to the 
attenuation of adipose tissue on CT (i.e. an attenuation of between -100 and -10 
Hounsfield units).  
 
2.1.9 Significance of Standardised Uptake Value (SUV)  
 
SUV, which is corrected for body weight and injected 18F-FDG doses, is a semi-
quantitative measurement for 18F-FDG uptake (Lucignani et al 2004362). 
 
SUV is commonly defined as the ratio of (1) tissue radioactivity concentration ‘c’ 
(MegaBequerel [MBq]/kg) at time point ‘t’, and (2) the injected activity (MBq, 
extrapolated to the same time ‘t’) divided by body weight (kg). SUV (g/ml) = 
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[Average activity in region of interest (ROI) (MBq/ml)/injected dose (MBq)] X body 
weight (kg). 
 
In simple terms, SUV is a way of determining PET activity. It is used to measure 
response of cancers to treatment and is considered a semi-quantitative value because 
it is vulnerable to various factors such as, image noise, low image resolution and 
variable user-biased ROI selection. The SUV cut-off between benign and malignant 
lesion is 2.0 or 2.5 g/ml, and can also be raised in inflammatory processes (Thie et al 
2004363). In absence of malignancy, if a ROI measured SUV of >2.5 g/ml in the 
usual BAT areas of neck, mediastinum, axilla, suprarenal areas, then this was 
considered BAT as detailed in Chapter 1.6.1 in keeping with other BAT PET studies 
(Saito et al 2009143, Cypess et al 2009141). 
 
Total Lesion Glycolysis (TLG) is another recent FDG-PET parameter, which 
represents a combined metabolic and morphologic tumour burden parameter, and 
hence is a reflection of BAT activity for this study purposes (Larson 1999364). It is 
calculated by multiplying SUVmean by tumour volume.  
 
2.1.10 BAT activity, BAT volume and BAT mass quantification 
 
Out of the 2685 patients who underwent 3295 scans, 151 patients were identified to 
have positive 18F-FDG BAT uptake on 175 scans, and hence were categorized as 
BAT responders, and the remaining 2533 patients as BAT non-responders. 2685 
scans with highest SUVmax were included in the analysis to avoid confounding of 
factors such as BMI, age and sex in analyses of BAT prevalence, activity and mass.  
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BAT activity was measured utilizing SUVmax, which denotes the highest 
concentration of the 18F-FDG dye greater than 2.5 g/ml in ROI at the given time ‘t’, 
a reflection of maximal putative BAT activity if ROI coincides with BAT recognized 
areas, in absence of malignancy diagnosis (Ouellet et al 2011166). 
 
BAT volume was measured using commercially available image fusion software 
(Mirada XD 4.3, Mirada Ltd, Oxford, UK). It semi-automatically defined 
isocontours around putative 18F-FDG BAT depots on axial PET/CT scans (Figure 
2.1.10 a and Figure 2.1.10.b) with a threshold set at an SUV of 2.5 g/ml, using a 
similar technique to that described by Huang et al365and van Marken Lichtenbelt et 
al 366. We found that this threshold provided the best compromise between capturing 
the extent of 18F-FDG uptake within BAT, whilst minimising artefactual ‘bleeding’ 
of signal into adjacent tissues. From this the volume and SUVmax were calculated for 
each depot. For BAT mass calculation, an assumption of fat having a density of 0.92 
g/ml was made as per validated methods used in literature (Ross et al 1991367).  
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Figure 2.1.10.a: Semi-automatic selection of 18F-FDG regions of interest by defining an 
isocontour set at SUV of 2.5 g/ml 
                                      
Figure 2.1.10.b: Coronal PET Maximum intensity projection (MIP) image, showing 
isocontours around BAT from which volumes were derived. The colours depicted in the 
figure are automated and are generated by computer software for distinction purposes and 
bears no clinical relevance. 
 
2.1.11 Statistical analyses 
 
The recorded data were entered into Microsoft excel spreadsheet. The data were 
analysed using SPSS IBM software Version 22 (SPSS Chicago, IL). Normally 
distributed continuous variables were compared between study groups with the use 
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of Student’s t-test, and non-normally distributed variables were compared with 
Mann-Whitney U test. The roles of sex, age, BMI, fasting glucose, outdoor 
temperature as predictors of BAT prevalence were tested by logistic regression with 
the use of univariate and multivariate models. The patients were also divided into 
four BMI groups (Underweight, Normal, Overweight and Obese), and also Fasting 
Glucose level (Normoglycaemia, Impaired Fasting Glycaemia, and Diabetes); 
Kruskal Wallis was used to compare between the categories for BAT mass and BAT 
activity. Missing values were dealt with pairwise deletion using SPSS software. 
Odds ratio and Confidence Intervals were estimated as measures of magnitude of 
associations. All P values presented are two-tailed, and values less than 0.05 are 
considered to be statistically significant. 
 
2.1 Materials and Methods for Magnetic Resonance Imaging of Brown Adipose 
Tissue (BAT) Study 
 
2.2.1 Introduction 
 
18F-FDG PET scan detects only metabolically active BAT and therefore grossly 
underestimates BAT’s prevalence and extent. Besides, it is not reliably reproducible 
and involves radiation exposure. This study was aimed at providing a proof of 
concept for a novel MRI imaging technique- Iterative Decomposition with Echo 
Asymmetry and Least Squares Estimation (IDEAL) to visualize BAT in humans. 
The concept of IDEAL MRI, which was shown to work in rat models to demonstrate 
BAT by Houchun Hu et al206 was reproduced in our centre, on a rat carcass. The 
same methodology was adopted in an adult human volunteer, who had already 
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undergone PET-CT for clinical indication. PET-CT images were co-registered with 
IDEAL MRI images using image fusion software, and the combined images were 
analysed by two radiologists. BAT presence in the region of interest was confirmed 
by histological and immunohistochemical staining. Black County Research Ethics 
Committee (Rec No. 11/H1206/3) provided ethics for this study.  
 
2.2.2 Basic principles of Magnetic Resonance Imaging 
 
Magnetic Resonance Imaging (MRI) or Nuclear Magnetic Resonance (NMR) is a 
non-ionising radiation method, which utilises strong magnetic fields and radiowaves 
to create diagnostic images. Two physicists Felix Bloch and Edward Mills Purcell 
simultaneously discovered MRI, for which they received Nobel Prize for Physics in 
1952. Herman Carr in 1952 first produced a 2-dimensional image in his Harvard 
thesis (Carr 1952368). Sir Peter Mansfield, Professor in University of Nottingham, 
United Kingdom developed a mathematical technique for speedy imaging 
acquisition and was awarded Nobel Prize in 2003 along with Paul Lauterber. 
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Figure 2.2.2 Bitar et al 2006369: Basic physics of the MR signal. (a) As 1H nuclei 
spin, they induce their own magnetic field (tan), the direction (magnetic axis) of 
which is depicted by an arrow (yellow). The 1H nuclei initially precess with a 
wobble at various angles (1–6), but when they are exposed to an external magnetic 
field (B0), they align with it. The sum of all magnetic moments is called the net 
magnetization vector (NMV). (b) When an RF pulse is applied, the net 
magnetization vector is flipped at an angle ‘α’, which produces two magnetization 
components: longitudinal magnetization (Mz) and transverse magnetization (Mxy). 
As the transverse magnetization precesses around a receiver coil, it induces a current 
(i). When the RF generator is turned off, T1 recovery and T2 and T2* decay occur. 
 
MRI is based on electromagnetic activity of atomic nuclei. Atomic nucleus has 
protons and neutrons, which have spins (wobbles). Odd numbered protons 
(Hydrogen, Fluorine, Phosphorous etc.) are preferred in MRI, as they do not cancel 
out with their neutron counterparts (Bouni et al 1992370). Hydrogen nuclei are most 
commonly used because of their abundance in the body (water). Protons are 
positively charged and their spin creates a magnetic field. When an external 
magnetic field is applied in a particular direction (B0), horizontally by an electric 
current in the case of MRI scanner, protons start to spin along, or wobble along the 
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lines of magnetic field, a phenomenon called ‘precess’. The frequency in which they 
precess is obtained from Larmor equation (Sands et al 2004371). 
 
  Precession frequency (ω0) = External magnetic field (B0) x Constant (γ)   
  (MHz)                                   (Tesla)                                        (42.5)                
 
The precession frequency of Hydrogen proton is 42.5 MHz in a magnetic field 
strength of 1 Tesla (42 million times per second). As illustrated in Figure 2.2.2, 
following the external magnetic field B0, all protons arrange themselves parallel or 
antiparallel to B0, and following cancellations of both parallel and antiparallel proton 
charges, the net effective direction is called Net Magnetic Vector (NMV), which is 
usually in the direction of B0, which is called ‘Longitudinal Magnetization’(Sands et 
al 2004371). 
 
When a radiofrequency (RF) wave is applied transversely in this field imparting ‘in 
phase’, NMV flips to a certain angle towards the direction of RF impulse causing 
‘Transverse Magnetization’. The protons continue to spin albeit facing the coil in the 
MRI from which RF is transmitted, and this moving magnetic field results in 
creation of current/electric impulse, which is the Magnetic Resonance (MR) signal 
(Bouni et al 1992370).  
 
When RF signal is switched off, NMV gradually reverts back to Longitudinal 
magnetization direction of B0. The time taken by NMV for 63% of Longitudinal 
relaxation to occur is called T1, or ‘Longitudinal Relaxation Time’ or ‘Spin-Lattice 
Relaxation Time’. Spin-lattice relaxation occurs as a result of exchange of thermal 
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energy to surrounding lattice from protons, which received energy originally from 
the RF waves. T1 depends on i) Water quantity ii) structure iii) surroundings of the 
tissue (Bitar et al 2006369).  
 
A simultaneous phenomenon when the RF signal is switched off is the Transversal 
relaxation when the NMV reverts to its original longitudinal direction from 
transverse position, and the time taken for 37% of this transversal relaxation process 
to happen is called T2, also called ‘Spin-Spin relaxation’. T2 depends on i) External 
magnetic fields and ii) Local magnetic fields. (Sands et al 2004371).  
 
Various tissues exhibit different T1 and T2 times, coupled along with proton density 
of Hydrogen nuclei in the tissue forms the basis for different contrast obtained in 
MR images. T1 (300-2000 milliseconds) is 2 to 10 times as long as T2 (30-150 
milliseconds). Water has a long T1 and T2, and fat has short T1 and T2 times.  
 
Repetition Time (TR) and Echo Time (TE) are the two key parameters in creation of 
a contrast image. TR is the time to repeat RF pulse sequence, and TE is the time 
from RF pulse to the time to detect a peak echo. The factors that influence signal 
intensity are T1, T2, proton density, flow, pulse sequence, TR, TE, flip angle and use 
of contrast media. Larger flip angles produce more T1-weighting, and longer TEs 
produce more T2*-weighting, which are special type of Gradient Echo sequences 
(Bitar et al 2006369). The imaging time is obtained from the equation: 
 
Acquisition time (a.t) = Repetition time (TR) x No of rows in an image (N) x No of 
excitations (Nexcitations). 
! 82!
2.2.3 Iterative Decomposition with Echo Asymmetry and Least Squares 
Estimation (IDEAL) MRI  
 
WAT is a lipid reservoir, and is made of cells with single large intracellular lipid 
droplet, whereas BAT is highly vascularised iron containing tissue possessing 
smaller intracellular lipid droplets and more water content. This difference in water-
fat content is exploited in a special form of MR imaging called IDEAL MRI. It is a 
type of chemical shift MRI (modified Dixon technique), which delivers 
computationally robust, consistent and accurate fat/water separation. This clear 
advantage of uniform fat suppression is clinically used in diagnosing and 
characterizing adrenal adenomas, hepatic steatosis, renal angiolipomas, soft tissue 
lipomas and ovarian teratomas.  
 
2.2.4 Proof of concept of IDEAL MRI study on Rat fat samples 
 
BAT and WAT from samples taken from sacrificed rats can be clearly delineated 
from one another, and provide distinct signals when imaged with existing technology  
This has already been demonstrated by Hu et al. using 6-echo IDEAL MRI (Hu et al 
2011206).  
For this purpose, following a normal feeding regimen 2 male Wistar rats (mean mass 
300g, age 6-8 weeks) were used. One was kept at thermoneutrality (30°C) for 8 
hours; the other was kept in the cold (4°C) for 8 hours. Both rats were sacrificed, and 
fat samples were dissected to extract Interscapular BAT, Subcutaneous WAT and 
Omental WAT. The samples were collected into 2 sets of 3 x 2 ml eppendorfs (cold 
and thermoneutral), and were photographed to demonstrate the macroscopic 
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difference between BAT and WAT. The specimens from rat kept in the cold, was 
transported to the MRI scanner on ice, while those from the rat kept at 
thermoneutrality, was transported at ambient temperature. 
 
All MR imaging was carried on 3T GE HDxt scanner (GE, Milwaukee, USA). Ex 
vivo MR scanning of the cold and thermoneutral rat carcasses, and dissected 
phantom samples (“rat test tubes”) was performed on Optima MR360 3T MR 
scanner using the IDEAL settings. The images had a 2.0mm slice width and 150mm 
square field of view and 256x256 matrix. 
 
2.2.5 Subject recruitment and Positron-emission tomography scanning  
 
Following written informed consent, a 25-year old female who underwent 
parathyroidectomy surgery for primary hyperparathyroidism, was recruited for MRI 
study. She underwent PET scan first for clinical indication to rule out malignancy. 
PET-CT image acquisition was conducted as per the protocol outlined in Chapter 
2.1.6. PET images were reconstructed using the computed tomography (CT) data for 
attenuation correction. PET image analyses, including BAT volume and BAT 
SUVmax estimation was done as outlined in Chapter 2.1.8. This part of methodology 
is further discussed in Chapter 4.2. The study was reviewed and approved by the 
Black County Research Ethics Committee (Rec No. 11/H1206/3). 
 
2.2.6 Magnetic resonance scanning of the study subject 
 
A 3-echo IDEAL sequence (Reeder et al 2005, Reeder et al 2004)372,373 was 
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performed on a 3T GE HDxt scanner (General Electric Medical Systems, 
Milwaukee, USA). The cardiac coil was placed around the cervical and upper 
thoracic regions. Axial images with a 5mm slice thickness were obtained from the 
upper cervical to mid-thoracic level. The T1 weighted IDEAL sequence parameters 
were: TR 440 ms, TE 10.8 ms, acquisition matrix size 320 x 256, NEX 3 and field of 
view of 30 cm. This generated water-only and fat-only (fat:IDEAL) images, of 
which the latter were used for subsequent analysis. 
 
A baseline MR scan was performed the same month as the PET-CT (December), 
upon which subsequent image analysis was performed. A second MR was performed 
2 months later using identical imaging parameters (apart from the field of view 
which was 34 cm), to determine whether there was any temporal variation in the 
distribution of BAT. 
 
PET-MR image co-registration, prospective and retrospective image analyses are 
further outlined in Chapter 4.2. 
 
2.2.7 Histology and Immunohistochemistry 
 
Histology and immunohistochemistry were performed on tissue obtained during 
parathyroidectomy, corresponding with high 18F-FDG uptake on the PET-CT scan 
and low-signal intensity on the fat-only MRI. Samples were prepared for 
morphology by keeping in formalin until moulded in paraffin and stained with 
haematoxylin-eosin (HE). For immunohistochemistry, Vectastain Elite ABC Kit 
(Vector Laboratories, PK-6101) and rabbit anti-UCP1 (1:500, Sigma U6382) were 
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used according to the manufacturer’s protocol. UHCW Histopathology department 
undertook the above examination and staining of the tissue as per hospital protocols.  
 
 
2.3 Meal Duration Study 
 
2.3.1 Introduction 
 
A clinical trial was conducted with obese female subjects. Only White Caucasian 
women were included in the study to reduce variability with gender and ethnicity. 
Each subject attended for two visits within a two-week period, and spent 8 hours in 
room calorimeters (9am to 5pm) for the assessment of energy expenditure and 
repeated blood sampling. Balanced standard meal was provided, and the subjects 
were instructed to eat the entire meal in 40 minutes in the first visit and in 10 
minutes in the subsequent visit. Regular blood sampling was conducted at fixed 
times over  the 4-hour postprandial period. Complete data from each visit was 
available for the 10 subjects. The study was reviewed and approved by the Black 
County Research Ethics Committee (Rec No. 11/H1206/3). 
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2.3.2 Inclusion and Exclusion Criteria 
 
Inclusion Criteria 
White Caucasian women 
Age 18-50 years  
BMI 30-50 kg/m2 
Premenopausal     
 
Exclusion Criteria 
Age <18 or >50 years 
Diabetes or dysglycaemia (HbA1c >6.0% or fasting glucose >6mmol/L)  
Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid 
problems, Cushings syndrome, PCOS, Obstructive Sleep apnoea etc) 
Prior bariatric surgery 
Chronic inflammatory disorders e.g. rheumatoid arthritis, or long term use of 
steroids or other immunomodulators like cyclosporine, azathioprine. 
Cholesterol lowering medication, anti-diabetes medications (oral or injectable), 
Beta-blockers 
Recent significant change in weight (>2.5 kg in 3 months) 
Vegans or vegetarians 
Depression or any psychiatric illness 
Claustrophobia or needle phobia 
 
Participants were recruited from Obesity Clinic in University Hospitals Coventry 
and Warwickshire (UHCW) National Health Service (NHS) Trust. Only women 
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subjects were recruited to study a focused group with the intent of reducing 
variability. Also, at the time of recruitment, approximately 78% of overall patients 
attending UHCW obesity clinics were women. Obese subjects were chosen for study 
participation, as the effects of meal duration intervention was intended to be studied 
first in the obese population, prior to exploration in lean and male subjects. As per 
the power calculations, 10 subjects had >80% power to detect a between-meal 
duration difference exceeding 50% of a Standard Deviation (SD) for plasma glucose 
from D10 and D40 (alpha=0.05). A total of 53 consecutive women in the age range 
of 18-50 years, and BMI range of 30-50 kg/m2 were approached during their 
outpatient visits. 21 women declined to participate, and 22 had one or more 
exclusion criteria, and therefore excluded. A total of 10 were recruited following 
written consent. 
 
2.3.3 Meal Duration Study Protocol 
 
The 10 study subjects were advised not to undertake vigorous exercise, or alter their 
lifestyle between visits. They were given lifestyle and dietary advice at the end of the 
study. Fasting glucose and HbA1c was measured in all subjects to rule out diabetes 
or dysglycaemia. Subjects with HbA1c <6.0% and fasting glucose <6mmol/L were 
considered not to have diabetes or dysglycaemia in accordance with the WHO 
criteria for diagnosis of diabetes (WHO guidance on use of HbA1c to diagnose 
diabetes mellitus 2011374).  
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Study Visit 1   Recruitment/Consent 
 
Following scrutiny of the inclusion/exclusion criteria, informed consent was 
obtained from eligible subjects. Baseline demographic information was collected as 
well as anthropometry including: weight, height, BMI, waist circumference, neck 
circumference (for obstructive sleep apnoea), hip circumference, blood pressure and 
BODPOD measurement. Fasting blood was taken for glucose, HbA1c, complete 
lipid profile, renal function, liver function, thyroid function, insulin growth factor-1 
(IGF-1) and bone profile as well as Vitamin D status. The subjects were shown 
around Human Metabolism Research Unit (HMRU) at UHCW.  
 
Study Visit 2  
   
Subjects attended HMRU at 8am after a light evening meal and overnight fast from 
10 pm the previous night. Following body composition measurement in the 
BODPOD, an intravenous cannula was inserted and fasting blood test obtained. 
Subjects were allowed to enter the calorimeter room at 8.45am. Measurements of 
energy expenditure began at 9am. On entry into the WBC and for the first 120 
minutes of the metabolic study, each subject was requested to lie still on the bed to 
allow for equilibration and to provide an estimate of baseline resting energy 
expenditure (REE). At 12 pm, the standard meal (ham sandwich, yoghurt, banana, 
crisps, and orange juice drink) was given. The caloric content was divided equally 
into eight separate food boxes, the food contents of each box eaten over 5 minutes 
for a total meal duration of 40 minutes (the lunch being completed by 12:40 pm). 
This is referred to as ‘D40’. Subjects were provided with timers and were monitored 
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to ensure compliance with eating rate. Subjects were instructed to vary chewing 
speed accordingly. Blood was drawn from indwelling cannula at baseline, 30, 60-, 
90-, 120-, 180- and 240-minute intervals- a total of 7 times. During pre- and 
postprandial periods, subjects watched TV or read quietly with minimal ambulation. 
At 5 pm, after total duration of 8 hours in the room calorimeters, subjects were 
invited to leave and offered an ad libitum standard buffet meal, consisting of various 
cold foods (sandwiches, chocolate bars, fruit, sausage rolls and drinks). The caloric 
content and macronutrient composition of the ad libitum food ingested was 
calculated. They also completed a visual analogue scale (hunger, satiety and 
fullness) at 10 set time points throughout the study including post-buffet meal.  
 
Study Visit 3   
 
For the second metabolic assessment, as in the previous visit, subjects attended the 
HMRU at 8am after a light evening meal and overnight fast from 10pm. An identical 
protocol was followed except that the duration of the standard lunch was 10 minutes 
rather than 40 minutes. For this assessment, the caloric content of the standard meal 
was divided into two halves, with the food contents of each box being eaten over 5 
minutes for a total meal duration of 10 minutes (the lunch being completed by 12:10 
pm). This is referred to as ‘D10’. Again with an indwelling intravenous cannula, 
blood samples were taken at 7 time points in the 4-hr postprandial period similar to 
the Visit 2. The subjects also completed the visual analogue scale similar to Visit 2. 
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2.3.4 Anthropometric Assessment 
 
Anthropometric assessments were undertaken in all subjects at the start of the study, 
with measurements of height on a wall mounted stadiometer, weight, waist 
circumference, hip circumference including calculation of body mass index (BMI in 
kg/m2) and waist hip ratio.  
 
2.3.5 Assessment of Body Composition Using the BODPOD 
 
At visit 2, accurate assessment of body composition was undertaken using the 
BODPOD (Air displacement plethysmography, Cosmed Inc, USA)375 (Fields et al 
2002). A finely calibrated weighing scale initially calculated the total mass, and the 
body volume was calculated using air volume displacement to calculate density. For 
these calculations, estimated lung volumes were used. All subjects wore swimming 
costumes or tight fitting lycra with a swimming cap, as advised by the manufacturer, 
as volume is affected by clothing and hair. Fat mass and fat free mass (lean mass) 
was calculated using the Siri equation, with a reported margin of error of only 1% 
(Siri et al 1961376). The Siri equation is as follows,   
Body fat percentage = (4.95/density − 4.50) × 100        (density measured in gm/cm3) 
 
2.3.6 Assessment of Energy Expenditure using Whole Body Calorimeter 
 
HMRU, a UHCW NHS Trust facility, houses two Whole-Body Calorimeter (WBC) 
rooms, built in partnership with Warwick Medical School, University of Warwick. 
The twin rooms are approximately 2m X 3m X 2.5m in dimensions, each equipped 
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with a bed, desk, chair, television, computer with internet connection, telephone, 
sink and toilet. Each WBC room replicates free-living envionment, and is 
hermetically-sealed to the outside environment. Double-doored hatches enable food 
to be delivered in and waste out. The rooms are linked to both the hospital fire alarm 
and emergency life support crash call system, for safety purposes. Experiments were 
held under constant supervision, and all subjects were given a health and safety 
briefing prior to entering the room. 
Throughout the experiment, the temperature in WBC room was regulated at 24°C, 
maintained within 0.5°C, and humidity was maintained at 57 ± 5%. The room was at 
a slight under pressure, 250 Pa below ambient. There was a constant flow of air 
going into the room at 117 L/min to ensure the air was thoroughly mixed to give 
more accurate readings of air that came out of the room. Physical activity was 
measured utilising analog ultrasound doppler system (Advisor DU160, Aritech BV, 
Roermond, Netherlands). Thermoneutral temperature (24°C) and relative humidity 
(57%) were kept constant. 
 
Automated calibration was performed in the WBC rooms, during the studies, every 5 
minutes in 3 ways. Initially nitrogen was passed into the analyser to give a 0 reading 
of O2 and CO2, subsequently scientific air was passed into the analyser to give a 
known concentration of 18% O2 and 0.8% CO2, and finally fresh air was passed into 
the analyser to give known concentrations of 21% O2 and 0.3% CO2 (Schofflen et al 
1997377). Using methanol combustion, whole room calibration was undertaken once 
a month. Pure methanol was burnt in each room for 24 hours, and the weight of 
methanol burnt was calibrated to the amount of O2 consumed and CO2 produced. 
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Methanol when burnt uses O2 and gives out CO2 whilst also producing small 
amount of moisture, replicating human respiration levels. 
 
Air coming out of WBC was analysed by the system consisting of model A0 2020 
dual pairs of infrared CO2 (ABB/Hartmann and Braun Uras, Frankfurt A.M., 
Germany) and paramagnetic O2 analysers (Servomex 4100, Crowborough, England 
and ABB/Hartmann and Braun Uras, Frankfurt A.M., Germany). Flow was 
measured utilising electronically modified dry gasmeters (G6, gasmeterfabriek 
Schlumberger, Dordrecht, Netherlands). Data acquisition was performed using 
custom built interfaces (IDEE, University of Maastricht, Netherlands), a computer 
(Apple Macintosh, Cupertino, United States) and graphical programming 
environment (Labview, National Instruments, Austin, United States). The vital gas 
levels of O2 and CO2 were sampled every minute and analysed, and an average 
reading was calculated for every 30 minutes to reduce variability in data inherent to 
such a large volume of air in the room compared to the small differences in respired 
air. Accurate minute-by-minute measurements of CO2 and O2 from air entering at 
inlet and air leaving the WBCs at outlet was undertaken. These gas measurements 
were used to calculate energy expenditure (including DIT) by using Weir’s equation 
(Weir et al 1949378). 
 
The Weir Formula used to calculate Energy Expenditure (EE) is: 
EE (Kcal) = [3.941 X O2 consumed (L)] + [1.106 X CO2 produced (L)]. 
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2.3.7  Calculation of Energy Expenditure including Diet Induced 
Thermogenesis (DIT)  
 
Pre- and postprandial energy expenditure (Kcal) was calculated using O2 and CO2 
gases using Weir’s equation. Resting Metabolic rate (RMR) was calculated using the 
lowest 30 minutes during the first 120 minutes of the study when the subjects were 
lying still on the bed. DIT (difference between postprandial and baseline EE) was 
calculated using validated methods reported in literature, and also expressed in 
percentage of energy intake ([Postprandial EE-Baseline EE]/Amount of calorie 
ingested) (Marno et al 2002220, Ravn et al 2013379). Although the units for EE 
represents power (Kcal/24 hours) instead of energy (Kcal), EE is used throughout the 
script without mentioning ‘over the 24 hours’, in order to be consistent with the 
literature.  
 
2.3.8 Assessment of Hunger, Fullness, Appetite and Satiety 
 
Visual analogue scales for hunger, fullness and satiety were completed by subjects at 
10 time points at both visits: -180 min, -60 min, -10 min, 0 min, 30 min, 60 min, 120 
min, 180 min, 240 min, and post buffet, with ‘0’ being the meal reference point. 
Mean and standard deviation of the scores at the above set time points pre- and 
postprandial were analysed. 
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2.3.9 Buffet meal 
 
At 1700h, subjects were invited to leave the WBC and offered an ad libitum standard 
buffet meal, consisting of various cold foods (sandwiches, chocolate bars, fruit, 
sausage rolls and drinks). The caloric content and macronutrient composition of the 
ad libitum food ingested was calculated.  
 
2.7.10 Statistical analyses and power calculation 
 
Statistical analyses were conducted in SPSS (version 21 Windows; SPSS Inc., 
Chicago, IL) and Microsoft Excel. Paired sample t-tests were used for comparisons 
of 4-hour postprandial ‘Area Under the Curve’ (AUC) metabolic and biochemical 
data between D40 and D10. Each subject acted as their own control thereby limiting 
confounding. We had >80% power to detect a between-meal duration difference 
exceeding 50% of a Standard Deviation (SD) for plasma glucose from D10 and D40 
(alpha=0.05). A P-value <0.05 was considered significant. AUC was calculated 
using the validated Trapezoid method in Excel (Pruessner et al 2003380). Variables 
are expressed as mean ± standard error of mean (SEM) unless otherwise specified. 
 
2.7.11 Collection of Human Blood samples 
 
For serum sample preparations, whole blood was drawn into a BD-vacutainer® (BD, 
UK) serum tube containing silica clot activator.  Blood was allowed to clot at room 
temperature for 30 minutes. Once clotted, the samples were centrifuged at 20°C and 
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2000rpm for 10 minutes. Supernatant was carefully drawn off; flash frozen and then 
stored in labelled 1.5 mL eppendorfs at -80°C.  
 
For plasma sample preparations, whole blood was similarly drawn into a BD-
vacutainer® (BD, UK) plasma tube containing EDTA. Samples were immediately 
centrifuged at 20°C and 2000rpm for 10 minutes. Supernatant was carefully drawn 
off; flash frozen and then stored in labelled 1.5 mL eppendorfs at -80°C. 4-(2-
aminoethyl)-benzenesulfonylfluoride hydrochloride (Pefabloc SC) and dipeptidyl 
peptidase-IV inhibitor were added to chilled EDTA tubes for measurements of 
pancreatic and gut hormones. 
 
2.7.12 Biochemical evaluation 
 
Fasting baseline serum samples taken at the first metabolic study for each subject 
were analysed for lipid profile (Total Cholesterol, LDL Cholesterol, HDL 
Cholesterol and Triglycerides), HbA1C, glucose, 9 am cortisol, IGF1, TSH, free T4, 
Testosterone, Sex Hormone Binding Globulin (SHBG) and 25-
hydroxycholecalciferol. Postprandial and pre-lunch blood samples (D40 and D10) 
were analysed for Insulin, Glucose, Total Cholesterol, LDL Cholesterol, HDL 
Cholesterol, Triglycerides, Endotoxin and NEFA. The analyses for these two panel 
of analytes were undertaken by the biochemistry department of UHCW NHS Trust 
laboratories. The individual assay techniques and kits used are mentioned further in 
Chapter 5. 
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2.7.13 Multiplex assay 
 
Postprandial and pre-lunch blood samples (D40 and D10) were also analysed for 
Ghrelin, Leptin, PYY, PP, GLP-1, Adiponectin, Cortisol were undertaken by 
researchers in CIBER Fisiopatología Obesidad y Nutrición (CB06/03), Instituto de 
Salud Carlos III (ISCIII), Santiago de Compostela, Spain (F·F·C, M·C·C). The gut 
hormone panel was analysed using Luminex Multiplex Assay technique.  
 
Using a 96-well format, a multiplex assay is a type of assay that simultaneously is 
capable of providing quantitative measurements of multiple analytes in a single 
run/cycle of the assay. Luminex-XMAP is bead based multiplexing, where beads are 
internally dyed using fluorescent dyes to produce a specific spectral address. 
Biomolecules (such as an oligo or antibody) can be conjugated to the surface of 
beads in order to capture analytes of interest. This technology uses flow cytometric 
or imaging technologies for characterization of the beads as well as detection of 
phycoerythrin emission due to analyte presence (Elshal et al 2006381). 
 
2.7.14 Endotoxin assay 
 
Serum endotoxin was analysed using a chromogenic limulus amebocyte lysate 
(LAL) test, which is a quantitative test for gram-negative bacterial endotoxin 
(Cambrex, New Jersey, USA). This assay is based on an ELISA principle. Gram-
negative bacterial endotoxin catalyzes the activation of a proenzyme in the LAL. The 
initial rate of activation is directly determined by the concentration of endotoxin. The 
activated enzyme catalyzes the splitting of p-nitroaniline (pNA) from the colourless 
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substrate Ac-lle-Glu-Ala-Arg-pNA. The pNA released was measured 
photometrically at 405–410 nm following termination of the reaction. The 
correlation between the absorbance and the endotoxin concentration is linear in the 
0.1–1.0 EU/mL range (intra-assay CV 3.9 ± 0.46%, inter-assay CV 9.6 ± 0.75%) 
(Creely et al 2007382). Lyophilized endotoxin (E. coli origin) was utilised to generate 
a standard curve with chromogenic LAL test kit from Cambrex, and this produced a 
corresponding curve in keeping with the manufacturer's instructions. All samples 
were run in duplicate within the same plate; therefore, no inter-assay variability was 
observed in this study.  
 
2.7.15 Measurement of Insulin Resistance 
 
Insulin resistance was calculated as per Homeostatic model assessment method 
(HOMA-IR) (Matthews et al 198549) using the following equation: 
HOMA-IR = [Fasting glucose (mmol/L) X Fasting Insulin (pmol/L)]/22.5 
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Chapter 3 
 
 
 
DETERMINANTS OF HUMAN BROWN ADIPOSE 
TISSUE BASED ON PHYSIOLOGIC 18F-FDG UPTAKE 
IN SEQUENTIAL PET-CT EXAMINATIONS 
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3.1 Introduction 
 
The formidable interest in BAT is from the hope that it is probably thought to be the 
panacea for obesity, given the energy expending, glucose and lipid clearance 
properties (Orava et al 2013168, Bartelt et al 2011242, Ouellet et al 2012232). 
Hybridisation of CT and PET was probably the defining moment in BAT research 
field. This technological advance resulted in anatomical integration of CT into the 
functional element of PET. The cervical and mediastinal high physiological uptake, 
which was noted for several decades in PET studies alone, was actually proven to be 
arising from adipose tissue, contrary to conventional thinking of skeletal muscle 
origin (Hany et al 2002)161.  As discussed in Chapter 1.4.2 and illustrated in Table 
1.5.1, this led to series of PET-CT studies (also involving immunohistochemical 
methodologies) which proved BAT presence in adults, and banished the myth of 
BAT disappearance from infants on reaching adulthood (Cypess et al 2009, Hadi et 
al 2007, Saito et al 2009, Virtanen et al 2009, Zingaretti et al)140,141,143,144,254. The 
challenge now is to manipulate BAT activity in order to achieve the hypothesized 
metabolic benefits.  
 
Current PET-BAT research is trying to address this particular challenge, and 
evidence from last few years whilst promising, has largely remained inconclusive, 
specifically as to the role of determining factors of BAT prevalence and activity. The 
reported prevalence of BAT taking up 18F-FDG in adults varies considerably. In the 
observational studies with large cohorts of patients evaluated for cancer, 18F-FDG 
BAT prevalence is low (ranging between 2 and 10%), whereas in prospective studies 
involving young subjects, the prevalence is reported to be very high (close to 
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100%)(van Marken Lichtenbelt et al 2009)142. Interventional studies examining two 
important triggers of BAT activation: cold exposure and increased sympathetic drive 
(Cannon et al 2004)149 showed higher prevalence (40 to close to 100%).  
 
BAT’s role in CIT is well validated and cold exposure increases BAT prevalence as 
noted in prospective as well as retrospective observational studies (Cypess et al 
2009141, Persichetti et al 2013383van Marken Lichtenbelt et al 2009)142. A review 
analysis of 8 retrospective PET studies suggested outdoor temperature to be the most 
vital determining factor of PET detected BAT uptake (Huang et al 2011)384. There 
was also seasonal variation noted with BAT detection increased in winter months 
than in summer (Au-Yong et al 2009190). It was thought that only temperate 
countries would have higher prevalence, but a recent Chinese study analysing over 
30,000 scans showed similar prevalence rates (2.6%), albeit slightly lower (Zhang et 
al 2014385). Mediterranean BAT prevalence rate (3.4%) also reflected the general 
trend.  
 
Perhaps, lifestyle parameters and other clinical factors dictate PET detected BAT 
prevalence and activity. Factors such as sex (Cypess et al 2009141, Persichetti et al 
2013383van Marken Lichtenbelt et al 2009)142, age (Cypess et al 2009141, Virtanen et 
al 2009140, Persichetti et al 2013383, van Marken Lichtenbelt et al 2009142, Ouellet et 
al 2011166), and body mass index (BMI) (Cypess et al 2009141, Virtanen et al 2009140, 
Persichetti et al 2013383, van Marken Lichtenbelt et al 2009142, Ouellet et al 2011166) 
have known to play a role in BAT’s detection through PET. Plasma glucose (Jacene 
et al 2011200, van der Veen et al 2012386), and day length (Au-Yong et al 2009190) are 
also suggested to be determinants of 18 F-FDG uptake in BAT. Nonetheless, there is 
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still controversy with regard to the relative importance of all those factors in 
determining the prevalence, mass, and glucose-uptake activity of 18 F-FDG PET 
BAT.  
 
Thyroid hormones are vital regulators of basal metabolism and play a significant role 
in thermogenesis during both shivering and non-shivering adaptation to cold. A 
small alteration in free thyroid hormone levels cause significant changes in tissue 
oxygen consumption, lipid oxidation and heat production (al-Adsani et al 1997387). 
As mentioned in Chapter 1 Section 1.8.3, role of thyroid hormones on BAT 
regulation is well recognized in animal studies: D2 is required for conversion of T4 
to T3, and TRβ receptor is required for UCP1 induction (Cannon et al 2004149). In a 
case report, BAT activation on PET was noted following thyroxine replacement 
therapy in a post-thyroidectomy hypothyroid patient with papillary carcinoma 
(Skarulis et al 2010266). In the only dedicated human study so far investigating direct 
role of thyroid hormones on BAT, 10 hyperthyroid patients showed 3-fold higher 
glucose uptake on PET, which was reversed on treatment of thyrotoxicosis. 
However, the study also showed 90% higher skeletal muscle glucose uptake and 
significantly higher skeletal muscle perfusion than BAT. The study concluded, that 
thyroid hormones of free T4 and Free T3 activated BAT, but to a lesser degree than 
BAT activation by cold exposure (Thyrotoxic state BAT glucose uptake versus Cold 
exposure BAT glucose uptake: 3-fold versus10- to 15-fold respectively). Whether 
these findings can be replicated in a clinical setting needs to be determined. One can 
currently hypothesise that thyroid hormones may play a role in BAT stimulation in 
humans, but this needs to be further clarified. 
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Therefore the hypothesis for this set of studies was that: 
 
1. Cold outdoor temperatures stimulate BAT through cold induced 
thermogenesis, and therefore may result in weight loss. 
2. Age, Sex, BMI may have a role in human BAT prevalence, quantity and 
function. 
3. Thyroxine hormone may have a role in stimulating BAT activity and mass. 
 
Therefore the aims of these studies were: 
1. To examine the determinants of the prevalence, mass, and glucose-uptake 
activity of 18F-FDG-detected BAT in a large cohort of subjects who 
underwent PET/CT examination for cancer diagnosis and staging.  
 
2. To ascertain whether iatrogenic thyrotoxic state resulting from 
levothyroxine/levothyronine therapy in post-thyroidectomy patients, 
increases 18F-FDG-detected BAT prevalence, activity and mass.  
 
 
 
 
 
 
 
 
 
! 103!
3.2 Methods 
 
3.2.1 Subjects data collection  
 
Methodology for this part of the study was discussed in detail in Chapter 2.1. In 
brief, consecutive 18F-FDG-PET/CT whole-body scans were performed on 2685 
patients (1497 males, 1188 females) for various diagnostic reasons between June 
2007 and August 2012, at UHCW NHS Trust PET centre. Data on age, sex, BMI, 
fasting glucose level, scan date and scan timing were obtained for all patients. BMI 
was categorised based on WHO (as illustrated in Chapter 1.1.4) and National 
Institute of Health criteria into 4 groups (Underweight ≤18.5; Normal=18.6-24.9; 
Overweight=25-29.9;Obese≥30, The Evidence Report, National Institutes of 
Heath360). Glycaemic group was categorised on American Diabetes Association’s 
criteria (Normoglycaemia<5.5 mmol/L; Impaired Fasting Glycaemia≥5.5-6.9 
mmol/L; Diabetes Mellitus≥7.0 mmol/L). Lean Body Weight and Basal Metabolic 
rate was calculated using validated equations (Ouellet et al 2011166, Roza et al 
1984361). Outdoor temperature in Coventry for the day of the scan was obtained from 
United Kingdom Meteorological Society. For the 151 patients who were detected to 
have putative BAT, electronic and medical records were reviewed for other relevant 
past medical history, drug history, smoking status, fasting lipid profile, and 
biochemical thyroid profile.  
 
Out of 229 patients who were treated for thyroid cancer in UHCW during the same 
period, 34 patients underwent PET scans, whose notes and electronic records were 
reviewed irrespective of their BAT status. This small group was further classified 
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into Thyrotoxic and Euthyroid subgroups, depending upon patients’ biochemical 
thyroid status at the time of the scan.  
 
3.2.2 PET-CT imaging protocol 
 
As outlined in Chapter 2.1.6, in accordance with standard administration and 
acquisition protocol, the subject was fasted for 6 hours, weight adjusted amount of 
18F-FDG radiotracer was injected one hour prior to the PET scan. PET was 
performed on a GE Discovery STE PET-CT scanner (General Electric Medical 
Systems, Milwaukee, USA). Two sets of emission data were obtained for 3 minutes 
in each bed position; from the skull base to mid thigh (with arms elevated).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2 van Marken Lichtenbelt et a 2009 (A) PET, (B) CT, and (C) integrated 
PET-CT scans, with BAT location indicated  
!
!
!
A 
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C 
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3.2.3 Image analyses  
 
The protocol for this part of the methodology is as detailed in Chapter 2.1.8. All 
PET/CT scans were initially reported by a Consultant Radiologist, possessing 
expertise in nuclear imaging as part of the patients’ routine clinical care. For the 
purposes of this study each PET/CT scan was re-evaluated by second radiologist to 
confirm the presence of 18F-FDG BAT. PET images were reconstructed using the CT 
data for attenuation correction. Areas of more than 5 mm with a CT density of 
adipose tissue (-100 to -10 Hounsfield units), and had maximal Standard Uptake 
Value (SUV) of 18F-FDG of at least 2.5 g per milliliter was considered as 18F-FDG 
detected BAT. Volume and activity of BAT were quantified with image fusion 
software Mirada XD 4·3 (Mirada Medical Ltd, Oxford, UK) in user-defined regions 
of interest by autocontouring in the cervical, supraclavicular and superior 
mediastinal depots as illustrated in Chapter 2, Figure 2.1.10.a and Figure 2.1.10.b. 
BAT mass was calculated based on assumption of density of fat being 0.92 g per 
milliliter (Ross et al 1984367).  
 
3.2.4 Statistical analyses 
 
The recorded data were entered into Microsoft excel spreadsheet. The data were 
analysed using SPSS IBM software Version 22 (SPSS Chicago, IL). Normally 
distributed continuous variables were compared between study groups with the use 
of Student’s t-test, and non-normally distributed variables were compared with 
Mann-Whitney U test. The roles of sex, age, BMI, fasting glucose, outdoor 
temperature as predictors of BAT prevalence were tested by logistic regression with 
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the use of univariate and multivariate models. For multivariate analyses of BAT 
mass, logarithmic transformation of the data was done as the scores were non-
normally distributed. The patients were also divided into four BMI groups 
(Underweight, Normal, Overweight and Obese), and also Fasting Glucose level 
(Normoglycaemia, Impaired Fasting Glycaemia, and Diabetes); Kruskal Wallis was 
used to compare between the categories for BAT mass and BAT activity. Missing 
values were dealt with pairwise deletion method using SPSS software. Odds ratio 
and Confidence Intervals were estimated as measures of magnitude of associations. 
All P values presented are two-tailed, and values less than 0.05 are considered to be 
statistically significant. 
 
3.3 Results 
 
3.3.1 General Characteristics and overall study parameters  
 
18F-FDG BAT was observed in 151 out of 2685 patients (5.6%) in a total of 175 out 
of 3295 scans (5.3%). The main biophysical, PET scan and environmental 
parameters are enlisted in Table 3.3.1. Generally individuals with BAT 18F-FDG 
uptake were on an average younger, had lower BMI, and had lower fasting glucose 
levels than BAT negative group. Lower outdoors temperatures and lesser sunshine 
was also noted in the BAT positive group.    
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Table 3.3.1 Characteristics of BAT positive and BAT negative patients based on 
18F-FDG BAT uptake  
Total 18F-FDG PET 
scans (n=2685) 
BAT Negative PET 
scans (n=2534) 
BAT Positive PET scans 
(n=151) 
Characteristics Mean SEM Mean SEM 
Age (yrs) 63.4 0.3 50.8 1.5 
Weight (kg) 76.1 0.3 66.6 1.1 
Height (cm) 168.7 0.2 165.0 0.8 
Body Mass Index (kg/m-
2) 
26.7 0.1 24.4 0.4 
Lean body mass (kg) 54.2 0.2 47.8 0.7 
Basal Metabolic rate 
(Kcal/24hr) 
1505 6 1395 19 
Fasting Glucose 
(mmol/L) 
5.7 0.0 5.3 0.1 
Diabetes (%) 10.3 NA 3.9 NA 
No of PETs undertaken 1.2 0.0 1.6 0.1 
18FDG dose (MBq) 363.3 0.6 360.6 2.7 
SUV mean (g/ml) NA NA 3.0 0.0 
SUV maximum (g/ml) NA NA 7.4 0.3 
SUV volume (cm3) NA NA 77.5 8.5 
BAT mass (0.92g/ml) NA NA 71.3 7.8 
Total Lesion Glycolysis 
(g) 
NA NA 263.1 32.3 
Minimum temp on scan 
date (°C) 
6.1 0.1 4.3 0.4 
Mean temp on scan date 
(°C) 
9.9 0.1 7.9 0.4 
Preceding week's mean 
temp (°C) 
9.9 0.1 7.8 0.4 
Mean monthly temp 
(°C) 
10.4 0.1 9.0 0.4 
Mean sunshine on scan 
date (hrs) 
4.1 0.1 3.6 0.2 
Total monthly sunshine 
(hrs) 
130.2 1.0 117.8 4.2 
 
BAT-Brown adipose tissue; SUV-Standard uptake value; 18 F-FDG – 18 Fluoro-
labelled -2-deoxy-glucose; PET- Positron emission tomography; MBq-
Megabecquerel; NA-Not applicable 
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3.3.2 Prevalence of 18FDG detected BAT  
 
Table 3.3.2.1 Logistic regression analyses on predictors of Brown Adipose 
Tissue prevalence based on 18F-FDG PET scanning (n=2685)  
 
  
Univariate analysis 
 
Multivariate analysis 
Variable Odds ratio 
(95%CI) 
P value Odds ratio 
(95%CI) 
P value 
Age 0.952 
(0.949-0.955) 
<0.001 0.965 
(0.955-0.976) 
<0.001 
Sex 0.025 
(0.018-0.035) 
<0.001 0.135 
(0.075-0.242) 
<0.001 
BMI  0.895 
(0.889-0.901) 
<0.001 0.894 
(0.845-0.946) 
<0.001 
Fasting Glucose 0.595 
(0.577-0.614) 
<0.001 1.130 
(0.987-1.294) 
0.07 
Diabetes status 0.023 
(0.010-0.051) 
<0.001 0.305 
(0.100-0.929) 
0.03 
Basal Metabolic 
rate 
0.998 
(0.998-0.998) 
<0.001 1.002 (1.001-
1.003) 
0.001 
Mean day temp 0.757 
(0.742-0.771) 
<0.001 0.917 
(0.861-0.977) 
0.007 
Mean monthly 
temp 
0.752 
(0.737-0.767) 
<0.001 1.130 
(0.953-1.114) 
NS 
Mean monthly 
sunshine 
0.496 
(0.473-0.519) 
<0.001 NS NS 
 
NS-Not significant (p>0.05); BMI- Body mass index; 18F-FDG- 18 Fluoro-labelled -
2-deoxy-glucose; PET-Positron emission tomography; P<0.05 is significant 
 
As depicted in Table 3.3.2.1, from univariate analyses, lower age, female sex, lower 
BMI, lower fasting glucose, non-diabetic status, lower outdoor day and month 
temperatures, and lesser monthly sunshine hours were all predictive of a higher 
prevalence of 18F-FDG BAT.  In multivariate analyses, following adjustment of all 
other variables, lower age (P<0.001), female sex (P<0.001), lower BMI (P<0.001), 
! 109!
diabetes status (P=0.03), outdoor day temperature (P=0.007) remained significant. 
Fasting glucose was seemingly trending towards significance (P<0.07). Interestingly, 
BMR was noted to be lower in BAT positive group as against conventional findings 
of higher BMR in this group owing to the metabolically active nature of BAT. The 
same determinants for BAT 18F-FDG uptake identified by multivariate, were 
consistently detected once again on performing the stepwise backward regression 
analyses as illustrated in Table 3.3.2.2 However, forward stepwise regression 
analyses only identified lower age, female sex and mean daily outdoor temperature. 
 
Table 3.3.2.2 Stepwise regression analyses on predictors of BAT prevalence 
based on 18F-FDG PET scanning (n=2685)  
 
                   Stepwise regression P-values 
Variable Backward regression 
 
P value 
Forward regression 
P value 
Age <0.001 <0.001 
Sex <0.001 <0.001 
BMI  <0.001  
Fasting Glucose 0.090  
Diabetes status <0.02  
Basal Metabolic 
rate 
<0.001  
Mean day temp <0.001 0.003 
 
PET-positron emission tomography; P<0.05 is significant; 18FDG- 18F-
Fluorodeoxy-glucose; BMI- Body mass index 
 
 
3.3.3 BAT mass and BAT activity (SUVmax) analyses 
The scores of BAT mass (0.92 x BAT volume) failed tests of normality. Hence, the 
scores were log10 transformed to satisfy normality criteria, and the Figure 3.3.3.1 
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illustrates Normal Q-Q plot with Kolmogorov-Smirnov test being statistical 
significant 0.200 (>0.05) for BAT mass. However, BAT activity reflecting SUVmax 
was not normally distributed despite log transformation or square root application. 
Therefore, multivariate Tobit model (Tobin et al 1958388), a recognised statistic 
model specifically designed for variables distributed with a large percentage of cases 
at lower limit or upper limit was used.   
 
 
Figure 3.3.3.1 Illustration of Normal Q-Q plot with Kolmogorov-Smirnov test being 
statistical significant 0.200 (>0.05) for BAT mass. 
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Table 3.3.3.2 Illustration of BAT mass determinants on 18F-FDG PET scans 
based on Tobit model univariate and multivariate analyses  
 
Variable Univariate  
P-value 
Multivariate 
P-value 
Age (years) <0.001 <0.001 
Gender <0.001 <0.001 
Fasting Glucose (mmol/L) <0.001 0.214 
BMI (kg/m-2) <0.001 <0.001 
Min daily temp (°C) <0.001 0.302 
Mean daily temp (°C) <0.001 0.884 
Max daily temp (°C) <0.001 0.008 
Mean monthly temp (°C) 0.001 0.067 
Daily sunlight hours 0.030 0.783 
Mean monthly sunlight hours 0.009 0.904 
Scan time  0.002 <0.001 
Max previous day temp (°C) <0.001 0.020 
Mean previous week temp (°C) <0.001 0.025 
 
 
PET-positron emission tomography; p<0.05 is significant; BAT-Brown adipose 
tissue; 18FDG- 18F-Fluorodeoxy-glucose; PET-Positron emission tomography; 
MBq-Megabecquerel; NA-Not applicable 
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Table 3.3.3.3 Illustration of BAT activity determinants on 18F-FDG PET scans 
based on Tobit model univariate and multivariate analyses 
 
Variable Univariate  
P-value  
Multivariate 
P-value 
Age (years) <0.001 <0.001 
Gender <0.001 <0.001 
Scan Date 0.226 0.923 
Fasting Glucose (mmol/L) <0.001 0.129 
BMI (kg/m-2) <0.001 <0.001 
Min daily temp (°C) <0.001 0.263 
Mean daily temp (°C) <0.001 0.827 
Max daily temp (°C) <0.001 0.008 
Mean monthly temp (°C) <0.001 0.039 
Daily sunlight hours 0.021 0.608 
Mean monthly sunlight hours 0.005 0.908 
Scan time 0.002 0.001 
Max previous day temp (°C) <0.001 0.024 
Mean previous week temp (°C) <0.001 0.016 
 
 
BMI- Body mass index; 18F-FDG- 18 Fluoro-labelled -2-deoxy-glucose; PET-
Positron emission tomography; P<0.05 is significant; BAT- Brown adipose tissue 
 
 
In line with logistic regression and stepwise regression for BAT prevalence, Tobit 
model analyses also show age (<0.001), sex (<0.001) and BMI (<0.001) as strong 
determinants of BAT mass and BAT activity. In summary, for this part of the 
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chapter, BAT prevalence, BAT mass and BAT activity are strongly determined by 
age, sex and BMI and moderately influenced by outdoor temperature.    
3.3.4 Influence of Age on BAT prevalence, BAT activity and BAT mass 
Increasing age was negatively correlated with BAT prevalence (P<0.001), BAT 
activity (P<0.001) and BAT mass (P<0.001) as depicted in Table 3.3.2.1 and Figures 
3.3.2. 
 
Table 3.3.4.1 Age decade wise 18FDG detected BAT positive scans   
 
Age 
(decade) 
Total PET 
scans 
BAT +ve 
scans 
%age of 
BAT +ve 
scans 
1st  1 0 0 
2nd  19 7 36.8 
3rd  65 21 32.3 
4th  118 17 14.4 
5th  253 21 8.3 
6th  499 29 5.8 
7th  851 32 3.8 
8th  686 19 2.8 
9th  191 5 2.6 
10th  2 0 0 
Total 2685 151 5.6 
 
18F-FDG- 18 Fluoro-labelled -2-deoxy-glucose; PET-Positron emission tomography; 
BAT- Brown adipose tissue 
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Figure 3.3.4.2 Schematic representation of effect of Age on BAT prevalence 
expressed in %age of BAT detection rate according to decade  
 
 
 
Figure 3.3.4.3 Schematic representation of effect of Age on BAT activity  
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Figure 3.3.4.4 Schematic representation of effect of Age on BAT mass  
 
3.3.5 Influence of Gender factor on BAT prevalence, BAT activity and BAT 
mass 
 
Out of 2685 patients (1188 females and 1497 males), 151 patients had BAT 18F-
FDG uptake on PET scans. 114 (9.6%) were females and 37 (2.5%) were males as 
shown in Figure 3.3.5.1. Younger leaner females were at increased chance of being 
detected to have 18F-FDG BAT uptake (P<0.001) and also showed significantly 
increased BAT activity (P<0.001) as shown in Table 3.3.2.  
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Figure 3.3.5.1 Schematic representation of effect of sex on BAT prevalence  
 
 
 
Figure 3.3.5.2 Illustration of brown fat mass in males and females on 18F-FDG PET 
scanning 
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BAT mass, which is calculated from measured BAT volume, was noted to be higher 
in females when compared to males (Mean ± Standard Error of Mean: Females 77.8 
grams ± 9.3; Males 53.3 ± 14.1 grams respectively, P<0.001), as illustrated in Table 
3.3.3.2.1 and Figure 3.4.2. Total lesion glycolysis, reflector of BAT activity was also 
noted to be higher in females, but was not statistically significant. Some of the 
anthropometry and PET scan related parameters comparing males and females in 
BAT positive PET scans are outlined in Table 3.4.3. 
  
Table 3.3.5.3 Comparison of biophysical, PET scan and environmental 
parameters related to 18F-FDG BAT uptake  
 
 Male 
n=37 
Female 
n=114 Characteristics Mean SEM Mean SEM 
Age (yrs) 49.8 3.6 51.1 1.6 
Weight (kg) 73.7 2.5 64.3 1.1 
Height (cm) 176.3 1.3 161.3 0.7 
BMI (kg/m-2) 23.6 0.6 24.7 0.4 
Lean body mass (kg) 58.1 1.3 44.4 0.4 
No of PET scans 1.9 0.3 1.5 0.1 
Basal Metabolic Rate (Kcal/24 
hr) 
1639.5 45.0 1316.0 13.1 
SUVmean (g/ml) 2.9 0.1 3.1 0.0 
SUV max (g/ml) 6.8 0.6 7.6 0.4 
SUVvolume (cm3) 57.9 15.3 84.6 10.1 
BAT mass (0.92g/ml) 53.3 14.1 77.8 9.3 
Total Lesion Glycolysis (g) 192.1 55.4 288.5 39.0 
Mean temp on scan date 6.8 0.9 8.3 0.5 
Mean monthly temp 8.2 0.7 9.3 0.4 
Daily sunshine (hours) 3.8 0.4 3.5 0.2 
Total monthly sunshine (hrs) 122.3 9.3 116.7 4.7 
 
BMI- Body mass index; 18F-FDG- 18 Fluoro-labelled -2-deoxy-glucose; PET-
Positron emission tomography; BAT- Brown adipose tissue; SUV- Standard uptake 
value; SEM- Standard Error of Mean 
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3.3.6 Influence of Body Mass Index (BMI) on BAT prevalence, BAT activity 
and BAT mass 
 
Lower BMI is statistically significant in detecting 18F-FDG BAT uptake as noted in 
both univariate (P<0.001, OR 0.895, 0.889-0.901 CI), and multivariate analyses 
(P<0.001, OR 0.894, 0.845-0.901 CI). BAT mass and BAT activity was anot 
statistically significant when BMI was categorised to WHO classification of obesity 
(P=NS) as demonstrated in Figure 3.3.6.2.  
 
 
 
Figure 3.3.6.1 Bar graph of BAT prevalence in PET scans according to Body Mass 
Index categories 
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Figure 3.3.6.2. Bar graph of BAT mass in PET scans according to Body Mass Index 
categories 
 
3.3.7 Influence of Fasting Glucose on BAT prevalence, BAT activity and BAT 
mass 
 
11 missing fasting glucose values were assorted with paired deletion method using 
SPSS software. Univariate analysis showed lower fasting glucose to enhance BAT 
FDG uptake (P<0.001), and when combined with rest of the variables it showed a 
trend towards significance (P=0.07). The different glycaemic groups did not show 
influence on BAT activity, however BAT mass was noted to be lesser in diabetes 
patients than in non-diabetics, specifically in females (P=0.03). 
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Figure 3.3.7 Bar graph of PET BAT detected patients in various glycaemic groups  
 
3.3.8 Influence of Outdoor temperature on BAT prevalence, BAT activity and 
BAT mass 
 
Exposure to colder temperature at the time of scanning seems to be the critical most 
triggering factor in PET BAT detection. An inverse correlation was noted in our 
study between mean monthly temperature and BAT FDG uptake prevalence 
(Pearson R= -0.72) and is shown in Figure 3.3.8. Summer months BAT prevalence 
markedly reduced as temperature rose, and winter BAT detection rates were higher 
(P=NS). We also noted that mean daily temperature irrespective of the season, can 
influence BAT detection (P=0.007). As illustrated in Tobit analyses in Table 
3.3.3.2.2, previous day mean temperature and previous week’s mean temperature 
bore some influence on BAT mass and BAT activity (P=0.024).  
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Figure 3.3.8.1 Graph representing the relation of mean monthly temperature with 
BAT FDG uptake prevalence rates. 
  
 
 
Figure 3.3.8.2 Seasonal variation of BAT detection from PET scanning 
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Figure 3.3.8.3 Monthly variation of BAT detection from PET scanning 
 
3.3.9 Influence of Thyroxine on BAT prevalence  
 
Out of 229 thyroid cancer patients treated in UHCW, 34 patients (8 male, 26 female) 
underwent 18F-FDG PET scanning. Biochemical thyroid profile, anthropometry and 
other PET scan parameters are depicted in Table 3.3.9.   
 
 19 patients were rendered iatrogenically thyrotoxic (TSH [Mean ± SEM]: 0.05 ± 
0.01 mU/L, Normal range 0.35-6.0) using thyroid replacement therapy to suppress 
TSH, and were classified as Thyrotoxic group. The remaining 15 patients were 
Euthyroid (TSH [Mean ± SEM]: 2.52 ± 0.65 mU/L, Normal range 0.35-6.0), and 
there was statistical significance between both groups (P<0.001). Only one patient in 
Thyrotoxic group (34-year old female, BMI 14, BAT mass 112 grams), and one 
patient in Euthyroid group (77-yr old lady, BMI 26, BAT mass 23 grams) 
demonstrated 18F-FDG BAT uptake. BAT prevalence rate of 5.3% in the Thyrotoxic 
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group, 6.6% in Euthyroid group is comparable to overall BAT prevalence of 5.6% 
for total 2685 patients.  
 
Thyroid profile was available for analysis on 126 out of 151 18F-FDG BAT positive 
patients. 7 out of 126 BAT positive patients were mildly thyrotoxic (TSH [Mean ± 
SEM]: 0.16 ± 0.06 mU/L). 2 were thyroid cancer patients on thyroxine replacement. 
The remaining 5 patients were incidentally thyrotoxic secondary to unintentional 
levothyroxine drug over-replacement. Despite TSH being significantly different in 
both groups, no correlation was noted between TSH and BAT activity (P=NS, 
Pearson R=0.04), as demonstrated in Figure 3.9.9.2, or with BAT mass (P=NS, 
Pearson R=0.08). Free T4 did not show correlation with either BAT activity (P=NS, 
Pearson R= -0.07), or with BAT mass (P=NS, R= -0.16). 
 
In summary, no correlation was noted between thyroid hormones and BAT indices in 
this study. 
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Table 3.3.9.1 Comparison data of patients’ characteristics in Thyrotoxic, 
Euthyroid and total 18F-FDG BAT +ve patients 
 
 Thyrotoxic 
patients 
(n=19) 
Euthyroid 
patients 
 (n=15) 
18F-FDG BAT 
+ve patients 
(n=152) 
Characteristics Mean SEM Mean SE
M 
Mean SEM 
TSH (mU/L) 
(0.35-6.0) 
0.05 0.01 2.52 1.90 1.90 0.01 
Free T4 (pmol/L) 
(9-26) 
26.8 1.6 18.1 18.1 18.1 0.3 
Free T3 (pmol/L) 
(2.8-7.1) 
11.2 1.2 4.8 5.0 5.0 0.1 
Age (yrs) 
 
58.3 4.3 49.8 4.0 50.8 1.5 
Fasting Glucose 
(mmol/L) 
5.1 0.1 5.2 0.2 5.3 0.1 
Weight (kg) 
 
80.8 5.1 73.8 7.2 66.1 1.1 
BMI (kg/m-2) 28.8 1.8 26.7 2.4 24.4 0.4 
Basal Metabolic 
Rate (Kcal/24hr) 
1527 81 1483 83 1395 19 
SUVmax (g/ml) 
 
0.4 0.4 0.8 0.8 7.4 0.3 
BAT mass (g) 
 
1.3 1.3 7.3 7.3 71.3 7.8 
BAT +ve %age 
 
5.3  6.7  100  
Total Lesion 
Glycolysis (g) 
4.4 4.4 27.7 27.7 263.1 32.3 
Mean day temp 
(°C) 
11.1 1.0 8.3 1.6 7.9 0.4 
Mean monthly 
temp (°C) 
11.3 1.0 8.6 1.3 9.0 0.4 
 
 
BMI- Body mass index; 18F-FDG- 18 Fluoro-labelled -2-deoxy-glucose; PET-
Positron emission tomography; BAT- Brown adipose tissue; SUV- Standard uptake 
value; SEM- Standard Error of Mean; TSH- Thyroid stimulating hormone 
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Figure 3.3.9.2 Correlation of Thyroid Stimulating Hormone and BAT activity  
(SUVmax) in 18F-FDG BAT uptake positive patients 
 
        
Figure 3.3.9.3 Correlation of Free T4 Hormone and BAT activity  
(SUVmax) in 18F-FDG BAT uptake positive patients 
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3.4 Discussion 
 
Many studies have indicated that BAT in rodents has profound effects on body 
weight, energy balance, and glucose metabolism, and therefore BAT route is worth 
pursuing in adults (Cannon et al 2004)149. Human PET studies based on 18F-FDG 
uptake by BAT have been successful in a sense, that they conclusively prove BAT’s 
presence in adults, but so far have not reached consensus regarding the determining 
factors of BAT prevalence, BAT activity and BAT mass (Cypess et al 2009389, 
Cronin et al 2009202. This study based on a large cohort of patients (n=2685) in a 
single centre, was carried out to further disentangle these anthropometric and 
environmental factors using robust statistical methods. The study concludes that 
lower age, female sex, lower BMI, lower outdoor temperatures and absent diabetes 
status influence 18F-FDG detected BAT prevalence; and lower age, female sex, 
lower BMI and lower outdoor temperatures influence BAT mass and BAT activity. 
There is no influence of thyroxine hormone on BAT uptake in a mild thyrotoxic 
state. 
 
The study’s BAT prevalence of 5.6%, is comparable to similar large retrospective 
PET-series studies (Cypess et al 2009141, Cronin et al 2012202, Perishetti et al 
2013383, Zhang et al 2013385). Prospective studies indicate a higher prevalence (40% 
to 96%) (van Marken Lichtenbelt et al 2011142, Saito et al 2009143). Also, 
postmortem studies have shown higher incidence, 26 out of 31 cases in over 30-year 
olds (84%) (Heaton et al 1972151). Furthermore, out of 6 patients who had incidental 
histological confirmation of BAT during routine pathological examination of their 
neck-dissection samples, only one revealed 18F-FDG detected BAT (data not 
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shown), indicating much higher actual BAT prevalence. It is an inherent nature of 
retrospective PET studies to underestimate the true BAT prevalence, as PET-CT 
shows only incidental metabolically activated BAT, as opposed to deliberately 
stimulated BAT. PET scans are usually performed in fasting and thermal comfort 
conditions with the room temperature set in the range between 22°C-25°C, 
depending upon the individual centre’s PET image acquisition protocol. Both these 
factors switch off BAT, as cold and diet are recognised stimulators of BAT as 
mentioned in detail Chapter 1.8.2. The PET-scans in the current study were done at 
thermo-neutral condition with the room temperature kept constant at 23°C. However, 
following adjustment of all other variables, multivariate analyses yielded lower age, 
female sex, BMI and diabetes status, as significant factors suggesting their 
independent influence on BAT activation, other than cold temperature and diet. 
 
The study also confirms the findings of other major case series, and adds to the 
evidence that sex, age, BMI, diabetes status and outdoor temperature are significant 
determinants of BAT prevalence (Cypess et al 2009141, Cronin et al 2012202, 
Perishetti et al 2013383, Zhang et al 2013385, Jacene et al 2011200, Pace et al 2011201). 
Majority of the PET-studies studied BAT prevalence, and only few studied BAT 
volume or mass (Ouellet et al 2011)166. We found BAT mass to be higher compared 
to other studies (70 grams versus 11 grams) (Cypess et al 2009141), indicating that 
other studies may be underestimating true BAT quantity. This can be attributed to 
advanced technology of imaging analysis MIRADA software, which yielded 
reasonably accurate automatic estimation of SUV volume, and hence BAT volume, 
when compared to other softwares used in the previous studies. Sexual dimorphism 
was clearly evident in both BAT prevalence (Female to male: 9.6% versus 2.5% 
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respectively) and BAT mass (Mean ± Standard Error of Mean: Females 77.8 grams 
± 9.3; Males 53.3 ± 14.1 grams respectively, P<0.001).  
 
One of the striking finding of our study is the pronounced variation of outdoor 
temperature to BAT prevalence, in this large case series. Although this confirms 
evidence form previous studies, it is an important reaffirmation of this vital outcome, 
given global warming and global obesity epidemic. Whilst a correlation between 
these two phenomena needs exploration, it is an important public health message to 
lower our living room thermostats in order to activate BAT. The study did not show 
correlation between sunshine hours and BAT indices, but found strong correlation 
between Season and BAT prevalence. This evokes speculations, that changes in 
diurnal, or possibly circannual rhythm variations of hormones such as prolactin and 
melatonin, may explain the increased BAT incidence in winter more than in summer. 
The endocrine mechanisms such as these and that related to sexual dimorphism may 
be complex, and it is imperative that we learn more about BAT’s physiology if at all 
we aim to use BAT as an anti-obesity strategy. 
 
 Although our study (in line with other major PET series studies) did not show a 
strong correlation between glucose and all BAT indices, overall evidence of effect of 
BMI points towards active BAT to offer protection against diabetes and obesity. This 
interpretation is substantiated by several animal studies, where BAT-deficient mice 
develop obesity, hyperphagia, and insulin resistance (Hamann et al 1995, Hamann et 
al 1996, Lowell et al 1993390-392). Furthermore, overall mean levels of fasting 
glucose was lower in FDG BAT detected groups than in FDG BAT negative groups 
in several other studies (Ouellet et al 2011) including that of ours.  
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We found unexpected findings of no correlation of thyroid hormones on BAT FDG 
uptake on PET scans, against conventional speculations. Only one of the 19 
thyrotoxic patients (34-year old female, BMI 14 kg/m-2) was detected to have 
significant BAT depots, but it could be argued that younger age, female sex and 
lower BMI may have had some influence, rather than thyroid status alone. 
Furthermore, BAT prevalence rates were similar across the Thyrotoxic, Euthyroid 
and BAT positive groups (approximately 5%), indicating co-incidental BAT 
detection, as opposed to thyroxine-stimulated detection. These findings are contrary 
to the evidence shown by Finnish group (Lahesmaa et al 2014393), where BAT 
showed increased glucose uptake in hyperthyroid patients, independent of BAT 
perfusion. However, the authors noted that skeletal muscle perfusion and glucose 
uptake was far higher than BAT perfusion and glucose uptake. One explanation is, 
skeletal muscle has more D2 and significantly contributes for facultative 
thermogenesis (van Marken Lichtenbelt et al 2011)210. Furthermore, thyroid 
hormones up-regulate glucose transporter protein type 4 (GLUT-4), which mediates 
the rate-limiting step of glucose metabolism in the skeletal muscle, resulting in more 
thermogenesis (Ezaki et al 1997)394. This excess thermogenesis from the skeletal 
route in hyperthyroid patients may centrally inhibit BAT pathway of non-shivering 
thermogenesis, which is usually modest even in maximal stimulated conditions. 
BAT contains high amounts of Type II 5’ Iodothyronine deiodinase (D2), which is 
required for T4 to T3 conversion. High local tissue T3 concentrations are necessary 
for up-regulation of UCP-1 in BAT as already highlighted in Chapter 3.1 (Silva et al 
1983)188. D2 levels of skeletal muscle in humans when compared to BAT are far 
higher than noted in mice, pointing out the diversification of tissue variations 
between the two species (Salvatore et al 1996395, Croteau et al 1996396). This might 
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explain the failure of replication of animal data in humans in our current study. To 
our knowledge, this is the first ever study evaluating thyroid hormones’ influence on 
BAT in a clinical setting. Interestingly, two phaeochromocytoma patients were in the 
2685 patients cohort, and both did not exhibit BAT despite, one being a metastatic 
phaeochromocytoma with grossly elevated metanephrines.  
 
The major limitation is retrospective nature of the study, and lack of control groups 
which did not allow registration of complete clinical histories, including diabetes and 
metabolic profiles evaluation. Majority of the PET studies conducted was for 
evaluation of malignancy and it is possible that various malignancies may have 
confounding variables, including influence from chemotherapy agents, which could 
alter the outcome of PET BAT detection. Only patients who had biochemical thyroid 
profiles within 6 weeks of range from the date of PET scan were included in the 
study, which may result in a selection bias.  
 
In conclusion, the results of this large PET case series study showed that the main 
determinants of 18F-FDG detected BAT prevalence, mass, and activity are age, sex, 
BMI, outdoor temperature and diabetes status. Thyroid hormones have no influence 
on BAT activation in mild thyrotoxic state. Major implications of these findings are 
public health messages: escalation of weight losing life style measures of exercise to 
reduce BMI, which will also may encourage environmental cold exposure; and 
reducing thermostat of indoor living spaces. Whilst awaiting the solutions of anti-
obesity BAT therapeutic manipulation methods/drugs, it cannot be ignored that 
perhaps the safest and simplest way to activate BAT is reducing thermal comfort 
through mild cold exposure. 
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Chapter 4 
 
 
 
IDENTIFICATION OF BROWN ADIPOSE TISSUE 
USING MR IMAGING  
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4.1 Introduction  
 
As stated in Chapter 1.7.3, BAT is postulated as a holy grail for metabolic disease, 
enhanced and sustained activity of which can potentially prevent obesity, 
hyperlipidaemia and type 2 diabetes mellitus. It is over a century that BAT was first 
discovered, described as ‘mulberry cells’ by Dr Betty H Shaw in 1901 (Shaw et al 
1901397), yet we do not know it’s entire anatomy, let alone physiology and 
therapeutics.  
 
A significant obstacle to the progress of research on human BAT has been the lack 
of a safe, sensitive, specific and reproducible imaging technique to quantify BAT 
volume and/or mass. Such a tool would be essential to evaluate the efficacy of novel 
therapies based on the manipulation of BAT. The mainstay research on human BAT 
in recent years, including that of our study as described in Chapter 3, have been 
based on retrospective assessments of images using the technique of 18Fluoro-2-
Deoxyglucose Positron Emission Tomography (18F-FDG PET), performed clinically 
mainly for the assessment of tumours and metastases (van Marken Lichtenbelt et al 
2009142, Cypess et al 2009141, Virtanen et al 2009140). The advent of PET technique 
has demonstrated BAT in human adults and it delineated the depots: supraclavicular, 
mediastinal and paravertebral (Virtanen et al 2009140). Another advantage of PET is 
that it shows metabolical activity of BAT, focusing on function and metabolism 
aspects of BAT research. However, 18F-FDG PET has got limitations as it may not 
be a reliable research technique to accurately identify BAT in all subjects, or 
accurately quantify human BAT volume/mas. Images derived from 18F-FDG PET 
are therefore influenced heavily by environmental temperature, given the 
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temperature-dependence of BAT activity as shown in Chapter 3 and in other studies 
(Zukotynski et al 2009203, Ouellet et al 2011166). Furthermore, 18F-FDG PET 
involves exposure to potentially harmful ionizing radiation, and is an expensive 
technique for imaging BAT in humans (Ouellet et al 2011166).  
 
Several attempts to differentiate BAT from WAT in rodents using techniques such as 
MR spectroscopy and chemical shift MR have been successful (Lunati et al 1999398, 
Hamilton et al 2011399). However, the delineation of BAT and WAT in human adults 
has so far remained elusive. A safe alternative to 18F-FDG PET as an imaging 
modality for human BAT, and one that can potentially overcome the obstacles 
outlined above is MR imaging. BAT and white adipose tissue (WAT) differ in their 
water:fat ratios due to the different functions of these two tissue types. As illustrated 
in Figure 1.5.2 and Table 1.5.2, BAT contains abundant mitochondria, wheras WAT 
consists mainly of triglyceride (Cinti et al 2005205). Therefore, BAT contains 
proportionately more water and less fat than WAT. This important difference 
provides a rationale for exploring MR as a potential imaging modality to discern 
BAT from WAT. As discussed in Chapter 1.6.2 and Chapter 2.2.3, MR technique of 
Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares 
estimation (IDEAL) has been used successfully in rats to clearly delineate BAT from 
WAT (Hu et al 2010206). The lower signal intensity of BAT compared to WAT has 
been exploited to obtain IDEAL fat-water imaging in rats. As illustrated in Figure 
4.2.1.1, reconstructed fat-fraction images, show a broad fat-fraction range for BAT 
(37-70%), in contrast to a higher and smaller range for WAT (90-93%), in both 
excised tissue samples and in situ (Hu et al 2010206). Intermediate signal intensity in 
comparison with hypointense subcutaneous fat and hyperintense muscle was noted 
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on T2- weighted MR images of presumed BAT in supraclavicular and axillary 
region of a 13-day old neonate (Carter et al 2008207). 
 
The aim of our study was to explore the use of IDEAL MR as as a means of 
identifying BAT in human adults. A further aim was to demonstrate proof of 
principle that MR is a potential future biomarker for human BAT. This would be an 
essential step for future novel therapeutic developments for the prevention and 
management of human obesity through manipulation of BAT. 
 
Therefore the hypothesis for this set of studies was that: 
1. Brown Adipose Tissue (BAT) contains more water content than White 
Adipose Tissue (WAT). IDEAL MRI, with its robust fat-water separation 
technique, may potentially discern BAT from WAT. 
2. Human BAT and WAT may possess similar characteristics as that of rat 
species, and may aid IDEAL MRI to delineate the two tissues as shown 
in rodent models.  
 
Therefore the aims of these studies were: 
1. To identify brown adipose tissue using IDEAL MR imaging in rat 
carcass, and reconfirm the results shown by Hu et al 2010 
2. To utilise the same IDEAL technique to identify BAT in a human adult 
volunteer to provide proof of concept.  
3. To provide confirmation with histological and immunohistochemical 
staining. 
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4.2 Materials and Methods 
 
4.2.1 Proof of concept of IDEAL MRI study on Rat fat samples 
 
BAT and WAT from samples taken from sacrificed rats can be clearly delineated 
from one another, and provide distinct signals when imaged with existing technology  
This has already been demonstrated by Hu et al. using 6-echo IDEAL MRI as 
outlined in Figure 4.2.1.1 (Hu et al 2011206). 
 
Figure 4.2.1.1 (Hu et al 2011206), IDEAL results from dissected tissues. (a) Brown 
and white adipose tissue (BAT, WAT) are macroscopically distinct. (b) Water-0nly 
IDEAL, (c) Fat-only IDEAL, and (d) Fat-fraction map: 92%, 51%, 93%, and 62% 
mean fat-fraction from left to right.  
 
To confirm the concept of IDEAL MRI technique, we chose to reproduce the above 
Hu et al experiment results on a rodent model, the methodology of which is outline 
in Chapter 2.2.4. In brief, following a normal feeding regimen 2 male Wistar rats 
(mean mass 300g, age 6-8 weeks), one kept at thermoneutrality (30°C) for 8 hours; 
the other was kept in the cold (4°C) for 8 hours were sacrificed. The fat samples 
were dissected to extract Interscapular BAT, Subcutaneous WAT and Omental 
WAT. The samples were collected into 2 sets of 3 x 2 ml eppendorfs (cold and 
thermoneutral), and were photographed to demonstrate the macroscopic difference 
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between BAT and WAT (Figure 4.2.2). The specimens from rat kept in the cold, was 
transported to the MRI scanner on ice, while those from the rat kept at 
thermoneutrality, was transported at ambient temperature. 
 
As described in Chapter 2.2.4, MR imaging of cold and thermoneutral rat carcasses, 
and phantom rat samples were carried on 3T GE MR scanner using IDEAL settings. 
Images had 2.0mm slice width, 150mm square field of view and 256x256 matrix. 
 
 
 
Figure 4.2.1.2: Macroscopic BAT and WAT samples dissected from Wistar rats 
kept at thermoneutrality (30 °C) and cold (4 °C). 
 
4.2.2 Subject recruitment and case study 
 
A 25-year old Caucasian female (BMI 22.6 kg/m2; waist circumference 90.5 cm; 
waist/hip ratio 0.93; fasting glucose 4.6 mmol/L; total cholesterol 3.9 mmol/L) was 
diagnosed with Hyperparathyroidism-Jaw Tumour (HPT-JT) syndrome based on 
biochemistry and imaging. She was not on regular medication and there was no other 
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medical history to note. Nuclear imaging detected a 0.5 mm right inferior 
parathyroid adenoma. In addition, a right-sided mandibular lesion was identified, and 
following surgical resection, histopathology revealed this to be a giant cell 
granuloma. HPT-JT syndrome was confirmed genetically, and the mutation shown to 
be heterozygous for a T to C nucleotide substitution in exon 2 of the gene, CDC73 
(c.191T>C), also called HRPT2 gene, which encodes for parafibromin was identified 
(Carpten et al 2002400). Following successful and complete enucleation of the 
parathyroid adenoma, the serum parathyroid hormone (PTH) level was partially and 
transiently elevated, raising a concern of parathyroid carcinoma. The patient 
therefore subsequently underwent an 18F-FDG PET-CT scan. This scan was negative 
for malignancy, but did reveal multiple areas of high 18FDG uptake within 
suprasternal and mediastinal fat (Figure 4.2.2). Written informed consent for study 
recruitment was obtained and appropriate ethical approval to perform an IDEAL MR 
scan was obtained from a Black County Research Ethics Committee (Rec No. 
11/H1206/3).  
 
 
Figure 4.2.2.1 Coronal image of 18F-FDG PET scan of the study subject exhibiting 
high physiological 18F-FDG BAT uptake in cervical, mediastinal and axillary areas 
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Table 4.2.2.2 Phenotypical characteristics of the human subject 
 
Phenotypical characteristics Values 
Age 25 years 
BMI 22·6 kg/m2 
Waist:hip ratio 0.93 
Fasting glucose 5 mmol/L 
Fasting insulin 105 pmol/L 
Total cholesterol 3.9 mmol/L 
HOMA2-IR 1.9  
Resting metabolic rate 1403 kCal/day 
Genetic diagnosis HRPT2 gene: T to C nucleotide 
substitution in exon 2 of the gene, 
CDC73 (c·191T>C) 
Brown fat mass 516 grams 
Brown fat Total Lesion glycolysis 
(TLG)  
2414 grams 
Brown fat tissue activity 14556 kBq 
Temperature on the day of PET 
scan 
Outdoor temperature: 8.5o Celsius 
Room temperature: 23o Celsius 
 
BMI- Body mass index; HOMA2-IR- Homeostatic model assessment 2-Insulin 
resistance; PET- Positron emission tomography 
 
4.2.3 Positron-emission tomography scanning 
 
PET was performed on a GE Discovery STE PET-CT scanner (General Electric 
Medical Systems, Milwaukee, USA). Two sets of emission data were obtained; from 
the skull base to mid thigh (with arms elevated); and the head and neck protocol 
(without elevation of arms). In accordance with standard administration and 
acquisition protocol, the subject was fasted for 6 hours, and 375 MBq of 18F-FDG 
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radiotracer was injected one hour prior to the scan. Emission data was obtained for 3 
minutes in each bed position. PET images were reconstructed using the computed 
tomography (CT) data for attenuation correction. 
 
4.2.4 Magnetic resonance scanning 
 
A 3-echo IDEAL sequence (Reeder et al 2004401, Reeder et al 2005372) was 
performed on a 3T GE HDxt scanner (General Electric Medical Systems, 
Milwaukee, USA). The cardiac coil was placed around the cervical and upper 
thoracic regions. Axial images with a 5mm slice thickness were obtained from the 
upper cervical to mid-thoracic level. The T1 weighted IDEAL sequence parameters 
were: TR 440 ms, TE 10.8 ms, acquisition matrix size 320 x 256, NEX 3 and field of 
view of 30 cm. This generated water-only and fat-only (fat:IDEAL) images, of 
which the latter were used for subsequent analysis. 
 
A baseline MR scan was performed the same month as the PET-CT (December) 
upon which subsequent image analysis was performed. A second MR was performed 
2 months later using identical imaging parameters (apart from the field of view 
which was 34 cm), to determine whether there was any temporal variation in the 
distribution of BAT. 
 
4.2.5 Retrospective image analysis  
 
This analysis used Region of Interests (ROIs) of high radiotracer uptake on the PET-
CT (considered to be BAT) transposed onto the fat:IDEAL MR images. To achieve 
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this, the PET-CT and enhanced MR images were co-registered using a combination 
of multi-modal rigid and non-rigid registration, employing image fusion software 
Mirada XD 4.3 (Mirada Medical Ltd, Oxford, UK) to facilitate direct positioning of 
ROIs between the images. Visual comparison and manual registration using vascular 
landmarks was employed when there was doubt.  
 
Image analysis was then performed on the MR images using ImageJ 1.45s (National 
Institutes of Health, USA). MR images were enhanced using the automated contrast 
enhancement and sharpen algorithms within ImageJ. ROIs were drawn on the MR 
scans around areas corresponding to greater-than-background levels of 18F-FDG 
uptake within adipose tissue on the PET-CT scans, indicating BAT. These ROIs on 
the MR images, derived from 18F-FDG uptake on PET, will be referred to as 
‘BATretro’. Radiotracer uptake in paravertebral regions was not assessed due to the 
difficulties of accurately identifying these areas on MR. 
 
The MR signals within the BATretro ROIs were compared with those from 
immediately adjacent adipose tissue to determine differences in signal intensity. 
These areas will be referred to as WATretro. The MR images were scrutinized with 
regard to adjacent image slices to ensure that any perceived variation in MR signal 
did not represent partial volume (or volume averaging) artefact. 
 
Differences in signal intensity in BATretro and WATretro ROIs were compared using 
the Wilcoxon matched pairs test (or paired t test) using GraphPad Prism version 5.00 
(GraphPad Software, San Diego California USA). Subsequently, a one-way 
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ANOVA was performed to determine whether the BATretro:WATretro signal ratios 
varied according to anatomical location. 
 
4.2.6 Prospective image analysis  
 
This analysis method positioned ROIs directly on the MR images, based on 
differences in signal intensity observed between BATretro and adjacent adipose tissue 
identified during the retrospective analysis. To reduce recall bias, 4 months later a 
single radiologist drew ROIs around areas of adipose tissue on the baseline MR 
scans that exhibited discrete low signal intensities in relation to neighbouring 
adipose tissue postulated to represent islands of BAT (‘BATprosp’). ROIs were 
restricted to adipose tissue within the upper mediastinum, base of the neck and 
supraclavicular fossae.  
 
4.2.7 Histology and Immunohistochemistry 
 
Histology and immunohistochemistry were performed on tissue obtained during 
parathyroidectomy, corresponding with high 18F-FDG uptake on the PET-CT scan 
and low-signal intensity on the fat-only MR scan. Samples were prepared for 
morphology by keeping in formalin until moulded in paraffin and stained with 
haematoxylin-eosin (HE). For immunohistochemistry, Vectastain Elite ABC Kit 
(Vector Laboratories, PK-6101) and rabbit anti-UCP1 (1:500, Sigma U6382) were 
used according to the manufacturer’s protocol.  
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4.3 Results 
 
4.3.1 IDEAL MRI results from Rat imaging 
  
Fat-fraction map on the rat phantom samples, showed BAT (40-60%) in fluorescent 
green, clearly delineated from WAT (>80%) in orange, based on fat-fraction map as 
shown in Figure 4.3.1.1. Skeletal muscle tissue contains more water than fat, and 
incidental presence of muscle displayed blue. There was no difference in mean fat 
fraction between interscapular BAT at 4°C and 30°C. Both fat-only IDEAL images 
and fat-fraction IDEAL images of rat carcass samples exhibited clear delineation of 
BAT from WAT as illustrated in Figure 4.3.1.2. This confirms the reliability and 
reproducibility of IDEAL technique in differentiation of BAT and WAT in rats. 
 
  
 
                                   a     b   
Figure 4.3.1.1 a) Fat-fraction images of dissected BAT, Subcutaneous WAT and 
Omental WAT (from left to right), from rats kept at 4°C, and, b) at 30°C. Images are 
coloured in 10% increments. The areas of blue correspond to skeletal muscle, orange 
is WAT and green/yellow is BAT.  
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               a) Fat IDEAL 
 
                b) Fat fraction 
                      
Figure 4.3.1.2 Axial MR slices through the upper thorax showing a) Fat-IDEAL and 
b) Low fat-fraction corresponding to BAT in the interscapular region 
 
4.3.2 IDEAL MRI results from Human imaging- Retrospective image analyses 
 
111 regions of 18F-FDG uptake on PET were identified which were consistent with 
BAT (Figure 4.3.2.1). 25 ROIs were within the upper mediastinum, 41 within the 
supraclavicular fossae, 31 within the neck, and 14 in the axillae (Table 1). These 
ROIs of increased 18F-FDG uptake had a total cumulative surface area of 9,031 mm2, 
of which the majority occurred within the mediastinum and supraclavicular regions. 
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                             a            b 
 
        c 
Figure 4.3.2.1 (a): Axial PET-CT image showing 18F-FDG uptake consistent with 
BAT in mediastinum (arrowed); (b): Fat:IDEAL MR image demonstrating low 
signal areas within the mediastinal fat (arrows) corresponding to BAT on PET-CT; 
(c): ROIs were drawn around high 18F-FDG uptake and transferred onto registered 
fat-only images. 
 
Visual comparison of the MR signal within these BATretro ROIs and adjacent adipose 
tissue (WATretro) revealed differences in signal between the two. The BATretro ROIs 
had a lower signal than surrounding adipose tissue, and were often delineated by a 
discrete margin, as shown in Figure 4.3.2.1.b.   
 
Overall 93 of the 111 BATretro ROIs (83.8%) had a lower MR signal than adjacent 
adipose tissue, although this did vary according to anatomical site (Table 4.3.2.2). 
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25/25 (100%) of the BATretro ROIs in the upper mediastinum had a lower MR signal 
than adjacent adipose tissue, 29/31 in the neck (93.5%), 31/41 in the supraclavicular 
fossae (75.6%) and 8/14 in the axillae (57%). A significant difference was found 
between the MR signal within BATretro and WATretro ROIs (Table 4.3.2.3) using the 
Wilcoxon matched pairs test, in all but the axillary region. Signal intensity varied 
considerably along the B0 axis (i.e. in a cranio-caudal direction), with a ten-fold 
difference in signal intensity between the cranial (neck) images and the caudal 
(mediastinal) images (Figure 4.3.2.4). There was no correlation between the level of 
the MR slice and the BAT:WAT signal ratio. There was, however, variation in the 
BATretro:WATretro signal ratio according to anatomical region (Figure 4.3.2.5), with 
significantly lower signal ratio (p<0.0001 found using the one-way ANOVA) within 
the mediastinum and neck (i.e. lower BAT signal with respect to WAT) than in the 
supraclavicular fossae and axillae. 
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Table 4.3.2.2 For each anatomical region the number of BATretro ROIs with low and 
normal signal intensity on MR is tabulated. The ROIs were retrospectively drawn on 
MR from areas of corresponding high 18F-FDG uptake on the PET-CT images. !
Anatomical 
region 
No of BATretro 
ROIs with lower 
signal with lower 
MR signal than 
adjacent fat 
Number of 
BATretro ROIs 
with similar MR 
signal to 
adjacent fat 
Total 
number 
of ROIs 
Total 
area of 
ROIs 
(mm2) 
All regions 93 18 111 9,030 
Mediastinum 25 0 25 2,348 
Supraclavicular 31 10 41 3,313 
Neck 29 2 31 1,451 
Axillae 8 6 14 1,918 
 
Table 4.3.2.3 Variation in BATretro and WATretro MR signal intensity and BAT:WAT 
signal ratio according to anatomical region !
Anatomical 
region 
Mean 
BATretro MR 
signal 
Mean 
WATretro MR 
signal 
Significance 
P value 
Signal ratio 
BAT:WAT 
All 485 (±229) 549 (± 260) <0·0001 0·89 ± 0·12 
Mediastinum 586 (±145) 750 (±197) <0·0001 0·79 ± 0·11 
Supraclavicular 541 (± 68) 594 (±90) <0·0001 0·92 ± 0·12 
Neck 196 (± 116) 219 (± 125) <0·0001 0·89 ± 0·09 
Axillae 783 (± 189) 788 (±184) NS 0·99 ± 0·08 
 
 
BAT- Brown adipose tissue; WAT- White adipose tissue; ROI-Region of interest; 
MR- Magnetic Resonance; P<0.05- significant 
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Figure 4.3.2.4: Variation in BATretro and WATretro signal according to slice and 
anatomical site, showing a ten-fold increase in signal intensity between cranial 
(neck) and caudal (mediastinal) MR slices 
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Figure 4.3.2.5: Variation in BATretro:WATretro signal ratio according to 
anatomical location, with significantly lower signal ratio within mediastinum and 
neck. The shaded area represents a ratio >1 (i.e. WATretro signal > BATretro 
signal). 
 
The repeat IDEAL MR scan demonstrated little change in the distribution of low 
signal regions. There are persistent areas of well-circumscribed low signal change 
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within the anterior mediastinum and suprasternal notch in a similar distribution to 
those identified on the comparable slice from the baseline MR (Figure 4.3.2.6). 
 
            
Figure 4.3.2.6: a) Baseline MR; b) Repeat axial fat:IDEAL MR image of the upper 
thorax performed 2 months after the baseline MR scan, showing a similar 
distribution of putative BAT within the anterior mediastinum and suprasternal notch. 
 
4.3.3 IDEAL MRI results from Human imaging- Prospective image analyses 
 
Fifty-four ROIs were prospectively identified on MR by a single investigator on the 
basis of having discrete areas of low signal intensity with respect to adjacent adipose 
tissue, and were presumed to represent BAT (‘BATprosp’). The total cumulative 
surface area of these BATprosp ROIs was 6,207mm2, compared with 5,661 mm2 in the 
mediastinum and supraclavicular fossae in BATretro ROIs. The total surface area of 
the 54 BATprosp ROIs comprised 2.4% of the total surface area of adipose tissue 
examined (257,181mm2). When these BATprosp ROIs were then compared with the 
PET-CT scans, 47/54 ROIs (87%) coincided with areas of 18F-FDG uptake.        
 
 
 
!
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4.3.4 Histology and Immunohistochemistry 
 
Haematoxylin-eosin staining of fat tissue obtained from the suprasternal area (as 
marked by the white arrowhead in Figure 4.3.4 demonstrates smaller multilocular 
cells with multiple small lipid droplets (yellow arrowhead in Figure 4.3.4.c 
consistent with BAT as opposed to larger unilocular WAT (white arrowhead in 
4.3.4.c) (Cinti et al 2005205). BAT was also unequivocally confirmed on 
immunostaining with anti-serum against rabbit UCP1, (Figure 4.3.4.d) as BAT has 
abundant mitochondria containing UCP1, as elegantly shown in multiple rodent as 
well as human studies (as illustrated in Chapter 1.5.2, Chapter 1.5.3) (Heaton et al 
1978150, Aquila et al 1985402, Saito et al 2009143, Lowell et al 1993392, Zingaretti et al 
2009144). 
  
Although samples were collected prior imaging procedures, our study subject amply 
demonstrates morphological and immuno-histological correlation in the ROI 
corresponding to brown fat in both PET and MRI, thus also corroborating the 
presence of BAT in humans. 
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                          a                          b 
            
                          c                                                            d 
Figure 4.3.4: (a) 18F-FDG uptake within the suprasternal notch on PET-CT (arrow); 
(b) fat:IDEAL MR at the same level showing corresponding low signal in the 
suprasternal notch; (c) Haematoxylin-Eosin staining and (d) UCP1 immunostaining 
providing confirmation of BAT obtained from this area. 
 
 
 
 
 
 
 
 
 
! !
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4.4 Discussion  
 
At the time of publication of this study, we reported for the first time, verification of 
BAT in a living human adult using MR imaging. We have shown MR scanning 
confirmation of presumed BAT from comparisons with 18F-FDG PET images. We  
also provided histological and immunohistochemical confirmation of BAT in 
samples taken from a low fat signal region identified prospectively on the MR 
images. The BATprosp images revealed clear delineation and unequivocal differences 
(p<0.001) in signal intensities between BAT and the adjacent WAT. The BATprosp 
ROI signals appeared more heterogeneous than the surrounding WAT signals, 
particularly in the mediastinal and midline neck areas. We believe that this signal 
pattern is entirely consistent with these ROIs being from BAT, and indeed the 
pattern that what one would expect given the characteristic histological appearance 
of human BAT often occurring in many islets within surrounding WAT (Cinti et al 
2000) 
 
The technique of 18F-FDG PET currently represents the gold standard for imaging 
human BAT in the research setting. PET-CT is also performed for clinical reasons, 
often for identification and monitoring of malignancy. PET-CT provides data on the 
metabolic activity of tissues, and therefore only provides information on BAT 
activity. It follows therefore, that inactive BAT would not be identified on PET-CT. 
MR differs fundamentally from PET-CT in that MR provides anatomical 
information, and the images generated are not dependent upon tissue activity. 
Therefore, a key advantage of MR over PET-CT is that this imaging modality offers 
the potential to measure BAT volume regardless of its activity, and thereby could be  
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developed, to provide an accurate and reliable biomarker for human BAT. Another 
advantage of this approach is that BAT activity (resulting from variations in daily 
temperatures for example) would not be expected to influence the measurements 
derived from the MR images. Furthermore, MR is an entirely safe imaging modality 
with no associated exposure to harmful ionizing radiation, in contrast to 18F-FDG 
PET-CT, MR is also comparatively cheap. 
 
Previous MR studies have successfully identified BAT in rodents both in inactive 
(Lunati et al 1999398, Hu et al 2010206, Sbarbati et al 1997206,403,404) and in active 
state (Sbarbati et al 2006405). We based our study on Houchun Hu’s study using 
IDEAL MR fat-water imaging technique, which observed a broad fat fraction range 
(37-70%) in mouse BAT, in comparison to a tighter and higher range for WAT (90-
93%) (Hu et al 2010206). The same group have also shown lower T2* relaxation and 
Proton-density fat fraction in BAT compared to WAT in mice (Hu et al 2012406). 
The challenge lies in extrapolating these gains on to in vivo human studies to non-
invasively characterise inactive BAT. BAT in rodents is well localised and hence 
easily studied, whereas anatomy and function of BAT in humans are yet to be 
characterised. Furthermore, WAT in some areas is thought to be amenable for 
transcription into BAT (Wu et al 2012146, Seale et al 2008182), which poses new 
challenges to image a constantly dynamic tissue. In general, in vivo BAT in humans 
using non-invasive modalities is yet to be demonstrated and our study aims to 
address this relevant question. 
 
T2-weighted images of presumed BAT found bilaterally in supraclavicular and 
axillary region of a prematurely born 13-day old live neonate, demonstrated 
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intermediate signal intensity on a clinical MR sequence in comparison to 
hyperintense muscle and hypointense subcutaneous fat (Carter et al 2008207). MR 
appearences of 8 consecutive hibernomas (benign, slow-growing, soft-tissue tumours 
resembling brown adipose tissue) detected in human adults, demonstated diffusely 
hypointense signals compared to the surrounding subcutaneous WAT (Lee et al 
2006407). In a postmortem study of a 3-month old infant, Hu et al demonstrated a 
lower fat-fraction for BAT (41.9+/-6.25%) in comparison to higher fat-fraction for 
WAT (>90%), using chemical shift two-point 3D spoiled gradient echo pulse 
sequence on a 3-Tesla MR scanner (Hu et al 2012408). In comparison to previous MR 
studies which were done on mouse and postmortem human models, our study 
demonstrates unequivocal identification of adult human inactive BAT in vivo, whilst 
also reiterating the feasibility of BAT imaging by IDEAL MR.  
 
Our study has some unavoidable limitations. It is possible (although not likely) that 
adipose tissue may be affected in some way in HPT-JT syndrome, which may in turn 
affect signal intensity on MR imaging. However, the histology and 
immunohistochemistry of fat samples obtained from this patient showed the 
characteristic features of BAT and WAT, similar to those from other studies on 
human adults without HPT-JT syndrome, thus proving that the morphology 
demonstrated is not disease related (van Marken Lichtenbelt et al 2009142, Saito et al 
2009143, Virtanen et al 2009140). A further potential limitation is that transposing 
areas of 18F-FDG uptake on PET-CT onto MR images may introduce bias. To limit 
this potential bias, the 18F-FDG PET-CT and MR scans were performed with the 
patient adopting a similar position with their arms down in accordance with the 
standard head and neck PET-CT protocol. Another limitation is that the MR axial 
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images had a 5-mm slice thickness. It is possible that greater differentiation of BAT 
from WAT signal could be obtained through a smaller slice thickness. Regardless of 
slice thickness, this does not detract from the main outcome of this study, which is 
the clear identification of BAT and delineation from WAT on MR images.  
 
In summary, at the time of publication of this study, we reported for the first time, 
demonstration of BAT, clearly delineated from adjacent WAT, in a living human 
adult using the technique of IDEAL MR. Our study provides a framework for future 
studies on MR-based detection of BAT in human adults. We provide proof of 
principle that IDEAL MR could be developed as a tool to provide an accurate, 
reliable and reproducible radiological tool for human BAT. Such a tool would be 
invaluable in the future pursuit of novel therapeutics to combat the global obesity 
epidemic through manipulation of facultative energy expenditure, BAT volume 
being a key modifiable contributor to such an approach.  
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Chapter 5 
 
 
EFFECT OF MEAL DURATION ON DIET INDUCED 
THERMOGENESIS AND BIOCHEMICAL METABOLIC 
MARKERS 
 
 
 
 
 
Definition of Fletcherism: 
…. the practice of eating in small amounts and only when hungry, and of chewing 
one’s food thoroughly 
 
Merriam-Webster dictionary 
 
Fletcher, Horace (1849-1919), American dietician. 
Fletcher was plagued by obesity and indigestion most of his life. Then in 1895 he set out to 
find the key to good health. He developed a set of principles, which he proceeded to 
propagate. The basic tenets were these: one should eat only when genuinely hungry and 
never when anxious, depressed, or otherwise preoccupied; one may eat only food that 
appeals to the appetite; one should chew each mouthful of food 32 times or, ideally, until the 
food liquefies; one should enjoy one’s food. 
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5.1       Introduction 
 
The global obesity epidemic is showing no signs of abating.  Obesity and its 
associated problems constitute the biggest threat to the health of our species, and 
form a major component of the global healthcare economy (Danaei G et al 2011409). 
It is imperative that novel strategies to tackle obesity are developed and 
implemented. To mitigate the adverse impact of obesity on global health and health-
care economies, a multi-faceted approach is required. Such an approach should 
incorporate the development of novel pharmacological strategies, re-design of our 
living spaces for enhanced energy expenditure (EE), governmental approaches to 
improve our diet and obesogenic environment and cultural and lifestyle changes, 
particularly for our children. 
 
Diet is a major determinant of fat mass, and an obvious target for the prevention and 
management of obesity (Forget et al 201384). It appears that behavioural and 
nutritional strategies that can help control appetite and energy intake should be 
developed and tested for their efficacy in body-weight management. Food-related 
lifestyle factors such as meal frequency (La Bounty et al 2011103), macronutrient 
composition (Karhunen et al 2008410), and viscosity (Juvonen et al 2009411) are 
studied. Other dietary factors are worthy of further exploration, and this includes 
duration of meal.  
 
Many characteristics of meals have been shown to promote energy intake in feeding 
studies, including large portion size (Orlet Fisher et al 2003412, Levitsky et al 
2004413)  rapid eating rate (Kral et al 2001414), energy density (Kral et al 2004415, 
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Karl et al 2013415) low levels of dietary fibre (Burton-Freeman et al 2000416), high 
palatability (McCroy et al 2006417), high fat content (Prentice et al 1998418), high 
glycaemic load Ludwig et al 1999419), and high sugar content of diet in liquid form 
(DiMeglio et al 2000420). It appears that meal duration is perhaps the only non-
nutritional factor amongst the above key parameters, and along with meal frequency 
constitutes a potentially modifiable behavioural entity towards reduced energy 
intake. 
 
According to Webster dictionary, ‘to gorge’ means ‘to swallow in large mouthfuls or 
quantities’ or ‘with greediness’. Ubiquity of fast foods has encouraged excess 
‘gorging’, reflecting increased portion size and quicker eating rates, resulting in 
increased energy intake (French et al 2001421). In a large self-reported survey 
conducted on Japanese civil servants, faster eating was directly proportional to BMI, 
and the survey concluded that faster eating leads to obesity (Otsuka et al 2006110). 
Multiple feeding studies in humans show faster eating rates increase energy intake 
during single meals (Andrade et al 2008106, Martin et al 2007107, Zandian et al 
2009108 and is associated with higher BMI (Hill et al 1984109, Otsuka et al 2006110, 
Maruyama et al 2008110). This observation is also supported by several animal 
studies (Clifton et al 1984422, Sclafani et al 1994423, Lucas et al 1988424).  
 
Contrarily, eating slowly is often advised for weight management as slower eating is 
thought to allow satiation to be perceived before too much energy is further 
consumed (Stuart et al 1972425). Appetite is regulated by a variety of neuro-
endocrine signals including gut and pancreatic hormones such as glucagon-like 
peptide-1 (GLP-1), ghrelin, pancreatic polypeptide (PP), peptide-YY (PYY), insulin, 
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adiponectin, leptin and non-esterified fatty acids (NEFA) (Wren et al 2007277). It has 
been proposed that slower rates of ingestion allow more time for these peripheral 
signals to act, lengthen satiety’s duration, and reduce total energy intake (Martin et al 
2007107, Stuart et al 1972425).   
 
Controversy exists in the current literature regarding the effects of meal duration on 
weight, appetite, food ingestion and metabolism (Tanihara et al 2011426, Sasaki et al 
2003427, Otsuka et al 2006110, Maruyama et al 2008111, Pliner et al 2006428, Sobki et 
al 2010429, Brindal et al 2011112). As mentioned in chapter 1.7.1, manipulation of 
BAT may provide an answer to obesity, and BAT is implicated in DIT (which 
constitutes 10% of TEE) as demonstrated extensively in both animal studies (Glick 
et al 1984235, Glick et al 1984234), as well as human PET studies (Orava et al 2011176, 
Vosselman et al 2013236). There are no studies so far in the literature looking at the 
effect of meal duration on DIT. It is therefore timely to develop a clearer 
understanding and insight into the metabolic effects of slower eating, including 
postprandial energy expenditure. Such insight will aid formulating future public 
health messages regarding population-wide weight-loss strategies based on food-
related behaviour such as meal duration to tackle the worsening obesity epidemic.  
 
 
 
 
 
 
 
! 159!
Therefore the hypothesis for this set of studies was that: 
1. Slower eating rate (increased meal duration) increases postprandial energy 
expenditure (through prolonged increase in DIT) in obese subjects. 
2. Change in meal duration may cause metabolically favourable postprandial 
pancreatic and gut hormonal effects in obese subjects. 
3. Hunger and satiety are not affected by meal duration since the overall calorie 
intake remains the same. 
 
Therefore the aims of these studies were: 
1. To establish whether longer meal duration compared to shorter duration 
increases energy expenditure in obese normoglycaemic females. 
2. To ascertain whether meal duration affects circulating insulin, glucose, lipids, 
GLP-1, ghrelin, PYY, PP, leptin and adiponectin levels in obese 
normoglycaemic females. 
3. To ascertain whether meal duration affects appetite (assessed both on a visual 
analogue scale [VAS] and through ingestion of a standard buffet). 
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5.2         Methods 
 
5.2.1      Subjects   
 
The methodology for this study is discussed in detail in Chapter 2.3. All subjects 
(n=10) were recruited from the Obesity clinic at the Warwickshire Institute for the 
Study of Diabetes, Endocrinology and Metabolism (WISDEM) centre at the 
University Hospitals Coventry and Warwickshire (UHCW), as described in Chapter 
2.3.2. In brief, all 10 subjects were obese (BMI >30Kgm-2) adult pre-menopausal 
women, with normoglycaemia (based on fasting and postprandial plasma glucose 
measurements, and no past history of dysglycaemia). All subjects were white 
Caucasian non-smokers and none had any other medical problems. Specifically, 
none had any weight-related conditions such as Polycystic Ovary Syndrome, 
Cushings Syndrome, Obstructive Sleep Apnoea or other adverse metabolic sequelae. 
Exclusion criteria included prior bariatric surgery, weight-loss medication or actual 
weight-loss of >2.5kg up to three months prior to recruitment and dislike of the 
standard meal. Inclusion and exclusion criterial are as outlined in section 2.3.2. All 
subjects had received standard lifestyle advice (dietary modification and exercise) 
from a specialist dietician prior to inclusion in the study. All clinical investigations 
were conducted in accordance with the guidelines in the Declaration of Helsinki. All 
subjects provided fully informed written consent, and a local Research Ethics 
Committee in the United Kingdom approved the study.  
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5.2.2    Protocol: Anthropometry, calorimetry and meal duration 
 
Following informed consent, each subject was invited to undergo metabolic studies 
on two separate days in Whole-Body Calorimeters (WBC) at the Human Metabolism 
Research Unit (HMRU), a University of Warwick and UHCW NHS Trust facility. 
HMRU facility and mechanism of WBCs are discussed in detail in Chapter 2.3.6.  
 
The two WBC metabolic studies were executed within 2 weeks of each other. 
Subjects were instructed to avoid caffeine ingestion and strenous physical activity 
for 24-hours preceding each visit, and to adhere to their normal diet and physical 
activity schedules. Subjects were fasted for 12 hours prior to commencement of each 
metabolic study. On each study day, the subject was requested to arrive at HMRU in 
a fasted state on the morning of their study. Prior to their first WBC metabolic study, 
waist circumference, BMI and body composition (fat mass and fat percentage) was 
measured, the latter with a BodPod using air displacement plethysmography as 
outlined in Chapter 2.3.5. 
 
Baseline fasting blood tests were taken following which the subject entered the 
WBC at 0900h. On entry into the WBC and for the first 120 minutes of the 
metabolic study, each subject was requested to lie still on the bed to allow for 
equilibration and to provide an estimate of baseline resting EE. During postprandial 
periods, subjects watched TV or read quietly with minimal ambulation.  
 
For each study day, standard lunch was provided at 1200h. The same standardised 
lunch (designed and prepared by a specialist weight-management dietician) was 
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served for all the metabolic studies. The standard lunch (ham sandwich, yoghurt, 
banana, biscuit and orange juice drink) contained a total of 763kcal; 50% 
carbohydrate, 18% protein, and 32% fat. On their first metabolic assessment day, 
each subject was served standard lunch, with caloric content of the meal divided 
equally into eight separate food boxes, the food contents of each box eaten over 5 
minutes for a total meal duration of 40 minutes (the lunch being completed by 
1240h). This is referred to as ‘D40’. For the second metabolic assessment (on a 
different day), an identical protocol was followed except that the duration of the 
standard lunch was 10 minutes rather than 40 minutes. For this assessment, the 
caloric content of the standard meal was divided into two halves, with the food 
contents of each box being eaten over 5 minutes for a total meal duration of 10 
minutes (the lunch being completed by 1210h). This is referred to as ‘D10’. Subjects 
were provided with timers and were monitored by study investigators to ensure 
compliance with eating rate. Subjects were instructed to vary chewing speed 
accordingly. 
 
5.2.3       Protocol: Postprandial phase 
 
During the 4-hour postprandial phase, subjects were requested to remain seated in 
the WBC with minimal activity and to refrain from ingestion of food or drink. Blood 
tests were taken at pre-defined time-points (at baseline, 30-, 60-, 90-, 120-, 180- and 
240-minute intervals). The timing of the postprandial blood tests was determined by 
the end-point of the standard meal (to avoid taking any blood tests during the D40 
meal), ie. time ‘0’ was defined by the end of the meal: for D40 at 1240h and for D10 
at 1210h. Blood was taken from an arm placed through a hatch of the WBC, a plastic 
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cover used to avoid any air exchange with the WBC. All samples were spun in a 
centrifuge immediately, and serum samples frozen at -80°C. Appetite was assessed 
just prior to each blood test through use of VAS. At 1700h, subjects were invited to 
leave the WBC and offered an ad libitum standard buffet meal, consisting of various 
cold foods (sandwiches, chocolate bars, fruit, sausage rolls and drinks). The carloric 
content and macronutrient composition of the ad libitum food ingested was 
calculated. DIT ([Postprandial EE - Baseline EE]/Amount of calorie ingested) was 
calculated using validated methods reported in literature, as outlined in Chapter 
2.3.7. 
 
5.2.4    Biochemical evaluation 
 
Fasting baseline serum samples taken at the first metabolic study for each subject 
were analysed for lipid profile (Total Cholesterol, LDL Cholesterol, HDL 
Cholesterol and Triglycerides), HbA1C, glucose, 0900h cortisol, Insulin-like Growth 
Factor 1 (IGF1), Thyroid  Stimulating Hormone (TSH), free T4, Testosterone, Sex 
Hormone Binding Globulin (SHBG) and 25-hydroxycholecalciferol. Postprandial 
and pre-lunch blood samples (D40 and D10) were analysed for Ghrelin, Leptin, 
PYY, GLP-1, Adiponectin, Cortisol, Insulin, Glucose, Total Cholesterol, LDL 
Cholesterol, HDL Cholesterol, Triglycerides, Endotoxin and NEFA, at predefined 
time points (at baseline, 30-, 60-, 90-, 120-, 180- and 240-minute intervals). The 
methodology of collection of blood samples and laboratory analyses are outlined in 
Chapter 2.7.11, Chapter 2.7.12, Chapter 2.7.13 and Chapter 2.7.14. Insulin resistance 
was calculated using HOMA-IR method as outlined in Chapter 2.7.15. 
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5.2.5    Statistical analyses and power calculations 
 
Statistical analyses were conducted in SPSS (version 21 Windows; SPSS Inc., 
Chicago, IL) and Microsoft Excel. Paired sample t-tests were used for comparisons 
of 4-hour postprandial ‘Area Under the Curve’ (AUC) metabolic and biochemical 
data between D40 and D10. Each subject acted as their own control thereby limiting 
confounding. We had >80% power to detect a between-meal duration difference 
exceeding 50% of a Standard Deviation (SD) for plasma glucose from D10 and D40 
(alpha=0.05). A P-value <0.05 was considered significant. Data are shown as mean 
and SD. AUC was calculated using the validated Trapezoid method in Excel 
(Pruessner et al 2003380). 
 
5.3   Results 
 
5.3.1 Baseline anthropometric, clinical and biochemical data 
 
Baseline anthropometric, clinical and biochemical (fasting) data from measurements 
taken prior to entry into the WBC on the first visit are shown in Table 5.3.1. The age 
[mean (SD)] of the subjects was 41.8 years (6.9). All subjects were obese by 
definition with BMI [mean (SD)] of 42.1Kgm-2 (4.6), and fat percentage [mean 
(SD)] of 50.7% (7.4). By definition, all subjects had normal fasting glucose and 
HbA1C, with mean (SD) values being 4.7mmol/l (0.6) [84.7mg/dl (10.8)], and 5.6% 
(0.3) respectively. All subjects were biochemically euthyroid and 
normoandrogenaemic.  
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Table 5.3.1: Baseline anthropometric, clinical and biochemical (fasting) data for 
all subjects (n=10) taken prior to entry into WBC at first metabolic study 
Subject parameters Mean  SD 
Age (years) 41.8  6.7 
Weight (Kg) 116.5 16.2 
BMI (Kgm-2) 42.1 4.6 
Waist Circumference (m) 1.20 0.09 
Hip Circumference (m) 1.35 0.13 
Waist:Hip Ratio 0.90 0.1 
Fat mass (Kg) 59.5 14.5 
Lean mass  (Kg) 57.0 8.7 
Fat % 50.7 7.4 
Glucose (mmol/l) 4.7 0.6 
Total Cholesterol (mmol/l) 5.0 0.9 
LDL Cholesterol (mmol/l) 3.2 0.8 
HDL Cholesterol (mmol/l) 1.3 0.1 
Triglycerides (mmol/l) 1.2 0.3 
HbA1C (%) 5.6 0.3 
9am Cortisol (ηmol/l) 356 165 
IGF1 (ηmol/ml) 20.7 5.8 
TSH (mIU/l) 2.4 1.1 
Free T4 (pmol/l) 15.2 1.6 
Testosterone (ηmol/l) 0.8 0.6 
SHBG (ηmol/l/ml) 54.4 31.5 
25-OH vit D (ηmol/ml) 36 18 
 
25-OH vit D-25-hydroxycholecalciferol; SHBG-Sex Hormone Binding Globulin; 
TSH-Thyroid Stimulating Hormone; IGF1-Insulin-like Growth Factor-1; HDL-High 
Density Lipoprotein; LDL-Low Density Lipoprotein; SD-Standard deviation; 
HbA1c- Glycated haemoglobin  
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5.3.2    The Effect of 10-minute Meals or 40-minute Meals on Diet Induced 
Thermogenesis in Obese Subjects 
 
RMR for D40 and D10 were equivalent (RMR [SD]: 37.4 Kcal/hr [2.5] versus 38.6 
Kcal/hr [3.7] respectively, P=NS). DIT for 4-hr postprandial duration was 
significantly greater in D40 than D10 (DIT mean [SEM]: 80.9Kcal [1.4] versus 
29.9Kcal [1.2] respectively, P=0.006; DIT AUC 71.7 Kcal versus 22.4 Kcal 
respectively, P=0.02). When calculated as a proportion of energy intake during the 
meal, DIT was also significantly higher in D40 than D10 (DIT mean % [SEM]: 
10.6% [0.2] vs 3.9% [0.2] respectively, P=0.006). 
 
Table 5.3.2.1   Diet Induced Thermogenesis (DIT) of 10-minute and 40-minute 
meals 
Time (min) DIT-D10 
(Kcal/hr) 
DIT-D40 
(Kcal/hr) 
Significance 
30 6.2 11.1   
60 6.7 14.4   
90 3.9 12.1   
120 2.6 11.4   
150 1.3 14.1   
180 2.2 3.4   
210 -1.8 7.2   
240 8.7 7.2   
Total DIT  29.9 80.9 P=0.006 
SD 3.4 3.8   
SEM 1.2 1.4   
AUC 22.4 71.7 P=0.02 
 
SD-Standard deviation; SEM- Standard error of mean; AUC- Area under the curve; 
DIT- Diet induced thermogenesis 
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Figure 5.3.2.2 Comparison of diet induced thermogenesis between 10-minute meals 
and 40-minute meals in obese females.  
 
 
 
Figure 5.3.2.3 Comparison of diet induced thermogenesis (expressed in percentage 
of the total meal calories ingested) between 10-minute meals and 40-minute meals in 
obese females.  
! 168!
5.3.3    The Effect of 10-minute Meals or 40-minute Meals on Delta Energy 
Expenditure rates in Obese Subjects 
 
The post-D40 energy expenditure rate was significantly higher than D10 (Mean ΔEE 
rate-D40 24.3 Kcal/hr [3.2] versus 20.2 Kcal/hr [3.7]. 
 
 
 
Figure 5.3.3 Comparison of energy expenditure rate difference between pre- and 
post 10-minute meals and 40-minute meals in obese females.  
 
5.3.4 The Effect of 10-minute Meals or 40-minute Meals on Serum Glucose and 
Insulin in Obese Female Subjects 
 
Postprandial serum glucose levels were lower and trending towards significance in 
D40 compared with D10 groups (Mean Glucose [SEM] 6.0 mmol/L [0.4] versus 6.4 
mmol/L [0.3], P=0.07; Glucose AUC [SEM] 23.8mmol.hr/L [0.7] versus 
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25.2mmol.hr/dl [0.9] respectively, P=0.07). Postprandial insulin levels were 
statistically equivalent between D40 and D10 (Mean Insulin 615pmol/L [143] versus 
693 pmol/L [130], P=0.24; Insulin AUC 2416pmol/L/hr [301] versus 2853pmol/L/hr 
[537] respectively, P=0.29). 
        
       
 
Figure 5.3.4 Comparison between the effect of 10-minute meals and 40-minute 
meals on serum insulin and serum glucose in obese females.  
 
5.3.5 The Effect of 10-minute Meals or 40-minute Meals on Serum Adiponectin 
and Serum NEFA in Obese Female Subjects 
 
Postprandial adiponectin was significantly higher for D40 than D10 (Adiponectin 
AUC 33385ηg.hr/ml [3939] versus 27293 ηg.hr/ml [3775] respectively, P=0.04; 
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Mean Adiponectin [SEM]: 8382ηg/ml [1262] versus 6880ηg/ml [389], P=NS]). 
Plasma NEFA in the postprandial period was significantly lower for D40 than D10 
(NEFA AUC 627µmol/L/hr [56] versus 769µmol/L/hr [60] respectively, P=0.02; 
Mean NEFA [SEM] 191µmol/L [50] versus 242µmol/L [69] respectively, P=NS) 
 
        
 
Figure 5.3.5 Comparison between the effect of 10-minute meals and 40-minute 
meals on serum adiponectin and serum NEFA in obese females.  
 
5.3.6 The Effect of 10-minute Meals or 40-minute Meals on Pancreatic, Gut 
hormones, Cortisol and HOMA-IR in Obese Female Subjects 
 
Ghrelin was significantly higher in D40 compared to D10 (Mean Ghrelin 78 pg/ml 
[5.3] versus 54pg/ml [5.7], P=0.04; Ghrelin AUC 305pg/ml/hr [77] versus 
226pg/ml/hr [43], P=NS). For all other postprandial analytes including leptin, GLP-
1, PYY, PP, cortisol, lipid profile, endotoxin and HOMA-IR, mean data and AUC 
data between D40 and D10 were equivalent.  
! 171!
        
        
!!!!!!!!  
!!!!!!!!
 
Figure 5.3.6    Comparison between the effect of 10-minute meals and 40-minute 
meals on serum pancreatic, gut hormones, cortisol, HOMA-IR in obese females.    
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Table 5.3.7: Postprandial biochemical data of study subjects following each 
standard meal (D10 versus D40)  
 
Analyte 
 
 
D10 
AUC 
(SEM) 
 
D40 
AUC 
(SEM) 
 
P-
value 
 
D10 
Mean 
(SEM) 
 
D40 
Mean 
(SEM) 
 
P-
value 
Glucose 
(mmol/l) 
25.2 
(0.9) 
23.8 
(0.7) 
0.07 6.4 
(0.3) 
6.0 
(0.4) 
0.07 
Insulin 
(pmol/l) 
2853 
(537) 
2416 
(301) 
NS 693 
(130) 
615 
(143) 
NS 
NEFA 
(µmol/l) 
769 
(60) 
627 
(56) 
0.02 242 
(69) 
191 
(50) 
NS 
Ghrelin 
(pg/ml) 
226 
(43) 
305 
(77) 
NS 54 
(5.7) 
78 
(5.3) 
0.04 
Leptin 
(ηg/ml) 
69645 
(19352) 
74291 
(15718) 
NS 17154 
(693) 
17837 
(1194) 
NS 
GLP1 
(pg/ml) 
292 
(34) 
274 
(29) 
NS 72 
(3.2) 
67 
(3.3) 
NS 
PYY 
(pg/ml) 
535 
(37) 
503 
(34) 
NS 132 
(6.2) 
127 
(6.4) 
NS 
Adiponectin 
(ηg/ml) 
27293 
(3775) 
33385 
(3939) 
0.04 6880 
(389) 
8382 
(1262) 
NS 
Cortisol 
(ηmol/l) 
1424 
(241) 
1575 
(93) 
NS 387 
(45) 
438 
(64) 
NS 
Total 
Cholesterol 
(mmol/l) 
18.9 
(0.8) 
18.8 
(1.1) 
NS 4.7 
(0.03) 
4.7 
(0.01) 
NS 
LDL 
Cholesterol 
(ηmol/l) 
12.0 
(0.8) 
11.8 
(1.0) 
NS 3.0 
(0.04) 
3.0 
(0.02) 
NS 
HDL 
Cholesterol 
(ηmol/l) 
4.1 
(0.1) 
4.1 
(0.2) 
NS 1.03 
(0.01) 
1.03 
(0.01) 
NS 
Triglycerides 
(ηmol/l) 
5.7 
(1.3) 
5.7 
(1.3) 
NS 1.4 
(0.05) 
1.4 
(0.06) 
NS 
Endotoxin 
(EU/ml) 
23.4 
(3.5) 
23.2 
(3.5) 
NS 6.0 
(0.4) 
5.9 
(0.4) 
NS 
HOMA-IR 846 
(11.0) 
701 
(5.5) 
NS 209 
(50.7) 
182 
(55.6) 
NS 
 
AUC=Area Under the Curve; SEM=Standard Error of Mean; HDL 
Cholesterol=High Density Lipoprotein Cholesterol; LDL Cholesterol=Low Density 
Lipoprotein Cholesterol; NEFA=Non-Esterified Fatty Acids; GLP1=Glucagon-Like 
Peptide 1; PYY=Peptide YY; For the AUC data, the units are multiplied by time 
(hours); HOMA-IR=Homeostatic model assessment estimated insulin resistance. 
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5.3.7  Postprandial Appetite (Visual Analogue Scale and ad libitum evening 
buffet) 
 
Postprandial data on appetite (VAS) and evening buffet consumption are as shown 
below in Table 5.3.7. As expected, appetite was at its height pre-meal (standard 
lunch), and was most suppressed in the early postprandial phase (0-90 minutes) 
following lunch. VAS for D40 and D10 however were equivalent throughout. For 
the early evening ad libitum buffet following the standard lunch, total calories 
ingested and macroconstituent food fractions for D40 and D10 were equivalent 
(mean [SD] total calories ingested 482Kcal [274] versus 448Kcal [243] respectively, 
P=NS).  
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Table 5.3.7 Data showing measures of appetite (visual analogue scales) in the 
postprandial phase, consumption of ad libitum evening meal data and energy 
expenditure in the postprandial phase  
 
 
Variable 
 
 
D10 Mean 
(SD) 
 
D40 Mean 
(SD) 
 
P-value 
Pre-meal appetite 
VAS 
7.4 (2.4) 7.5 (2.6) NS 
Early postprandial 
appetite VAS  
(0-90 mins) 
 
1.7 (0.9) 
 
1.6 (1.1) 
 
NS 
 
Late postprandial 
appetite VAS  
(120-240 mins) 
 
3.3 (2.1) 
 
3.2 (2.2) 
 
NS 
 
Post-buffet VAS 
4.1 (3.1) 2.6 (3.0) 
NS 
 
Buffet total calories 
ingested (Kcal) 
448 (243) 482 (274) 
NS 
 
Buffet total protein 
ingested (g) 
21 (9.0) 24 (7.6) 
NS 
 
Buffet total CHO 
ingested (g) 
41 (24.1) 45 (29.6) 
NS 
 
Buffet total fat 
ingested (g) 
23 (16.4) 23 (17.6) 
NS 
 
 
 
VAS- visual analogue scale (0- no hunger and fully satiated; 10- extremely hungry); 
g-grams; CHO- carbohydrate; Kcal- Kilocalories; SD-standard deviation 
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5.4    Discussion 
 
We have demonstrated in a well-phenotyped, well-controlled and objective study on 
meal duration, that eating a standard lunch over 40-minutes versus the same lunch 
over 10-minutes, is associated with significantly enhanced DIT, postprandial 
suppression of plasma NEFA and elevated adiponectin levels in obese women. Our 
study is the most comprehensive one to date on the metabolic and appetitive effects 
of meal duration, and to our knowledge this is the first report of effects of meal 
duration on DIT in a WBC.  
 
Adoption of a consistently slow eating rate over time may, through effects on serum 
adiponectin levels, confer positive metabolic effects (including improved insulin 
sensitivity) given the known beneficial functions of adiponectin (Turer et al 2012430). 
We hypothesize that the importance of the relative changes in postprandial serum 
adiponectin levels in D40 compared with D10 may facilitate an increased action of 
insulin on NEFA through enhanced peripheral lipoprotein lipase activity (Lambert et 
al 2012431, Farese et al 1991432). This in turn may result in reduced ‘spill-over’ of 
NEFA within adipose tissue, and associated increased uptake of fatty acids from 
chylomicrons into adipocytes (Padwal et al 2007433). As such the enhanced 
postprandial suppression of NEFA associated with slower eating behaviors would, 
over time, result in reduced exposure of organs such as the liver and heart to fatty 
acids. Reduced ectopic fat deposition within these organs would improve insulin 
sensitivity and risk of future development of T2D and other features of the metabolic 
syndrome. Previous studies support this, highlighting an association between short 
meal duration and development of impaired glucose tolerance, T2D and other 
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cardiometabolic risk factors (Totsuka et al 2011434, Sakurai et al 2012435). The 
effects of slow duodenal infusion of a fat-containing, stable isotope-labelled liquid 
meal versus a bolus oral meal-feeding paradigm on NEFA ‘spill over’ in healthy 
men was reported by Barrows and colleagues (Khanna et al 2012436). The quantity of 
NEFA ‘spill over’ over 9-hours was similar between the two regimes. The effects of 
meal duration on NEFA levels could therefore be influenced by macronutrients (with 
variable effects on insulin release according to duration of ingestion).  
 
Ingestion of food results in increased oxygen consumption and body temperature 
primarily from digestive processes accounting for DIT (Westerterp-Plantenga et al 
1999437). Between D40 and D10, a mean difference in DIT of 51Kcal per 763Kcal 
standard lunchtime meal was observed during the 4-hour postprandial period. If 
extrapolated for an entire year, the expected difference in DIT between D40 and D10 
would be 18,626Kcal. Assuming that 3500 Kcal is equivalent to 395g of fat 
(Wishnofsky et al 1958438), this equates to a difference in body weight of 2.1 
kg/year. Although varying the protein content of meals may also influence DIT and 
body weight (Veldhorst et al 2008439), the macronutrient constituents (including 
protein) of the lunch in our study was fixed, suggesting that this disparity in DIT is a 
reflection of the difference in meal duration between D40 and D10.  
 
Furthermore, in a recent study involving eleven healthy human subjects, following a 
single meal, brown adipose tissue was postprandially activated, and maximal glucose 
uptake in brown adipose tissue was noted in comparison to rest of peripheral tissues, 
as demonstrated in 18-FDG-PET scans, implicating its role in DIT and hence energy 
homeostasis (Vosselman et al 2013440). Similar finding was noted in Orava and 
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colleagues human PET studies (Orava et al 2011176). These studies implicate BAT’s 
role in DIT, and prolonged activation of BAT from longer duration of meal may 
possibly explain our study findings of greater DIT in D40 than D10, and also 
enhanced plasma glucose suppression in D40 than D10 (although only trending 
towards significance p=0.07). Overall, this study provides evidence to suggest that 
slowing eating rate may, with time result in weight loss through enhanced DIT. 
 
Most reported studies on meal duration have been limited however by reliance upon 
subjective self-reported measures of eating behaviors in a cross-sectional design. 
Using such an approach, a positive association between BMI and speed of eating has 
been reported (Otsuka et al 2006110, Maruyama et al 2008111, Tanihara et al 2011426, 
Sasaki et al 2003427). In one of the largest studies to date on a Japanese cohort 
(n=7,275), each subject was divided into one of four groups according to self-
reported eating rate: slow, medium, relatively fast and very fast (Ohkuma et al 
2013441). It was demonstrated that the prevalence of obesity increased progressively 
with increased eating rate. There were also changes in blood pressure, lipid levels 
and glycaemic control according to eating rate (Ohkuma et al 2013441). Despite the 
compelling nature of the data, causality cannot be inferred. One potential mechanism 
whereby longer meal durations may reduce fat mass is through enhanced DIT, as 
directly observed in our current study.   
 
With regards to effects of meal duration on food intake and appetite, there is 
controversy. In one study, it was observed that subjects tend to eat more food with 
longer meal durations (Pliner et al 2006428). One explanation could be that eating 
food slowly has been associated with prolonged elevation of postprandial plasma 
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ghrelin levels (Sobki et al 2010429). Such an effect might be expected to reduce the 
satiating effects of food and lead to over-eating. Other reported studies showed 
variable effects of meal duration on postprandial appetitive factors although these 
were limited by inaccurate replication of normal eating patterns (Karl et al 2013415, 
Karl et al 2011442). In a study by Scisco and colleagues, implementation of a slow 
eating rate through use of a ‘bite-rate counter’ device was shown to reduce caloric 
intake (Scisco et al 2011443). We showed no differences in postprandial ghrelin 
(AUC data), appetite or subsequent ingestion of an ad libitum meal. 
 
The study subjects could be classed as normal metabolically healthy obese and not 
insulin resistant, and therefore might not have impacted on some of the biochemical 
changes despite the different transit time of meals. This could explain the equivalent 
results of endotoxin, a biomarker for metabolic inflammation. Also the meal itself 
contained 50% carbohydrate, 18% protein, and 32% fat and as such was balanced 
and not necessarily provoking a considered insult to the system as would a large 
meal or a high fat or high glucose meal could. Other postprandial gut hormone 
effects such as elevated PYY and GLP1, noted in previous studies (Kokkinos 
2010444) were not observed in our study. Whether there appears a blunted effect for 
these appetite-suppressing hormones in obese women (mean BMI [SD]: 42.1 [4.6]), 
remains to be clarified with future dedicated studies.    
 
Limitations of our study include the small number of subjects (although comparable 
to other reported studies in the field). This was necessary due to the detailed 
phenotyping of subjects. Another limitation was that we only studied the 
postprandial effects of meal duration. There may be other delayed metabolic and 
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appetitive effects of meal duration that would not have been identified with our study 
design. Finally, menstrual cycle phase has been shown to affect appetite and thereby 
may have influenced ad libitum energy intake (Brennan 2009445), which was not 
controlled for this trial. A long-term prospective study on the effects of meal 
duration on body weight, ectopic fat deposition and future cardiometabolic health 
would provide invaluable mechanistic insight.  
 
To summarize, these studies have identifed the beneficial effects on metabolism 
(including enhanced DIT, and imporved postprandial NEFA and adiponectin 
profiles) of eating a standard meal slowly. We hypothesize that the divergent effects 
of meal duration on metabolism over time would influence body fat mass, ectopic 
fat, insulin resistance and inherent cardiometablic risk including T2D development. 
Future prospective studies should focus on the longer-term cardiometabolic effects 
of meal duration. These studies would provide further data to provide invaluable 
insight into the complex mechanisms that link meal duration with metabolism and 
longer-term health. The current availability of high calorific foods and a culture and 
lifestyle for rapid consumption of such foods poses a challenge. Increased fibre 
content of food would tend to increase consumption time, and may also impact 
beneficially on overall metabolic health. This and other cultural, environmental and 
lifestyle strategies for modifying our eating behavior and adopting a more prolonged, 
leisurely and sociable ‘Frenchesque’ attitude towards food and mealtimes, are 
perhaps important public-health messages.     
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6.1 Introduction 
 
Given the limitations of current therapies, the current global obesity epidemic and 
escalating incidence of obesity-related deaths, it is imperative to identify novel and 
effective therapeutic options for obesity. Obesity results when energy intake exceeds 
expenditure chronically. Therapeutic strategies for obesity have mainly targeted 
caloric restriction through central appetite suppression and inhibition of fat 
absorption, and have not been so far successful (Padwal et al 2004, Cochrane 
review446). Centrally acting drugs can potentially cause adverse psychotropic side 
effects through cross-reactivity with a variety of other receptors within complex 
central circuits (Padwal et al 2004, Cochrane review446). Compared with those acting 
on central appetite regulation, therapies acting peripherally, termed as ‘cellular 
bioenergetics’, may prove beneficial whilst causing fewer harmful effects, and the 
most physiological ‘cellular bioenergetic’ is exercise (Tseng et al 2010447). The 
concept of increasing energy expenditure through therapeutic manipulation of 
peripheral mechanisms is therefore attractive and worthy of focused research and 
development. One such strategy is BAT. As outlined in Chapter 1.7.1, BAT’s role in 
beneficial metabolism is persuasive. Two independent but congruent human PET 
studies estimated an energy expenditure of 200-400 kcal/day, a 10 to 20% rise in 
daily basal metabolic rate through BAT activation (Yoneshiro et al 2011196, Muzik et 
al 2012240). Therefore, the glucose disposal (Orava et al 2011241) and triglyceride 
clearance properties of BAT (Bartelt et al 2011242), on sustained activation may act 
as an energy sink, and these properties form an attractive anti-diabesity solution. 
Appropriately, there is frantic activity in BAT research area, ranging from 
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characterisation of its physiology to pursuit of BAT-targeted ‘cellular bionergetic’ 
drugs. 
 
From this background, the thesis sought to undertake exploration of factors that 
stimulate and activate BAT. The turn of 21st century also marked rejuvenated interest 
in BAT, purely attributable to a significant technological advancement of integration 
of PET with CT scan enabling visualization of metabolically active BAT. 18Fluoro-
labelled-2-deoxyglucose Positron Emission Tomography (18F-FDG PET) is currently 
the gold standard and the most sensitive method to study BAT and its function. 
These studies concluded that younger-age, lower body mass index, female sex and 
cooler outdoor temperatures are strong determinant factors, and non-diabetes state as 
weak determinant factors of BAT prevalence. These BAT prevalence findings are in 
line with several PET-series research studies (Saito et al 2009143, Cypess et al 
2009141, Cronin et al, Pace et al 2011201, Persichetti et al 2013383, Zhang et al 
2014385). Information technological advances (MIRADA software) yielded robust 
calculation of BAT mass, which was strongly determined by younger subjects, 
females and lower BMI subjects, and weakly determined by previous week’s mean 
outdoor temperature. BAT activity was stronger in younger subjects, females and 
lean individuals. Scanning in cooler times of the day and when mean outdoor 
temperatures are lower were also noted to be weak determinant factors for BAT 
activity. Major limitation of the study is the inherent nature of PET to detect only 
metabolically activated BAT; which underestimates true prevalence given the scans 
are done in thermoneutral conditions which may switch off the BAT activity.  
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Surprisingly, modest elevation of thyroid hormones in a sustained iatrogenically 
created thyrotoxic state (levothyroxine and liothyronine replacement therapy for 
sustained TSH suppression in post-thyroidectomy thyroid cancer patients), did not 
influence any of the BAT indices of BAT prevalence, activity or mass, contrary to 
conventional wisdom and recent findings of Lahesmaa and colleagues (Lahesma et 
al 2014393). Excess thermogenesis from the skeletal route in hyperthyroid patients 
may centrally inhibit BAT pathway of non-shivering thermogenesis, which is usually 
modest even in maximal stimulated conditions. D2 levels of skeletal muscle in 
humans when compared to BAT are far higher than noted in mice, pointing out the 
diversification of tissue variations between the two species (Salvatore et al 1996395, 
Croteau et al 1996396). This might explain the failure of replication of animal data in 
humans, and the conventional hypothesis is based largely on animal studies. This 
negative finding also should be seen in the context of limitations of PET, which is a 
suboptimal modality of BAT imaging. Being a retrospective study, thyroid status 
based on biochemical thyroid function nearer to the scan date was determined, as 
opposed to thyroid function test on the day of the scan, possibly questioning the 
credibility of the scan findings in this sub-study. This leads on to the basis of next 
study, to find a suitable imaging method to identify and characterise BAT in its 
entirety during active and in inactive state. 
 
It is vital to know BAT’s anatomy and physiology, and this would aid achieve a 
targeted and meaningful therapeutic pursuit. A significant obstacle to the progress of 
research on human BAT has been the lack of a safe, sensitive, specific and 
reproducible imaging technique to quantify BAT volume and/or mass. Such a tool 
would be essential to evaluate the efficacy of novel therapies based on the 
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manipulation of BAT. Given the presence of ‘beige’, the intermediate type of fat, 
and the recognised phenomenon of beige transformation of WAT, it is all the more 
important to unequivocally identify and quantify different types of fat. The IDEAL 
MRI study first reproduced the experiments done by Hu and colleagues (Hu et al 
2010206) on a rat carcass to confirm the validity of IDEAL technique, and 
subsequently used the same technique on a human volunteer, also providing 
immunohistochemical confirmation of BAT from a fat sample obtained from the 
neck surgery. The BAT signals appeared more heterogeneous from the surrounding 
WAT and this is indeed the pattern that one would expect given the characteristic 
histological appearance of human BAT often occurring in many islets within 
surrounding WAT (Cinti et al)172. Key advantages of MR over PET-CT is that it is 
safe, measures BAT volume irrespective of activity status, and is not influenced by 
transient influential factors such as outdoor temperature. Our study thus provided 
proof of principle that MR can successfully delineate BAT from WAT, and has 
encouraged a large-scale study in UHCW to validate the methodology. It is possible 
that adipose tissue may be affected in some way in HPT-JT syndrome, which may in 
turn affect signal intensity on MR imaging. However, the histological and 
morphological characteristics of BAT samples obtained were comparable to that of f 
well validated studies (Virtanen et al 2009140, Cinti et al 2000172) .Few promising 
MR studies on BAT imaging have been reported in human subjects following our 
study, and more evaluation and validation are required at this stage before embarking 
on large-scale evaluations of BAT quantities (Hu et al 2013448, Khanna et al 
2012449).  
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It is appropriate to look for new therapeutical solutions for obesity; often, complex 
problems may have simple solutions. Change in behaviour and lifestyle is a 
recognized, inexpensive, and beneficial intervention. Recognised stimulators of BAT 
are cold exposure (Cold induced Thermogenesis-CIT) and diet (DIT). The thesis 
sought to evaluate manipulation of speed of DIT, and other bio-chemical metabolic 
factors involved in regulation of hunger, appetite and glucose metabolism. To our 
knowledge, this is the first-ever reported effort to investigate meal duration in the 
context of energy expenditure. These set of studies have identifed the beneficial 
effects on metabolism (including enhanced DIT, and improved postprandial NEFA 
and adiponectin profiles) of eating a standard meal slowly. Limitations include small 
number and limited to only obese women. However, similar published energy 
expenditure experiments recruited comparable number of study subjects (Zhang et al 
2002218, Johnston et al 2002450) and detailed phenotyping was required to boost the 
power of the study; therefore the recruitment limitation to obese caucasian pre-
menopausal women.  We hypothesize that the divergent effects of meal duration on 
metabolism over time would influence body fat mass, ectopic fat, insulin resistance 
and inherent cardiometablic risk including T2D development.  
 
6.2 Future directions 
 
The thesis provides some useful insights regarding determinant factors of BAT 
prevalence, including that of lack of thyrotoxicosis effect on human BAT. This may 
possibly be due to retrospective nature of the study. Dedicated prospective studies 
exploring effect of thyroid hormones on BAT is advised. Similar to thyrotoxicosis, 
phaeochromocytoma is a hyperadrenergic state and theoretically should enhance 
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BAT activation. Apart from few case reports and small retrospective study, a 
dedicated study is lacking (Lean et al 1986250, Simonsen et al 1993248). 
 
HMRU at UHCW offers an excellent opportunity allowing study of 24- hour energy 
expenditure, and at the same time enabling the accurate assessment of energy intake 
in the form of Whole Body Calorimeters. Characterising BAT in metabolically 
relevant conditions such as thyrotoxicosis, phaeochromocytoma, diabetes, polycystic 
ovarian syndrome, cushings syndrome and various other metabolic states would be 
useful. The whole body physiology studies such as these are clearly important to 
study the effects of organ cross-talk during periods of food consumption, exercise 
and sleep, which cannot be undertaken in vitro, with isolated cell systems.  
 
PET-MRI with its capabilities to study thermoregulatory areas like hypothalamus 
may be able to provide answers for central regulation of brown fat. Functional MRI 
and other nuclear medicine advances in radiology field holds promising prospects for 
BAT research. 
   
In addition to augmentation of BAT content and/or enhancement of BAT activity, 
other approaches include trans-differentiation of non-BAT progenitors into BAT pre-
adipocytes, and surgical implantation of BAT. Development of novel BAT-related 
therapies will require a complete understanding of the embryological and 
transcriptional mechanisms of BAT specification and development in human 
models. Several transcriptional regulators of brown adipocyte differentiation are 
described in rodents, with some revealing promising effects even in human models 
(Wu et al146).  
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6.3 Conclusion 
 
In summary, this thesis provided useful insights into environmental, 
anthropometrical, behavioural, and hormonal factors regulating BAT. It also 
provided a proof of principle for an imaging tool to be developed in order to 
visualise full extent of both metabolically active and inactive BAT, adding evidence 
for future pursuits of BAT therapeutics to combat the global obesity epidemic. 
Whilst awaiting solutions for obesity, evidence from this thesis advocates simple 
behavioural modifications, such as adopting ‘Fletcherism’ (eating only when 
extremely hungry and chewing food for long durations)  and reducing thermostat of 
indoor living spaces. 
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Patient 
name:……………………
………. 
 
Patient DOB:………………………….. 
 
Patient 
address:.................................................................................. 
 
 
Dear Dr………………………, 
 
The above patient has given informed consent to be involved in a study 
looking into the development of biomarkers for human brown adipose 
tissue. This study is based at the University Hospital in Coventry. The study 
will involve collection of phenotypic and biochemical data, blood and urine 
samples, MRI scans and, in some patients (undergoing thyroidectomy for 
clinical reasons), analyses on fat samples taken peri-operatively from the 
neck. There may also be more detailed metabolic studies in the future. 
Confidentiality will be maintained at all times.  
 
Clinically relevant data requiring further investigation and management 
will be discussed with the patient and, if permission is given, their GP also. 
Appropriate follow-up will be arranged.  
 
If you have any queries relating to this study, please address them to the 
chief investigator who is Dr. Tom Barber (based at the WISDEM centre at 
the University Hospital, Coventry and Warwickshire). 
 
Yours sincerely, 
 
 
  Dr. Tom Barber 
  Associate Professor in Endocrinology and Diabetes 
  WISDEM Centre 
  University Hospital, Coventry and Warwickshire 
 
                     
                    Dr. Narendra Reddy 
  NIHR Clinical Lecturer in Endocrinology and Diabetes 
  WISDEM Centre 
  University Hospital, Coventry and Warwickshire 
 
Chief Investigator: Dr. Tom Barber; Letter to GP; Version 1; 4th January, 2011 !
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Information sheet for possible participation in the ‘Meal duration study’ 
 based at the University Hospital, Coventry and Warwickshire 
Version 1; 05/11/2011   
Chief investigator: Dr Tom Barber (WISDEM Centre, UHCW, Coventry) 
Dear Patient, 
This is an information sheet containing details about a study on ‘Effect of 
meal duration on human metabolism’ based here at the University 
Hospital, Coventry and Warwickshire. We are currently inviting patients 
who attend clinics at the WISDEM centre and healthy volunteers to take 
part. This is an important study as the results will provide a clearer 
understanding of how metabolism in humans (the burning off of ingested 
calories) is regulated and whether meal duration is a factor that affects 
metabolism. This study thus provides essential data of enormous public 
health importance.  
 
We would like to give you an opportunity to be involved in this study. 
Involvement would in no way compromise your care, data would be kept 
confidential and you would be kept fully informed at all times. If you are 
interested in taking part in this study, please indicate this by placing a tick 
in the box below, complete the requested details, detach this front sheet 
and either hand it to the clinic receptionist following your clinic 
appointment today or alternatively send the completed sheet to the Chief 
Investigator at the address provided at the top of this letter. If you are not 
interested in taking part, simply leave the box blank. 
 
If you are interested in taking part, it would be helpful if you could also 
provide your name, date of birth and contact number below so that the 
Chief Investigator or a member of his research team can contact you to 
make arrangements to meet up to gain informed consent and to provide an 
opportunity for you to discuss the study in more detail. Any information 
you give will be treated confidentially.   
  In am interested in taking part in this study   
My name is……………………………………………………………. 
My date of birth is………………………………………………… 
  My contact number is…………………………………………… 
   
Yours sincerely, 
   Dr. Tom Barber, Chief Investigator 
Other members of the research team: Dr. Narendra Reddy 
Prof. Kumar, Dr. H Randeva, Dr. M Weickert, Dr. J Hattersley, Louise 
Halder 
Chief Investigator: Dr. Tom Barber; Information sheet ; Version 3; 05/05/2011 
!
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Information sheet for participation in the ‘Effect of Meal Duration on 
Human Metabolism Study’ based at the University Hospital, Coventry 
and Warwickshire 
Version 1; 5th November, 2011 
Chief investigator: Dr. Tom Barber 
 
Introduction 
You are being invited to take part in a research study. Before you decide if 
you want to take part, it is important that you understand why the 
research is being done and what it would involve. Please take time to read 
the following information carefully and discuss it with others if you wish. 
There will be an opportunity to ask the Chief Investigator or a member of 
his research team if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take 
part. We thank you for taking the time to read this information sheet, and 
for taking part in this study if you decide to do so. 
 
 
What is the purpose of this study and why have I been asked to 
participate? 
You are being asked to take part in this study because you are either a 
patient who attends one of the outpatient clinics at the WISDEM centre or 
a healthy volunteer with physical attributes that are relevant to this study. 
 
Human metabolic disorders (including obesity) are some of the most 
important medical problems facing us today. It is crucial to gain a 
complete understanding of human metabolism so that we can adopt better 
life style or have a better chance of developing more effective drugs to 
treat metabolic problems in the future. Your involvement in this study 
would help us to achieve these goals. 
 
In Meal duration Study, volunteers will have some measurements taken 
(including height and weight) and will undergo non-invasive fat percentage 
estimation. This is undertaken with the help of a machine called BODPOD 
where the volunteer is requested to sit with minimal clothing on for 2-4 
minutes. There are no risks or complications involved from undergoing this 
test, specifically no exposure to radiation involved. 
 
     In phase 2, we will select appropriate participants involved in phase 1 
to be involved in more detailed metabolic studies on the Human Metabolic 
Unit (based at the University Hospital Coventry): this will involve attending 
for one day and having measurements of your fat mass (how much fat you 
have) and assessment of your metabolic rate (how much energy you use up) 
during resting, following a meal and following some exercise. 
 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take 
part you would be asked to sign a consent form. You would still be free to 
withdraw from the study at any time (and to withdraw your samples) 
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without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, would not affect the standard of care you receive. If you 
do decide to consent to be included in this study, with your consent we 
would inform your General Practitioner and any other relevant Heath Care 
Professionals of your inclusion in the study. 
 
What would happen if I took part? 
There are two phases to this study. All participants shall be invited to take 
part in phase 1. The phase 2 study is more detailed. You may be invited to 
take part in this also, although this will only be applicable to some of the 
participants who take part in the phase 1 study. 
 
Phase 1 study: If you agree, we would ask you to allow us to take a fasting 
blood sample and urine sample. You would be asked to come to the 
WISDEM Centre, University Hospital, Coventry to have the blood taken after 
an overnight fast (we would ask you not to eat or drink anything except for 
water for 12 hours prior to your morning appointment). Measurements from 
this blood test would include blood fats, sugars and other factors related to 
metabolism, in addition to blood to be used for extraction of DNA 
(discussed in more detail below). During this visit, we would also take a 
brief medical history from you and perform some measurements including 
height, weight and an estimation of how much fat you have in your body. 
Your urine sample and some of your blood samples will be kept in a tissue 
bank pending ethical approval for future studies. Following the fasting 
blood samples being taken, we will offer you breakfast. 
 
Phase 2 study: At a later date, we may invite you to attend for more 
detailed metabolic studies to take place on the Human Metabolic Unit at 
the University Hospital, Coventry. This would involve you attending for a 24 
to 36 hour period. We would take an accurate measurement of how much 
fat you have and then assess your metabolism over the course of 22.5 to 36 
hours (starting at 4pm). To do this, we will ask you to stay in a specially 
designed room (a ‘metabolic chamber’) while we measure the gases that 
you breathe in and out. A plan of the metabolic chamber is shown in figure 
1 at the end of this document.  To ensure that we can take accurate 
measurements, you would ideally need to stay in the room for the duration 
of the study (a maximum of between 22.5 and 36 hours) so it is equipped 
with a bed, desk and chair, computer access, TV, private toilet and sink.  
Metabolic rate will be assessed whilst at rest, during and following a 
‘standard meal’ and also possibly during and following some moderate 
exercise (for 15 minutes on an exercise bike). This latter assessment of 
exercise metabolism will only be applicable to certain participants who are 
able and willing to perform this exercise. A ‘standard meal’ means that the 
caloric content and quantities of protein, fats and sugars are kept constant 
and standardised between studies. These types of foods are widely used in 
both clinical and research practice. Any dietary requirements will be 
respected and catered for. In addition to these studies, we would also 
assess your sleep quality with a portable sleep machine whilst you are in 
the metabolic chamber. 
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What could be the possible disadvantages and risks of taking part? 
There are no obvious disadvantages or risks other than possible discomfort 
from having blood samples taken. To avoid inconvenience, the blood for 
research purposes would, if possible, be taken at the same time as any 
blood samples that are planned as part of your routine medical care. 
 
What could be the possible benefits of taking part? 
Your participation in the study is unlikely to provide any direct benefit for 
yourself. However certain results relevant to your medical care will be fed 
back (see section on “Will I be told the results” below). Your participation 
in this study would help us to understand better the determinants of 
human metabolism. This might help with the development of future 
treatment options. 
 
What would happen to my samples? 
The levels of a number of different hormones, blood fats, sugar and insulin 
would be measured. Some of those levels are measured routinely in 
patients who attend the WISDEM clinics and some are being measured for 
research purposes only. DNA (the body’s genetic blueprint) would be 
extracted from your blood as well so that we could identify which genes 
control the levels of these substances and human metabolism. Your 
samples would only be used to investigate factors related to human 
metabolism. Some of the blood will be stored within a laboratory in the 
University Hospital, Coventry until genetic analysis takes place. You have 
the right to withdraw your samples at any stage. The samples we collect 
and associated data may be shared with other investigators in the UK and 
elsewhere (both academic and industrial partners) working to understand 
the basis of human metabolism. However, when samples are passed to 
other investigators, no information that would allow personal identification 
will be shared.     
 
Would taking part in this study be kept confidential? 
If you consent to take part in the research, your medical records would be 
inspected by medical and nursing members of the research team. 
Information about you might be used when the results of the study are 
published in a medical journal, but your name would not be revealed. If 
you give your consent, then your General Practitioner would be notified, by 
letter, of your participation in the study. 
If you consent to take part in this research project, you will be allocated a 
unique personal identification number for the sole purpose of this study. 
This number will be used to label your blood samples and also in electronic 
datasets. This will ensure that all samples/data related to you will be 
anonymised throughout and will therefore ensure that confidentiality is 
maintained at all times. 
 
Would I be told the results? 
If any of your results have clinical relevance for you (such as results of the 
routine and research hormones, fats and sugar tests indicating a possible 
new diagnosis of Diabetes), then we would inform you of these. Your 
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General Practitioner would receive results of the routine tests and if you 
wanted, we would also send a copy of the research results to him/her.  
 
As with the other stored blood samples the samples for genetic research 
will also be anonymised with a unique patient identification code. We do 
not intend to feed back results of genetic tests to participants or their 
General Practitioners. However it would be possible for the Chief 
Investigator to use a participant’s genetic data to make associations with 
their clinical data. The link between a participant’s unique identification 
code and their other data collected during this study will be stored in a 
secure location within the University Hospital, Coventry. Only the Chief 
Investigator or a member of his research team will have access to this 
database. Some of the data and some of the samples collected may be 
used for future research studies.  
 
 
What if something goes wrong? 
This study is covered by the University of Warwick’s Clinical Trial Policy for 
standard fault claims based on the design of the study.  In the event that 
something does go wrong and you are harmed during the research and this 
is due to someone‘s negligence then you may have grounds for a legal 
action for compensation against University Hospitals Coventry & 
Warwickshire NHS Trust but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
 
Will I receive any payment for taking part in the study? 
If you incur any travelling expenses as a result of participating in this study 
through attending for blood tests or the more detailed metabolic studies 
then these will be fully reimbursed. You will not receive any other 
payment for taking part in this study. 
 
 
Who has reviewed the study? 
To ensure that the study is being conducted safely and ethically, the 
Birmingham East North & Solihull Research Ethics Committee have 
reviewed the study. This committee is a panel comprising medically 
qualified people and laypersons from the local community. 
 
 
Who is funding the study? 
The consumable costs are being provided from a variety of grants including 
existing funds available within the department and from the University of 
Warwick. The Chief Investigator will not be paid for including you in this 
study. 
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Future studies 
If you decide to give consent to be involved in this study, you will also be 
asked to give separate consent for the Chief Investigator to contact you at 
a later date regarding your possible involvement in future research studies 
relating to human metabolism that have relevant ethical approval.  
 
 
Contact for further information 
Should you require it, further information can be obtained from Dr. Tom 
Barber, Chief Investigator, Warwickshire Institute for Diabetes, 
Endocrinology and Metabolism, University Hospital, Coventry. 
 
 
If you have any concerns or complaints about the research, staff or 
conduct, please contact: 
 
 
Ms Nicola Owen, 
Deputy Registrar, 
University of Warwick,  
Research Support Services, 
University House, 
Kirby Corner Road, 
Coventry, 
CV4 8UW. 
 
E-mail: Nicola.Owen@warwick.ac.uk 
Telephone: 024 7652 2785 
Fax: 024 7652 4751 
 
 
Thank you. 
 
 
 Dr. Tom Barber (Chief investigator)  
          Dr Narendra Reddy (NIHR Clinical Lecturer) 
          Prof. Sudhesh Kumar, 
          Dr. Randeva, Dr. Weickert, Dr. Hattersley, Prof. Wilson 
University Hospital, Coventry 
 
 
 
Figure 1: Plan of the Human Metabolic Research Unit at the University 
Hospital, Coventry and Warwickshire illustrating the two whole-body 
metabolic chambers: 
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Consent form (phase 2) for participants recruited into the ‘Meal Duration Study’ 
 based at the University Hospital, Coventry and Warwickshire 
Version 2, 05/05/2011 
Chief investigator: Dr. Tom Barber 
    Please 
    initial  
    boxes 
1. I have already provided informed consent for inclusion in the first part of this 
study and have already had blood and urine samples taken for storage.          
  
   
 
2. I give consent for more detailed metabolic studies to be undertaken, including 
an assessment of the amount of fat tissue I have, and also my metabolic rate 
to be measured. I understand that this will involve living in a specially designed 
room (a ‘calorimetry chamber’) for between 2 to 36 hours.               
  
 
 
3. I give consent for my sleep quality to be assessed during the metabolic 
assessment in the calorimetry chamber, and understand that this will involve 
wearing a sensor on my finger, nasal prongs (for airflow assessment) and leads on 
my chest and head to detect electrical signals during sleep.   
  
 
 
4. I understand that I will be free to leave the chamber at any time, although to 
do so would invalidate the metabolic study results.   
   
 
5. I confirm that I do not suffer from claustrophobia or isolophobia.            
  
 
 
6. I confirm that I have not done any abnormal exercise and have not had any  
exposure to any radiation within 24 hours of entering the calorimeter chamber,  
that I do not feel unwell in any way and am not known to be pregnant.  
   
Chief Investigator: Dr. Tom Barber; Consent form phase 2, Version 2; 
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…………………………                …………………………….        …………………………. 
Name of participant           Date            Signature 
(BLOCK CAPITALS) 
 
 
 
…………………………..              …………………………….       ………………………….. 
Name of person taking consent     Date             Signature 
(if different from researcher) 
 
 
 
…………………………….              …………………………….       ……………………………. 
Name of researcher              Date    Signature 
 
 
 
 
 
 
1 copy for participant 
1 copy for researcher 
1 copy to be kept in hospital notes 
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Consent form for participants recruited into the ‘Development of Biomarkers  
for Human Brown Adipose Tissue study’ based at the University Hospital,  
Coventry and Warwickshire (MRI Study) 
Version 2, 23rd March, 2011 
Chief investigator: Dr. Tom Barber 
 
 Please 
 initial  
 boxes 
1. I have read the information sheet, version 1 dated January 2011, 
on the  
above project and have been given a copy to keep. I have had the 
opportunity to ask questions about the project and understand why 
the research is being done and any foreseeable risks involved. 
               
        
 
 
2. I give my consent to have MRI scans performed on two separate 
occasions 
for research purposes to provide images of fat tissue. I understand 
that MRI 
is a safe technique with no associated exposure to harmful ionising 
radiation and that a check-list of contra-indications (outlined in the 
information sheet) will be completed just before I have these 
scans.                                                                   
  
 
 
3. I give my consent to have blood and urine samples taken for storage.                     
 
  
  
Chief Investigator: Dr. Tom Barber; Consent form (IDEAL MRI), Version 2;                          
23rd March, 2011 !
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4. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.                  
  
 
5. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from the research team, from  
regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these 
individuals to have access to  
my records.               
           
                                      
 
6. I understand that I will be informed about the results of my 
medical blood tests if any of these have clinical implications for my 
health but I shall not be informed about the results of the genetic 
tests.   
  
 
7. I understand that I will not benefit financially if this research leads to the  
development of a new treatment or medical test.                 
  
 
 
8. I give consent for my General Practitioner to be informed of my 
involvement in this study and for him/her to be informed of the 
results of the investigations carried out during this study.  
  
  
 
 
9. I understand that some of my blood and urine samples will be 
stored within a  
laboratory in the University Hospital, Coventry and Warwickshire and 
that future studies with relevant ethical approval, using the samples I 
give may include genetic research aimed at understanding the 
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genetic influences on disease, but that the results of these 
investigations are unlikely to have any implications for me personally.  
  
 
 
10. I agree that the samples I have given and the information 
gathered about me can be looked after and stored in the University 
Hospital, Coventry for use in future studies with relevant ethical 
approval, as described in the information sheet. I understand that 
some of these ethically approved projects may be carried out in the 
future by researchers other than the study team, including 
researchers working for commercial companies. However when 
samples are passed to other investigators, no information that would 
allow personal identification will be shared.       
           
   
  
            
11. I know how to contact the research team if I need to.    
            
   
 
 
 
12. I give consent for the Chief Investigator or a member of the 
research staff working with him at the University Hospital, Coventry 
to re-contact me at a later date regarding my possible involvement in 
more detailed human metabolic studies with relevant ethical 
approval.         
  
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13. The following is a safety check-list relating to MRI scans. All the answers need 
to be answered carefully. They are designed to identify items which may either 
interfere with the scan or are potentially hazardous in a strong magnetic field:  
 
  Yes No 
1. Have you had an MRI scan before?   
2. Do you have or have you ever had a cardiac pacemaker?   
3. Have you ever had any surgery to your 
       a) heart or chest? 
  
        b) head or brain? eg. Aneurysm clips or programmable 
hydrocephalus shunt 
  
        c) eyes?   
        d) ears?   
4. Do you have any metal plates, screws or joint replacements?   
5. Do you have any electronic, mechanical or metal implants in any 
part of your body? 
  
6. Have you had any surgery in the last 8 weeks?   
7. Have you ever had any incidents to your face or eyes where 
metal splinters have entered at high speed (eg. While drilling or 
grinding)? Please tick yes even if these have been removed at an 
eye hospital. 
  
8. Have you had any incidents where bullets, shrapnel or other 
pieces of metal have entered your body? 
  
9. Do you suffer from diabetes, blackouts or epilepsy?   
10. Do you have any of the following? 
      a) Removable dentures containing metal. 
  
       b) A hearing aid.   
       c) Body piercing   
       d) Jewellery   
       e) An artificial limb, caliper or corset.   
       f) A transdermal patch.   
       g) Permanent cosmetics (eg. eyeliner)   
       h) Tattoos   
11. For females of child bearing age 
      a) Are you pregnant? 
  
       b) Are you breast feeding?   
            
      Tick 
box 
 
I confirm that I have been asked the above questions and the information is  
correct to the best of my knowledge.  
  
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…………………………                …………………………….        …………………………. 
Name of participant           Date            Signature 
(BLOCK CAPITALS) 
  
 
…………………………..              …………………………….       ………………………….. 
Name of person taking consent     Date             Signature 
(if different from researcher) 
 
 
…………………………….              …………………………….       ……………………………. 
Name of researcher              Date    Signature 
 
 
1 copy for participant 
1 copy for researcher 
1 copy to be kept in hospital notes 
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Information sheet for participants recruited into the ‘Development of 
Biomarkers for Human Brown Adipose Tissue study’ based at the 
University Hospital, Coventry and Warwickshire (MRI study) 
Version 2, 23rd March, 2011 
Chief investigator: Dr. Tom Barber (WISDEM Centre, UHCW, Coventry) 
 
Introduction 
You are being invited to take part in a research study. Before you decide if 
you want to take part, it is important that you understand why the 
research is being done and what it would involve. Please take time to read 
the following information carefully and discuss it with others if you wish. 
There will be an opportunity to ask the Chief Investigator or a member of 
his research team if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take 
part. We thank you for taking the time to read this information sheet, and 
for taking part in this study if you decide to do so. 
 
What is the purpose of this study and why have I been asked to 
participate? 
You are being asked to take part in this study because you are a patient 
who attends one of the outpatient clinics at the University Hospital in 
Coventry. Human metabolic disorders (including obesity) are some of the 
most important medical problems facing us today. It is crucial to gain a 
complete understanding of human metabolism so that we can have a better 
chance of developing more effective drugs to treat metabolic problems in 
the future. Your involvement in this study would help us to achieve these 
goals. 
 
The Adipose (fat) Tissue Study involves selection of patients to undergo a 
special scan involving MRI (a safe procedure with no associated exposure to 
harmful ionising radiation). The purpose of this would be to image fat 
depots important for metabolism. The scan would be repeated a few 
months later to see if there has been any change in your fat depots over 
time. Patients selected for this part of the study will be identified from 
review of previous images using other techniques (previous images taken 
for clinical reasons).  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take 
part you would be asked to sign a consent form. You would still be free to 
withdraw from the study at any time (and to withdraw your samples) 
without giving a reason. A decision to withdraw at any time, or a decision 
not to take part, would not affect the standard of care you receive. If you 
do decide to consent to be included in this study, with your consent we 
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would inform your General Practitioner and any other relevant Heath Care 
Professionals of your inclusion in the study. 
What would happen if I took part? 
Following informed consent and an opportunity to discuss the study 
with the Chief Investigator and to ask any questions, you would be 
invited to attend for a special Magnetic Resonance Imaging (MRI) scan on 
two separate occasions (separated by approximately 6 weeks). This will 
be to image your fat depots. Recruited patients will have already had 
other imaging taken for clinical reasons. MRI is a safe procedure and 
there is no exposure to harmful ionising radiation. There is a checklist 
of contra-indications (provided at the end of this information sheet) 
that will be completed just prior to each of your scans. Prior to the MRI 
scan, you will be invited to provide blood and urine samples for further 
analyses. At this time, we would also request a full medical history to be 
taken from you and for a non-invasive measurement of body fat mass to 
be taken, both for the purpose of this study. 
 
 
What could be the possible disadvantages and risks of taking part? 
There are no obvious disadvantages or risks other than possible discomfort 
from having blood samples taken. To avoid inconvenience, the blood for 
research purposes would, if possible, be taken at the same time as any 
blood samples that are planned as part of your routine medical care. 
 
 
What could be the possible benefits of taking part? 
Your participation in the study is unlikely to provide any direct benefit for 
yourself. However certain results relevant to your medical care will be fed 
back (see section on “Will I be told the results” below). Your participation 
in this study would help us to understand better the role of fat tissue in 
human metabolism. This might help with the development of future 
treatment options. 
 
 
What would happen to my samples? 
The levels of a number of different hormones, blood fats, sugar and insulin 
would be measured. Some of those levels are measured routinely and some 
are being measured for research purposes only. DNA (the body’s genetic 
blueprint) would be extracted from your blood as well so that we could 
identify which genes control the levels of these substances and human 
metabolism. Your samples would only be used to investigate factors related 
to human metabolism. Some of the blood will be stored within a laboratory 
in the University Hospital, Coventry until genetic analysis takes place. You 
have the right to withdraw your samples at any stage. The samples we 
collect and associated data may be shared with other investigators in the 
UK and elsewhere (both academic and industrial partners) working to 
understand the basis of human metabolism. However, when samples are 
passed to other investigators, no information that would allow personal 
identification will be shared. Some of your samples will be kept in long-
term storage.      
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Would taking part in this study be kept confidential? 
If you consent to take part in the research, your medical records would be 
inspected by medical and nursing members of the research team. 
Information about you might be used when the results of the study are 
published in a medical journal, but your name would not be revealed. If 
you give your consent, then your General Practitioner would be notified, by 
letter, of your participation in the study. 
 
If you consent to take part in this research project, you will be allocated a 
unique personal identification number for the sole purpose of this study. 
This number will be used to label your blood samples and in electronic 
datasets. This will ensure that all samples/data related to you will be 
anonymised throughout and will therefore ensure that confidentiality is 
maintained at all times. 
 
 
Would I be told the results? 
If any of your results have clinical relevance for you (such as results of the 
routine and research hormones, fats and sugar tests that may indicate a 
possible new diagnosis of Diabetes), then we would inform you of these. 
Your General Practitioner would receive results of the routine tests and if 
you wanted, we would also send a copy of the research results to him/her.  
 
As with the other blood samples taken for storage, samples for genetic 
research will also be anonymised with unique patient identification codes. 
We do not intend to feed back results of genetic tests to participants or 
their General Practitioners. However it would be possible for the Chief 
Investigator to use a participant’s genetic data to make associations with 
their clinical data. The link between a participant’s unique identification 
code and their other data collected during this study will be stored in a 
secure location within the University Hospital, Coventry. Only the Chief 
Investigator will have access to this database. Some of the data and some 
of the samples collected may be used for future research studies.  
 
 
What if something goes wrong? 
This study is covered by the University of Warwick’s Clinical Trial Policy for 
standard fault claims based on the design of the study.  In the event that 
something does go wrong and you are harmed during the research and this 
is due to someone‘s negligence then you may have grounds for a legal 
action for compensation against University Hospitals Coventry & 
Warwickshire NHS Trust but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
 
Will I receive any payment for taking part in the study? 
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If you incur any travelling expenses as a result of participating in this study 
through attending for blood tests or scans then these will be fully 
reimbursed. You will not receive any other payment for taking part in this 
study. 
 
Who has reviewed the study? 
To ensure that the study is being conducted safely and ethically, a local 
Research Ethics Committee have reviewed the study. This committee is a 
panel comprising medically qualified people and laypersons from the local 
community. 
 
 
Who is funding the study? 
The consumable costs are being provided from a variety of grants including 
existing funds available within the department and from the University of 
Warwick. The Chief Investigator will not be paid for including you in this 
study. 
 
 
Future studies 
If you decide to give consent to be involved in this study, you will also be 
asked to give separate consent for the Chief Investigator to contact you at 
a later date regarding your possible involvement in future research studies 
relating to human metabolism that have relevant ethical approval. 
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Further information regarding the MRI scans:  
 
Important safety notice 
You should notify the Chief Investigator in clinic if you have any of the 
following: 
 Heart pacemaker; 
 Heart valve; 
 Aneurysm clips in your head; 
 Any previous injuries to your eyes involving metal fragments. 
 
Before your scan you must remove all metal objects you are wearing or 
have in your pockets. 
eg. jewellery, watches, keys, credit cards, body piercing, hair clips, 
hearing aids, coins. 
 
What is MRI? 
Magnetic Resonance Imaging (MRI) combines a powerful magnet, radio-
waves and an advanced computer to make very clear pictures of any part 
of the body. MRI does not use X-Rays and there are no known risks provided 
that the safety form has been correctly filled in. 
 
What do I need to do before the scan? 
Unless specifically instructed, you may eat and drink normally. 
You can continue with any medication. 
Try to wear clothing with no metal fastenings. 
You may be asked to change into a gown. 
 
What happens during the scan? 
A friend or relative may accompany you into the scan room if necessary. 
The scanner is shaped like a large hollow cylinder. It is open at both ends 
and remains so throughout. Depending on the part of you that is to be 
scanned, you will enter the magnet either head or feet first. 
The machine will make a very loud buzzing or banging noise when 
scanning. Different scans make different noises. You will be asked to wear 
earplugs or headphones to protect your ears from the noise. 
 
The radiographer normally takes several sets of pictures, each requiring a 
few moments to set up, so the machine will be quiet for periods. The 
radiographer will communicate with you over a microphone at stages 
throughout the exam. There are microphones within the scanner so you will 
be able to communicate with the radiographer during the exam as well. 
The radiographer is very experienced in looking after nervous patients and 
has many methods of ensuring that your examination is as comfortable as 
possible. An average exam takes 20-30 minutes. 
 
What happens after the scan? 
The scan has no effect on you and you can leave as soon as you are ready 
Contact for further information 
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Should you require it further information can be obtained from Dr. Tom 
Barber, Chief Investigator, Warwickshire Institute for Diabetes, 
Endocrinology and Metabolism, University Hospital, Coventry. 
 
 
If you have any concerns or complaints about the research, staff or 
conduct, please contact: 
 
 
Ms Nicola Owen, 
Deputy Registrar, 
University of Warwick,  
Research Support Services, 
University House, 
Kirby Corner Road, 
Coventry, 
CV4 8UW. 
 
E-mail: Nicola.Owen@warwick.ac.uk 
Telephone: 024 7652 2785 
Fax: 024 7652 4751 
 
 
 
 
Thank you. 
 
 
 
 
 Dr. Tom Barber (Chief investigator)  
          Dr Narendra Reddy,(NIHR Clinical Lecturer) 
Prof. Kumar, Dr. Randeva, Dr. Weickert, Dr. Hattersley, Prof. Wilson 
University Hospital, Coventry 
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Meal Duration Study  
University Hospital, Coventry 
Participant Recruitment Pack 
 
 
 
 
Signature of researcher taking consent 
............................................ !!!!!!
Chief Investigator: Dr. Tom Barber; Recruitment Pack NMD study; Version 1;                         
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! 238!
Unique Participant Identification Number:.................... 
Meal Duration Study  
Medical History 
Personal Details 
Name  …………………………...... DOB……………………………....... 
Age   …………………………........ Tel. no.   ………………………….. 
Ethnicity   …………………........ Birth weight (if known)   …………………... 
Consanguinity?................... Place of birth................... 
Birthplace of father................. Birthplace of 
mother.................. 
 
Past Medical History 
 Endocrine diagnosis:....................................................... 
Any history of DM (type and date of diagnosis):....................... 
Any history of IHD, CCF, liver or renal problems 
(specify):..................................................................... 
Any history of respiratory problems (specify):.......................... 
Other past medical history:................................................ 
 ................................................................................. 
 
Family History 
 Any family history of medical problems?................................. 
 .................................................................................. 
 Any family history of DM (type):........................................... 
 
Medications 
 Insulin or any other oral anti-diabetic drug (specify):................. 
 ................................................................................. 
Steroids or other hormonal therapies (specify, including OCP):   
................................................................................. 
Other medication list:...................................................... 
................................................................................. 
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................................................................................. 
 Allergies:..................................................................... 
Social History 
 Current smoker          Ex-smoker            Non-smoker    
 Units of alcohol per week:..................................... 
 
Systemic Enquiry 
 Any history of snoring:.......................................... 
 Any weight change in the last year (give details):......... 
 ..................................................................... 
 Any diets in the last year:..................................... 
 .................................................................... 
 Number of hours sun exposure per day (average):......... 
 Number of times per week for exercise: 
Mild exercise (10-30 minutes, no breathlessness or sweating  
eg. walking):......................... 
Moderate exercise (between 10 and 30minutes with sweating  
eg. running):......................... 
Strenuous exercise (>30 minutes with sweating  
eg. long run):......................... 
 
Menstrual/fertility History (if female) 
 Last menstrual period (date)   …………….. Age at menarche    
……………. 
Intervals between menstrual periods in days (over the last 2 years) 
  Shortest interval   …………………Longest interval   ………………… 
 Number of days bleeding per menstrual period (over the last 2 
years) 
  Shortest duration    ……………… Longest duration    ……………… 
 Any history of hirsutism? (regions 
affected):................................ 
Number of cosmetic treatment(s) for hirsutism needed per 
week:...... 
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(specify treatments):............................................ 
Any history of acne or alopecia? (please 
specify):.........................                                          
 Number of pregnancies:.....Number of miscarriages/TOP 
(specify):.... Chance of current pregnancy?    
Current use of contraception? (specify)    
.................................. 
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Meal Duration Study 
Anthropometric and Body Composition Data 
 
Anthropometric measurements 
 Height (m)   ………………..  
 Weight (kg)   ………………. 
 BMI    …………………. 
 BP (mmHg)   …………….. 
 Waist (W) circumference   ………………  
(mid-point between superior iliac crest and lower costal margin) 
 
 Hip (H) circumference   ………………… 
 W:H ratio   ………………….. 
 
Body Composition Data  
(These data are derived from the Tanita machine that uses foot-to-foot 
bioimpedance technology) 
 Lean percentage............. 
 Fat mass.................. 
 Fat percentage................ 
 
Fasting blood samples for immediate analysis at the 
UH 
Biochemistry: U&E, LFT, fasting lipid profile, glucose, HbA1C 
Endocrinology: LH, FSH, Oestradiol, Testosterone, SHBG, Prolactin, TSH, 
fT4, fT3, IGF1, cortisol (cortisol and testosterone at 9am where possible)   
 
Fasting blood samples for storage at -80 degrees C 
Serum samples x3 small tubes 
Plasma samples x3 small tubes 
EDTA blood sample x2 (for future DNA extraction) 
1x sample sent for insulin analysis (for calculation of HOMA measures) 
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F igure 2 : Sub jec t i n s i de 
chamber. Each chamber is 
equipped with a pull-down bed, 
sink, toilet, chair, desk, phone 
and computer with internet 
access. There is also an intercom 
system for communication with 
the outside, and ports for 
delivery of food  
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The Human Metabolism Research Unit (HMRU) is a 
£1.5 million investment funded by a variety of 
sources including Science City and the University of 
Warwick. Based at the University Hospitals Coventry 
and Warwickshire, HMRU will prove an invaluable 
resource for University of Warwick-based clinical 
research into human metabolism 
Figure 1: Plan of the Human Metabolism 
Research Unit, showing two whole-body 
calorimeters 
A major feature of the HMRU is two whole-body 
calorimeters. These are hermetically-sealed 
chambers that are capable of precisely measuring 
human metabolic rate in real-time through the use 
of indirect calorimetry. Gas concentrations of CO2 
and O2 are measured accurately for this purpose. 
The HMRU also houses a BodPod. This measures 
body volume precisely through use of Boyles Law 
(P1V1 = P2V2). Through precise measurements of 
body volume and weight, it is possible to calculate 
body composition, including fat mass. 
Figure 3: The BodPod. Inside is the BBC 
Health Correspondent, Jane Hughes during 
the recent media profile of HMRU 
Through calculation of metabolic rate from CO2 and 
O2 concentrations, data from the whole body 
calorimeters within HMRU are used to produce 
metabolic profiles. These provide an assessment of 
energy expenditure during the resting and post-
prandial states, and can be used for comparison 
between subjects. 
lunch lunch 
Figure 4: Metabolic profiles. On the left is a lean 
male control subject showing resting energy 
expenditure and post-prandial energy expenditure. 
On the right is the profile of a lean female with 
untreated hyperthyroidism. Units on y-axis are Kcals 
per minute. Time is shown on x-axis. This profile 
clearly demonstrates heightened resting energy 
expenditure in the hyperthyroid state which is 
probably one reason why weight loss is a 
characteristic feature of hyperthyroidism 
The HMRU facility holds great potential for 
important research into human metabolism. In 
addition to the study of the aetiology and 
management of obesity through food-based 
solutions and novel therapeutic strategies, HMRU 
will also provide a unique opportunity to gain 
insight into the endocrine determinants of human 
energy expenditure, and the complexities of the 
gut-brain-metabolic axis. 
Figure 5: ‘Does eating slowly 
help you to lose weight?’ This 
is on ongoing HMRU study into 
the effects of meal duration 
on post -prandia l energy 
expenditure and appetite. 
Through a simple design, each 
subject will act as their own 
control. The data will have 
important publ ic hea l th 
implications. This study was 
recently profiled on BBC 
national news 
Figure 6: Professor Kumar 
during a recent interview on 
BBC news, discussing obesity 
and the potential of HMRU for 
tackling the most important 
health issue of our age  
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Unequivocal identification of brown adipose tissue in an adult 
human using MRI  
 
 
 
 
 
Narendra L Reddy1, Terence A Jones1, Sarah C Wayte2, Oludolapo Adesanya3, Yen Yeo4,  
Harpal Randeva1, Sudhesh Kumar1, Charles E Hutchinson1,3, Thomas M Barber1 
 Warwick Medical School1, University of Warwick, Clinical Sciences Research Laboratories, Coventry, UK  
Departments of Medical Physics2, Radiology3 & Histopathology4, University Hospitals of Coventry & Warwickshire, UK 
 
We provide the first ever report that MR can be used 
reliably to identify BAT in a human adult, with 
histological and immunohistochemical confirmation. 
Our data demonstrate proof of concept to support the 
development of MR, a safe and reproducible imaging 
modality, as a biomarker for human BAT. 
 
                       Methods 
Initial scanning with 18F-FDG PET-CT radiotracer 
uptake on a 25-year old Caucasian female with 
primary hyperparathyroidism, showed avid uptake 
within mediastinum, neck, supraclavicular fossae 
and axillae, consistent with BAT. Subsequently, 
serial MR scans were performed using 3-echo 
IDEAL (iterative decomposition of water and fat 
with echo asymmetry and least-squares estimation) 
sequence. Retrospectively, regions of interest 
(ROIs) were identified on MR corresponding to 
PET-CT. Prospectively, ROIs were identified on MR 
images based on signal intensity and appearance, 
and compared with PET-CT. Immunohistochemical 
staining using uncoupling protein-1 antibody was 
performed on fat samples corresponding to low 
MR-signal, obtained during parathyroidectomy. 
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Figure 1: Variation in 
BATretro:WATretro signal ratio 
according to anatomical 
location, with significantly 
lower signal ratio within 
mediastinum and neck. 
The shaded area 
represents a ratio >1 (i.e. 
WATretro signal > BATretro 
signal). 
 
Conclusion 
Figure 2: (a) 18F-FDG uptake within the suprasternal notch on PET-CT 
(arrow); (b) fat:IDEAL MR at the same level showing corresponding low 
signal in suprasternal notch; (c) Haematoxylin-Eosin staining and (d) UCP1 
immunostaining providing confirmation of BAT obtained from this area. 
 
a b 
d c 
                     Results 
111 retrospectively identified ROIs from PET-CT 
scans: 88 (79%) showed corresponding low signal 
on MR images: 100% in mediastinum, 29/31 
(93.5%) in neck, 31/41 (75.6%) supraclavicular, 
and 8/14 (57%) in axillae. Prospectively, 87% of 
ROIs identified on MR scans corresponded to 
increased areas of uptake on PET-CT. Histology 
and immunohistochemistry confirmed BAT. 
                          Aim 
Manipulation of human brown adipose tissue (BAT) 
represents a novel therapeutic option for type 2 
diabetes mellitus and obesity. The aim of our study 
was to develop and test a novel Magnetic 
Resonance Imaging (MR) based method to identify 
human BAT and delineate it from white adipose 
tissue (WAT), and validate it by providing 
histological and immunohistochemical confirmation 
of BAT  
Anatomical 
region  
No of BATretro 
ROIs with 
lower MR 
signal than 
adjacent fat  
No of BATretro 
ROIs with 
similar MR 
signal to 
adjacent fat  
Total number 
of ROIs  
Total area of 
ROIs (mm2)  
All regions 93 18 111 9030 
Mediastinum 25 0 25 2348 
Supraclavicular 31 10 41 3313 
Neck 29 2 31 1451 
Axillae 8 6 14 1918 
Table 1: For each anatomical region number of BATretro ROIs with low and 
normal signal intensity on MR are tabulated. The ROIs were retrospectively 
drawn on MR from areas of corresponding high 18F-FDG uptake on PET-CT  
Acknowledgements: Sean James, Mirada Medical Ltd & MR Radiographers in UHCW: Study funded by Strategic Impact Fund grant from University of Warwick 
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Brown adipose tissue: endocrine determinants of
function and therapeutic manipulation as a novel
treatment strategy for obesity
Narendra L Reddy1,2†, Bee K Tan1,3†, Thomas M Barber1,2† and Harpal S Randeva1,2*†
Abstract
Introduction: Recent observation of brown adipose tissue (BAT) being functional in adult humans provides a
rationale for its stimulation to increase energy expenditure through ‘adaptive thermogenesis’ for an anti-obesity
strategy. Many endocrine dysfunctions are associated with changes in metabolic rate that over time may result in
changes in body weight. It is likely that human BAT plays a role in such processes.
Review: In this brief review article, we explore the endocrine determinants of BAT activity, and discuss how these
insights may provide a basis for future developments of novel therapeutic strategies for obesity management.
A review of electronic and print data comprising original and review articles retrieved from PubMed search up to
December 2013 was conducted (Search terms: brown adipose tissue, brown fat, obesity, hormone). In addition,
relevant references from the articles were screened for papers containing original data.
Conclusion: There is promising data to suggest that targeting endocrine hormones for BAT modulation can yield a
cellular bioenergetics answer for successful prevention and management of human obesity. Further understanding
of the physiological link between various endocrine hormones and BAT is necessary for the development of new
therapeutic options.
Keywords: Brown adipose tissue, Obesity, Hormone
Introduction
According to the World Health Organization (WHO) re-
port, worldwide obesity rates have more than doubled
since 1980. Global figures from 2008 showed that 1.5 bil-
lion adults were overweight and that obesity affected 200
million men and 300 million women, with the numbers ex-
pected to rise exponentially [1]. Obesity is associated with
significant morbidity and mortality that result from the
related complications of type 2 diabetes mellitus (T2DM),
non-alcoholic fatty liver disease, cardiovascular events,
obstructive sleep apnoea, musculoskeletal and psychi-
atric diseases, and various malignancies [2]. In 2010,
overweight and obesity were estimated to cause 3.4 million
deaths, 3.9% of years of life lost, and 3.8% of disability-
adjusted life-years (DALYs) worldwide [3]. Obesity, in
1980’s was limited to affluent countries such as North
America, Western Europe and Australasia, but now mani-
fests as a true pandemic, with its increasing prevalence in
developing countries such as India, China and Brazil, and
spreading even to sub-Saharan Africa [4,5], placing an
enormous financial burden on the global economy.
The management of obesity through lifestyle is notori-
ously difficult and the resulting effects on weight are vari-
able and often transient. Weight regain following weight
loss is common and results from a number of mechanisms
that redress any loss of energy storage capacity. Such mech-
anisms include changes in the levels of appetite-regulating
hormones following weight loss that encourage weight re-
covery [6]. Weight loss also reduces energy expenditure [7]
and brown adipose tissue (BAT) activity, and this com-
bined with enhanced appetite promotes weight regain.
Current therapeutic options for obesity management are
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limited following recent withdrawals of sibutramine and
rimonabant amid safety concerns, and problems relating
to the supply, unacceptable side-effect profile and long-
term efficacy of orlistat [8]. Despite its effectiveness as a
weight-loss intervention, bariatric surgery is only applic-
able to a sub-group of obese patients who meet funding
criteria and as such, does not represent a practical solu-
tion to the global obesity epidemic [9]. Given the limita-
tions of current therapies, the current global obesity
epidemic and escalating incidence of obesity-related
deaths, it is imperative to identify novel and effective
therapeutic options for obesity.
Obesity results when energy intake exceeds expend-
iture chronically. Therapeutic strategies for obesity have
mainly targeted caloric restriction through central appe-
tite suppression and inhibition of fat absorption [10].
Compared with those acting on central appetite regula-
tion, therapies acting peripherally may prove beneficial
whilst causing fewer harmful effects [11]. The body is,
by default, genetically predisposed to store energy in
preparation for prolonged periods of starvation [12].
Even minor weight-loss through appetite suppression is
often redressed through multiple peripheral counter-
regulatory mechanisms to maintain ‘isoenergetic’ condi-
tions [6]. Centrally acting drugs can potentially cause
adverse psychotropic side effects through cross-reactivity
with a variety of other receptors within complex central
circuits (such as the endocannabinoid receptor blocker,
Rimonabant) [10]. The concept of increasing energy ex-
penditure through therapeutic manipulation of periph-
eral mechanisms is therefore attractive and worthy of
focused research and development.
The main physiological function of BAT, to generate
heat for the organism to protect against development of
hypothermia, has been well understood for nearly 50 years
[13]. Recent studies using 18fluoro-labelled 2-deoxyglucose
(FDG) positron emission tomography computed tomog-
raphy (PET-CT) have demonstrated the presence of BAT
depots in the axillary, paravertebral, supraclavicular and
cervical regions in adult humans [14-16]. Data from vari-
ous animal studies have demonstrated that through BAT
activation, triglyceride stores within white adipose tissue
(WAT) can be utilized for heat generation through modu-
lation of adaptive thermogenesis [17]. Therapeutic ma-
nipulation of human BAT therefore represents a novel
mechanism to promote weight-loss. It is noted that endo-
crine disorders such as phaeochromocytoma and thyro-
toxicosis play a role in activating BAT [18,19]. To
maximize its future therapeutic potential, it is important
to appreciate the mechanisms by which endocrine dys-
function influences human BAT activity. In this brief re-
view article, we explore the main mechanisms linking
various endocrine hormones and human energy expend-
iture, mediated by effects on BAT activity.
BAT energetics
There are two main types of adipose tissue, white adi-
pose tissue (WAT) and BAT that have evolved for com-
pletely different purposes: to survive famine and prevent
hypothermia respectively. WAT and BAT, as energy stor-
age and thermogenic tissues respectively, therefore evolved
to protect mammalian organisms from important environ-
mental threats, including lack of food and exposure to
cold climates [20]. In addition to WAT and BAT, a third
intermediate-type of adipose tissue that is termed ‘beige’
has recently been identified. Adipocytes from beige adi-
pose tissue (BeAT) depots resemble white adipocytes but
possess the classical properties of brown adipocytes. Par-
tial success noted in animal models in converting WAT to
BeAT, has set a tone in BAT research field to replicate the
concept in humans too [21,22]. The characteristic features
of WAT, BAT and BeAT, and the origin of BAT are shown
in Table 1 and Figure 1 respectively.
Heat production plus external work account for the aver-
age daily metabolic rate or total energy expenditure (TEE).
TEE can be classically divided into resting metabolic rate
(RMR; normally 55–65% of TEE), activity related energy
expenditure (AEE; normally 25–35% of TEE), and diet-
induced thermogenesis (DIT) (about 10% of TEE) [23,24].
Alternative classification is obligatory energy expenditure,
which includes RMR, involuntary AEE and obligatory part
of DIT, and facultative energy expenditure, which includes
voluntary AEE, cold-induced non-shivering thermogenesis
(NST), cold-induced shivering thermogenesis, and faculta-
tive part of DIT [23].
Cold-induced activation of BAT has resulted in a high
incidence (60% to 96%) of detection as shown in recent
PET studies [25,26]. The presence of the 32 kDa un-
coupling protein-1 (UCP1) in BAT mitochondria enables
heat dissipation rather than generation of adenosine tri-
phosphate (ATP) [27], thereby resulting in non-shivering
thermogenesis (NST). Although controversial, BAT is
thought to influence DIT through sympathetic nervous
system activity via UCP1 [27,28]. Using PET studies with
radio-labeled fatty acid tracers, Ouellet et al. quantified
BAT oxidative metabolism, glucose and non-esterified
fatty acid (NEFA) turnover in 6 healthy human subjects,
demonstrating unequivocally that BAT contributes to
energy expenditure in humans [29]. Extrapolating rodent
experiments of thermogenic potential of BAT (300 W/kg),
Rothwell and Stock calculated that 40-50 g of BAT in
humans, might account for 20% of total energy expend-
iture [30]. Human PET studies estimated that maximal
activation of 63 g of BAT would result in 4.1 kg of
weight loss during one year [14]. Two independent but
congruent human studies estimated an energy expend-
iture of 200–400 kcal/day, a 10 to 20% rise in daily basal
metabolic rate through BAT activation [31,32]. There-
fore, the glucose disposal [33] and triglyceride clearance
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properties of BAT [34], when fully utilized may act as an
energy sink. There are three ways in which enhanced
energy expenditure through manipulation of BAT could
be theoretically achieved: i) maximal and continual acti-
vation of BAT; ii) trans-differentiation of WAT to BAT
(to form BeAT), and; iii) transplantation of BAT stem cells.
The presence of BAT in adult humans represents a po-
tentially important therapeutic target for future novel
weight-loss strategies. The origins and functions of BAT,
WAT and BeAT differ in important ways, and studies on
the energetics of BAT have shown promising results. In
the next sections, we discuss the main endocrine determi-
nants of human BAT activity, and how each of these
mechanisms could be therapeutically manipulated for pro-
motion of weight-loss.
Review of endocrine determinants of BAT activity
Thyroid and BAT
We have known for over a century that thyroid hormone
(TH) increases metabolic rate and thermogenesis in
homeothermic species, and hence is an important physio-
logical modulator of energy homeostasis [35,36] TH stim-
ulates both obligatory and facultative thermogenesis [37]
and plays an important role in the regulation of lipid me-
tabolism within adipose tissue [38,39]. TH also enhances
oxidative phosphorylation through induction of mitochon-
drial biogenesis and modulation of the expression of genes
implicated in the regulation of the mitochondrial respira-
tory chain [40]. The weight gain and decreased cold toler-
ance observed in individuals with hypothyroidism, and the
weight loss and sweating/heat intolerance observed in pa-
tients with hyperthyroidism, are predictable clinical mani-
festations of alterations in BAT activity [41]. It follows
therefore that differences in BAT quantity and/or activity
between individuals may also influence the clinical mani-
festations of hypo- or hyperthyroid states. This may also
explain the inter-individual variability of weight changes
and heterogeneity of other clinical manifestations of dys-
thyroid states.
The physiological effects of TH are exerted at the level
of transcription through the thyroid receptors (TR): TRα
and TRβ [42]. TRβ mediates thyronine (T3) induced
UCP1 gene expression, whilst the TRα isoform through
T3 regulates facultative thermogenesis in BAT [43].
Type 2 deiodinase (D2) plays an essential role in mediat-
ing the full thermogenic response of BAT to adrenergic
stimulation via increased thyroxine (T4) to T3 conver-
sion within this tissue [44]. From a therapeutic perspec-
tive, it would be desirable to selectively activate TRβ for
UCP1 stimulation to avoid the widespread unwanted ef-
fects of TRα, the predominant receptor in non-BAT tis-
sues. Thyroid hormone analogues have been explored
with variable outcomes. GC-1 compound, a selective TRβ
agonist, induces UCP1 gene expression in rats [43], im-
proves glucose homeostasis [45], increases energy expend-
iture and reduces fat mass and plasma cholesterol [46].
High-fat feeding and concurrent treatment with the TRβ-
selective agonist GC-24 (with a 40-fold higher affinity for
TRβ than TRα) resulted in only a partial improvement
in metabolic control, probably related to acceleration
of resting metabolic rate [47]. Treatment with another
TRβ-selective agonist, KB-41 in rats resulted in a 6-8%
weight-loss with significant improvements in glucose
homeostasis, cholesterol and triglyceride levels without af-
fecting heart rate, probably due to lack of TRα effects [45].
There are also some promising data from human studies
that implicate thyroid hormones having important effects
on BAT activity. T3 treatment of differentiated human
Table 1 Morphological features of BAT, WAT and BeAT
WAT BAT BeAT
Cell shape Variable, but classically spherical Polygonal Resembles WAT
Cell size Variable, but large (25-200 μm) Comparatively small (15-60 μm) Variable
Nucleus Peripheral, flattened Central, round or oval in shape To be determined
Cytoplasm Thin, peripheral rim Large volume evenly distributed throughout cell To be determined
Lipid content Single large droplet occupying
up to 90% of cell volume
Multiple small lipid droplets To be determined
Mitochondria Few Abundant Intermediate
Endoplasmic reticulum (ER) Little, but recognizable as rough
and smooth ER
Present, but poorly developed To be determined
Tissue organization Small lobules of densely packed cells Lobular, gland-like To be determined
Cell content Multiple other cell types present Few other cell types present Few other cell types
present
Vascularity Adequate Highly vascularised To be determined
Gene expression PPAR-gamma, aP2, Adiponectin,
adipsin, perilipin
UCP-1, PGC-1alpha, β-3 adreno receptor
(ARB3), PRDM16, de-iodinase type II (D2)
Low UCP1, but activated
by cAMP stimulation
Cell markers CD34, ABCG2, ALDH EVA1, EBF3, FBXO31 CD137, TMEM26, TBX1
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multipotent adipose-derived stem cells in vitro induces
UCP1 expression and mitochondrial biogenesis through ef-
fects on TRβ [48]. Following thyroidectomy and subsequent
treatment with thyroxine replacement therapy in a patient
with papillary carcinoma, BAT activity was enhanced with
concurrent weight-loss and remission of T2DM [49]. Thy-
roxine may cause ‘brownification’ of WAT [48], and holds
immense potential given the mechanism of action in BAT,
and hence needs to be robustly tested in humans.
Catecholamines and BAT
Epinephrine causes vasodilatation and enhances glucose
and oxygen consumption in skeletal muscle [50] whilst also
enhancing thermogenesis in humans [51]. BAT is also acti-
vated in patients with phaeochromocytoma, (excess cat-
echolamine producing benign adrenal medullary tumour)
with increased UCP1 expression similar to levels in cold-
exposed rodents [18,52]. BAT activity is greater in patients
with phaeochromocytoma [53,54] due to over-activity of
the sympathetic nervous system and elevated levels of cir-
culating catecholamines, that in turn stimulate β3 adrener-
gic receptors, thereby activating UCP1 expression via cyclic
adenosine monophosphate (cAMP) and protein kinase-A
(PKA) pathways [55]. Hadi et al. demonstrated active BAT
to be present in 27% (26/96) of phaeochromocytoma pa-
tients undergoing FDG PET-CT scans [56], indicating
higher detection rates compared to 5.37% (106/1972) of all
cause PET-CT studies reported by Cypess and colleagues
[16]. Recent human observational studies demonstrate a
correlation between plasma metanephrine levels and BAT
activity [57].
Nor-epinephrine action on β3-adrenergic receptor in ma-
ture human brown adipocyte is the most studied pathways.
β3-adrenergic receptor would appear to be a convenient
Figure 1 Origin and transcriptional regulation of brown adipocyte. Multipotent mesenchymal stem cells commit to brown adipocyte
lineage following developmental triggers such as bone morphogenic proteins (BMP) and fibroblast growth factors (FGFs) leading on to cascade
resulting in a fully developed brown adipocyte. Myf5-expressing progenitors give rise to skeletal muscle and brown adipocytes in traditional sites
such as interscapular area. Myf5-negative progenitors are common precursors for both white adipocyte and recruitable brown adipocyte or beige
adipocyte. Beige adipocyte is formed from either the trans differentiation from white adipose tissue in response to cues such as Irisin or from
recruitable brown preadipocyte.
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therapeutic target based on evidence from rodent studies
using “selective” β3-agonists (CL-316,243) [58] and knock-
out mouse models [59]. β3-agonists have not yielded de-
sirable results in humans due to differences in β3-receptor
binding properties in humans and rodents. Second-
generation β3-agonist trials in humans were unsuccessful
due to poor oral bioavailability and unfavorable pharmaco-
kinetics [60]. Another β3-agonist, L-796568, showed an ini-
tial increase in energy expenditure effect in 12 healthy
obese subjects that failed to be sustained beyond 28 days
[61,62]. Catecholamines may also ‘brownify’ WAT. Two
case reports of extensive brown fat deposits in omental and
mesenteric regions detected on human FDG-PET scans in-
dicate a possible role for catecholamines in the ‘browning’
of WAT [63,64]. Therapeutically, catecholamine-like mol-
ecules may trans-differentiate WAT into BeAT, but such
an approach would need to avoid the associated sym-
pathomimetic effects to be safe.
Glucocorticoids and BAT
Both BAT and WAT contain glucocorticoid receptors
[65]. Excessive levels of glucocorticoids increase WAT
mass and result in weight gain [66]. Conversely, gluco-
corticoids have an inhibitory effect on BAT activity in ro-
dent models [67]. Glucocorticoids enhance appetite,
stimulate lipolysis, suppress thermogenesis [68] (specific-
ally facultative thermogenesis [69]) and profoundly sup-
press norepinephrine-induced UCP1 activation [67].
Glucocorticoids also inhibit the expression and function
of β1 and β3 adrenergic receptors within BAT. [70,71]
Corticosterone reduces NST and increases lipid storage
within BAT in an in vivo rodent study, possibly as a re-
sult of steroid-induced hyperinsulinaemia [69]. Within
rodent models, it has been observed that adrenalectomy
results in stimulation of BAT thermogenesis and also
weight-loss [72]. This mechanism is probably mediated
through removal of glucocorticoid-induced hypothal-
amic inhibitory influences on BAT activity, and is re-
versed following glucocorticoid administration [72,73]. A
similar reduction in body fat mass was seen in a 46-year
old female with Cushing’s syndrome following adrenal-
ectomy [74]. The therapeutic challenge here would be to
develop the beneficial effects of steroid depletion on me-
tabolism and adipose-regulation whilst avoiding its po-
tentially life-threatening effects.
Mineralocorticoid and BAT
Mineralocorticoid receptors in rodent BAT, were first
demonstrated by Zennaro and colleagues [75]. Following
aldosterone treatment of a T37i cell line derived from
hibernoma in mice, there was increased expression of
adipogenic genes such as Lpl (lipoprotein lipase), PPAR-γ
(Peroxisome proliferator receptor activated-gamma) (PPAR-γ)
and aP2 (adipocyte-specific fatty acid binding protein)
[75,76]. Treatment with aldosterone also results in in-
hibition of Ucp1 expression, favouring lipid storage rather
than heat dissipation [77,78]. Within WAT, aldosterone
induces inflammation resulting in the release of pro-
inflammatory cytokines such as Interleukin-6 (IL-6),
tumour necrosis factor-alpha (TNF-α) and Monocyte
chemo attractant protein (MCP-1) [79]. Aldosterone also
appears to inhibit thermogenesis within BAT, and also in-
hibits the differentiation of WAT into BAT [80]. Given
that mineralocorticoids have a negative effect on BAT,
it follows that aldosterone antagonists may represent
a combined therapy for both hypertension and obesity
(through possible activation of BAT). This also supports
the findings that high aldosterone levels are noted in
obesity-induced hypertension in humans, which reverses
on weight loss [81].
Growth hormone/Insulin Growth Factor-1 and BAT
BAT-status in growth hormone (GH)-deficient patients and
acromegalics remains unknown. GH replacement in GH-
deficient humans results in sustained improvement of body
composition and reduction of insulin resistance [82,83].
Conversely, GH excess in acromegalics promotes insulin
resistance [82], resulting in dysglycaemia and hyperlipid-
aemia. GH replacement (1 mg/kg/day) for 10 days in ex-
perimental mice resulted in significant reduction of WAT
mass, increased skeletal weight and reduction of insulin re-
sistance. Despite an increase in Ucp-1 mRNA by 2.8 fold,
there was no change in the inter-scapular brown fat mass
[84], although a substantial increase (2 to 6 fold) in inter-
scapular brown fat mass was noted at higher doses of GH
(3.5 mg/kg/day).
Insulin Growth Factor-1 (IGF-1) receptors are highly
expressed in the plasma membrane of rat brown adipo-
cytes [85]. In vitro studies in murine foetal brown adipo-
cytes have shown that IGF-1 is intensely mitogenic and
prevents TNF-α induced apoptosis [86,87]. IGF-1 induces
the expression of Ucp-1 and CCAAT/enhancer binding
protein alpha (C/EBP-α) in rat brown adipocyte primary-
cell cultures [88]. Transient up-regulation of Igf-1 gene ex-
pression and BAT hyperplasia was noted in rats exposed
to cold (4°C) in the first 48 hours [89]. One of the factors
influencing the dramatic rise in human foetal UCP-1 con-
tent during late gestation, especially prior to birth, is
thought to be due to increased IGF-1 and IGF-2 levels
[90]. There may therefore be a role for IGF-1 in BAT dif-
ferentiation and activation, although the precise molecular
mechanisms remain unclear. As a therapeutic strategy, the
effect of GH or recombinant human IGF-1 (or truncated
IGF-1) on BAT and WAT functioning is worth exploring.
Prolactin and BAT
Functional prolactin receptors (PRLR) are highly expressed
in both WAT and BAT and are essential for adipogenesis
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and adaptive thermogenesis [91]. Prolactin plays import-
ant roles in carbohydrate metabolism through its effects
on pancreatic β-cell mass and energy homeostasis through
lipid metabolism [92]. Prolactin suppression, through use
of dopamine agonists in hyperprolactinaemic patients, re-
sults in metabolic effects [93]. Lactation in experimental
mice is strongly and negatively associated with expression
of thermogenic genes in BAT [94]. PRLR−/− male mice
subjected to a high fat diet for 16 weeks exhibited resist-
ance to weight-gain and a reduction in WAT compared
to wild-type mice. These mice also showed 2–3 fold
increased expression of BAT-specific markers (PR do-
main containing 16 [PRDM16], UCP1, PPAR-coactivator
1-alpha [PGC1α]) and brown-like adipocyte foci, indicat-
ing a possible role in BeAT differentiation from WAT
[95]. Further studies are required to establish whether
prolactin blockade by either dopamine agonists or pure
prolactin receptor antagonists may represent a targeted
approach for browning of human WAT.
Sex hormones and BAT
Androgen and oestrogen receptors (ERα) are expressed
in BAT in both sexes [96]. Furthermore, sex hormones
play an important role in the BAT thermogenic program
by acting at several steps of the lipolytic signal cascade
and on UCP1 transcription control. Observations such
as cessation of ovarian function at menopause resulting
in weight-gain, loss of insulin sensitivity and increased
incidence of cardiovascular disease [97], coupled with
greater BAT activity in young females in PET-CT studies
[16], fuel the argument that ovarian hormones probably
influence BAT function. Ovariectomy in female rodents
reduced BAT mitochondrial functionality through reduc-
tion in the oxidative capacity and anti-oxidant defenses.
Furthermore, 17-β oestradiol (E2) supplementation par-
tially reversed these effects indicating oestrogen’s partial in-
fluence on BAT [98]. There may also be non-oestrogenic
ovarian signals stimulating BAT activity [98]. Interestingly,
in vitro cell culture studies by Rodriguez-Cuenca show a
dual effect of 17-β oestradiol on the mitochondrial bio-
genic program [99,100].
Addition of testosterone reduced norepinephrine-induced
Ucp1 mRNA expression in a dose-dependent manner in
cultured rodent brown adipocytes, and these effects were
reversed by flutamide (an androgen receptor antagonist)
[101]. Furthermore, testosterone reduces the thermogenic
and lipolytic capacity of BAT [100]. In contrast, proges-
terone is shown to have the opposite effect to that of
testosterone on brown adipocytes [101] by positively stimu-
lating mitochondriogenesis and BAT differentiation as
demonstrated by an increase in the mRNA expression
of the GABPA-TFAM axis and PPAR-γ, respectively
[99]. These apparent opposite influences of testosterone
and progesterone on BAT activity may explain the gender
dimorphism displayed by BAT in human PET studies [16,102].
Dehydroepiandrosterone (DHEA, a precursor sex steroid),
when administered to obese and lean rats caused reduced
food intake and enhanced energy expenditure resulting in
weight-loss through increased expression of Pgc-1α, Ucp1
and β3-Ar [103].
In summary, these animal studies demonstrate variable
effects of sex hormones on BAT activity: testosterone ap-
pears to have a negative influence, oestrogen probably
has a dual effect and progesterone and DHEA both ap-
pear to have positive influences on BAT activity. How-
ever, the increase in both, BAT amount and BAT activity
in both sexes in human adolescents, (during peak surge
of sex hormones) [104] fuels speculation that sex hor-
mones may have a strong influence on BAT. Therefore
it is worth exploring the influences of flutamide, select-
ive oestrogen-receptor modulators (SERMs) and DHEA
on human BAT activity.
Insulin and BAT
In cultured murine brown and white adipose tissue, insulin
has a role in differentiation of pre-adipocytes into adipo-
cytes [105]. Furthermore, insulin-signaling in BAT is similar
to that of WAT and other tissues, displaying similar ana-
bolic effects of glucose uptake and lipid accretion [106].
The studies suggest that uptake of glucose into BAT is both
insulin-mediated (mainly occurring in non-thermogenic
conditions) and norepinephrine-mediated (occurring dur-
ing thermogenic conditions) [107]. In rodent models, BAT
is shown to be one of the most insulin-responsive tissues
with respect to glucose-uptake [108] and is mediated via
GLUT4, similar to that in WAT [109].
Animal studies suggest that chronic insulin deficiency re-
duces the thermogenic capacity of BAT [110,111]. Further-
more, in type 1 diabetes mellitus glucose homeostasis is
reverted to normalcy by increasing BAT quantity [112].
Contrarily, compensatory hyperinsulinaemia induces apop-
tosis of endothelial cells in rat BAT, thereby reducing BAT
quantity [113]. This may explain reduced BAT activity ob-
served in insulin-resistant states such as human obesity
and T2DM in human PET-case series [16,102]. In human
PET studies, insulin-mediated glucose-uptake by BAT in-
creased 5-fold (independent of perfusion) in comparison
to WAT, and gene expression of GLUT4 (Glucose trans-
porter type 4) was higher in BAT than WAT [33]. In sum-
mary, it appears that insulin is required in maintenance of
BAT thermogenic capacity, but the potential therapeutic
role of insulin and insulin-related molecules in BAT ma-
nipulation is yet to be determined.
Central or peripheral intravenous leptin administration
in rats is shown to increase insulin stimulated glucose util-
isation, and to favour expression of uncoupling proteins
predominantly through central pathways of increasing
sympathetic tone [114,115]. However, the lack of success
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of human recombinant leptin infusions on weight loss in
obese subjects [116], and adverse cardiovascular profile of
hypertension, left ventricular dysfunction, and possible
cardiovascular risk [117] may need to be factored in for
contemplating leptin route of BAT activation. Adiponectin
is noted to inhibit UCP-1 gene expression by suppression
of β3-adrenergic receptor in rats [118]. Conversely, adipo-
nectin levels were significantly higher in BAT compared to
WAT in active phaeochromocytoma patients, and conse-
quently serum adiponectin levels reduced markedly fol-
lowing adrenalectomy [119]. The relation between BAT
and adiponectin in humans is yet to be clarified before
considering on therapeutic prospects.
Endocannabinoids and BAT
Acting centrally and peripherally, the endocannabinoid
system positively regulates appetite and energy balance
[120] and has a role in adipose tissue metabolism [121],
mainly through cannabinoid receptors (CB1 and CB2),
and their natural endogenous ligands anandamide and
2-arachidonoyl glycerol [120]. In rodents, weight-loss as-
sociated with chronic CB1 antagonism was accompanied by
increased energy expenditure, enhanced insulin-stimulated
glucose utilisation, and marked activation of BAT thermo-
genesis [122]. Similar mice studies have shown a sustained
increase of BAT temperature and up-regulation of UCP1
on CB1 blockade [123]. Through peripheral CB1 recep-
tor inhibition, in vitro murine white adipocytes trans-
differentiate into a mitochondria rich, thermogenic BAT
phenotype [124]. Experiments with BAT denervation have
attenuated such browning responses, indicating that cen-
tral regulation is essential. Recent withdrawal of rimona-
bant from the market owing to concerns regarding an
adverse psychotropic profile, poses a problem for CB1 be-
ing a target for activation of brown fat, unless a more
selective peripheral blocker of CB1 is identified. Table 2
enlists effect of various hormones on BAT and possible
therapeutic options through manipulation of individual
hormonal actions.
Current trends in BAT therapeutics
Given that adult humans have BAT, it is important to ex-
plore BAT manipulation as a means of promoting weight-
loss through enhanced energy expenditure via BAT
manipulation. In addition to augmentation of BATcontent
and/or enhancement of BAT activity, other approaches in-
clude trans-differentiation of non-BAT progenitors into
BAT pre-adipocytes, and surgical implantation of BAT.
Development of novel BAT-related therapies will require a
complete understanding of the embryological and tran-
scriptional mechanisms of BAT specification and develop-
ment in human models. We also need to characterize and
confirm the physical and genetic attributes of BAT includ-
ing anatomical and histological distributions of human
BAT. Further challenges will be to develop a sustained
long-term BAT stimulating or recruiting molecular circuit
with adequate knowledge of counter-regulatory mecha-
nisms for an acceptable safety profile, and to identify a re-
liable and safe imaging modality to monitor the effects of
such therapies on BAT once developed and administered.
Several transcriptional regulators of brown adipocyte dif-
ferentiation are described in rodents, with some revealing
promising effects even in human models. Irisin is a 112-
amino-acid polypeptide hormone, and is a cleaved and se-
creted fragment of fibronectin type III domain containing
5 (FNDC5) membrane protein, in turn released by muscle
through increased PGC-1α expression following exercise
in both rodents and humans [125]. Irisin showed a power-
ful browning effect on certain white adipose tissues in
mice, both in culture and in vivo [125]. Human irisin is
Table 2 Effect of hormones on BAT and possible therapeutic options
Hormone Influence on BAT Probable BAT therapeutic suggestions
Epinephrine +ve Selective human β3 receptor agonists
T3 +ve TR β selective agonists- GC-40, KB-41
Testosterone -ve To be determined
Estradiol +/− (? dual effect) Selective estrogen receptor modulators (SERM)
Progesterone +ve To be determined
DHEA +ve To be determined
IGF-1 Probably + ve Recombinant human IGF-1 or truncated IGF-1
GH +ve at higher dose To be determined
Insulin Unclear To be determined
Cortisol -ve To be determined
Prolactin -ve Bromocriptine, pure prolactin receptor antagonists eg., ∆1–9-G129R- hPrl (∆1–9)
Aldosterone -ve Eplerenone, Spironolactone
Endocannabinoids -ve Peripheral CB1 antagonists
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believed to be identical to mouse irisin, and in healthy
adult subjects showed a 2-fold increase in plasma levels
following 10 weeks of supervised endurance exercise
training, as compared to the non-exercised state [125].
This PGC-1α dependent myokine alludes to the super-
added beneficial effects of exercise via BAT, which need to
be further explored.
The PRDM16-C/EBP-β transcriptional complex acts in
Myogenic Factor-5 (Myf5) positive myoblastic precur-
sors or pre-adipocytes to drive the thermogenic program
with co-activation of PPAR-γ and PGC-1α [126,127]. The
cAMP-dependent thermogenic program is potentiated by
Forkhead Box Protein C2 (FOXC2) [128] and PRDM16
and repressed by receptor-interacting protein-140 (RIP140)
[129] (Figure 1). Other transcriptional regulators of Bone
Morphogenic Protein-7 (BMP7) [130], Fibroblast Derived
Growth Factor-21 (FGF21) [131], PPAR-γ ligands [132]
and Atrial Natriuretic Peptide (ANP) [133], have been de-
scribed in rodents. The transcripted cells through these
various regulators are termed as BeAT as opposed to clas-
sical BAT and the success of these compounds depend
upon extrapolating the gains in human models.
The discovery of brown adipocyte stem/progenitor
cells, CD34+ in skeletal muscle [134] and human multi-
potent adipose derived stem cells (hMADs) in subcuta-
neous tissue [135] in adult humans, serve as novel mo-
lecular targets for the development of BAT therapeutics
as they have self-renewing capacity, and hence are ex-
pandable. In response to specific agents, muscle-derived
CD34+ cells differentiate exclusively into brown adipo-
cytes [134]. The WAT-derived hMADs, in contrast, first
differentiate into WAT and following chronic exposure
to PPAR-γ co-activators, gain brown adipose phenotype
[135]. These human cell models provide a unique oppor-
tunity to study the formation and energy dissipation
functions of human brown adipocytes, whilst simultan-
eously exploring therapeutic options. Such cells can po-
tentially be externally induced into BAT, expanded and
implanted back as an autologous implantation for meta-
bolic beneficial effects as shown in recent mouse models
[136]. Subcutaneous transplantation of embryonic BAT
corrected type 1 diabetes in immune-competent mice as
evidenced by reversal of diabetes symptoms, weight re-
gain and normalization of glucose tolerance and the
mice that remained euglycaemic 6-months following the
procedure [137].
Conclusion
There is compelling evidence to suggest that targeting
cellular bioenergetics will yield an effective anti-obesity
therapy. There are also complex practical concerns to be
addressed. Recent key advances in the fields of molecu-
lar cell biology and metabolic science have raised rele-
vant questions relating to the duration of the acquired
BAT-like properties of cells following transcriptional regu-
lation, the long-term fate of transcriptionally converted
non-BAT (BeAT) tissues, the total amount of inactive
BAT in humans and the fate of inter-scapular BAT in in-
fants. Compensatory enhancement of appetite through
central feedback regulation via complex neurological cir-
cuits following sustained chronic peripheral energy loss is
a concern. Therefore, combining novel therapies that en-
hance BAT activity with an appetite-suppressant may be
required. Therapeutic manipulation of peripheral energy
expenditure through increasing BAT quantity and/or ac-
tivity remains one of the most promising strategies for the
successful prevention and management of human obesity.
Although there are significant hurdles, there is also great
potential for BAT manipulation to promote weight-loss
through enhanced facultative metabolism.
Abbreviations
BAT: Brown adipose tissue; WHO: World Health Organization; T2DM: Type 2
diabetes mellitus; FDG: 18-Fluoro-labelled- 2-deoxyglucose; PET-CT: Positron
Emission Tomography- Computed Tomography; WAT: White adipose tissue;
BeAT: Beige adipose tissue; UCP-1: Uncoupling protein- 1; ATP: Adenosine
tri-phosphate; AEE: Activity energy expenditure; TEE: Total energy
expenditure; RMR: Resting metabolic rate; NST: Non-shivering thermogenesis;
DIT: Diet-induced thermogenesis; NEFA: Non-esterified fatty acids;
TH: Thyroid hormone; TR: Thyroid receptor; D2: type-2-deiodinase;
T4: Thyroxine; T3: Thyronine; c-AMP: cyclic adenosine-mono-phosphate;
PKA: Protein kinase-A; Lpl: Lipoprotein lipase; PPAR-γ: Peroxisome proliferator
receptor activated-gamma; aP2: Adipocyte-specific fatty acid binding protein;
IL-6: Interleukin-6; TNF-α: Tumour necrosis factor-alpha; MCP-1: Monocyte
chemoattractant protein; GH: Growth Hormone; IGF-1: Insulin Growth
Factor-1; C/EBP- α: CCAAT-enhancer binding protein- alpha; PRDM-16: PR
domain containing 16; PGC-1α: Peroxisome proliferator activated receptor
gamma coactivator 1- alpha; CB-1: Cannabinoid receptor-1; ER-α: Oestrogen
receptor-alpha; E2: 17-β-Oestradiol; NRF-1: Nuclear respiratory transcriptional
factor-1; GABPA: GA-binding protein transcription protein- alpha; TFAM:
Mitochondrial transcription factor-A; PTEN: Phosphatase and tensin homolog
deleted on chromosome 10; AR: Adrenergic receptor; SERMs: Selective
oestrogen receptor modulators; GLUT-4: Glucose transporter type 4;
FNDC-5: Fibronectin type 3 domain containing 5; Myf-5: Myogenic factor-5;
FOXC2: Forkhead box protein C2; RIP140: Receptor interacting protein-140;
BMP-7: Bone morphogenic protein-7; FGF21: Fibroblast derived growth
factor-21; hMADs: Human multi-potent adipocyte derived stem cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NLR researched the data, contributed to discussion, wrote, reviewed and
edited the manuscript. BKT and TMB contributed to discussion and edited
the manuscript. HSR contributed to conception/design, data interpretation
and manuscript preparation. All authors read and approved the final
manuscript.
Authors’ information
NLR is a Clinical Lecturer in Division of Metabolic and Vascular Health
(DMVH), University of Warwick, and Honorary Consultant in Diabetes &
Endocrinology, University Hospitals Coventry and Warwickshire NHS Trust
(UHCW). BKT is an Associate Professor in Warwick Medical School, University
of Warwick, and Consultant in Department of Obstetrics and Gynaecology,
Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust,
Birmingham, UK. TMB is an Associate Professor in DMVH, University of
Warwick and Consultant in Diabetes & Endocrinology, UHCW. HSR is a Senior
Lecturer in DMVH, University of Warwick and Clinical Director/Consultant in
Diabetes & Endocrinology, UHCW.
Reddy et al. BMC Obesity 2014, 1:13 Page 8 of 12
http://www.biomedcentral.com/2052-9538/1/13
Acknowledgements
We would like to acknowledge the many patients, nurses, scientists and
doctors who have contributed towards ascertaining the data referred to in
this review.
Author details
1Clinical Sciences Research Laboratories, Division of Metabolic and Vascular
Health, Warwick Medical School, University of Warwick, University Hospitals
Coventry and Warwickshire, Clifford Bridge Road, Coventry CV2 2DX, UK.
2Warwickshire Institute for Study of Diabetes, Endocrinology and Metabolism,
University Hospitals Coventry and Warwickshire NHS Trust, Clifford Bridge
Road, Coventry CV2 2DX, UK. 3Obstetrics and Gynaecology, Birmingham
Heartlands and Solihull Hospitals, Heart of England NHS Foundation Trust,
Birmingham B9 5SS, UK.
Received: 27 January 2014 Accepted: 18 July 2014
Published: 22 August 2014
References
1. WHO global infobase: data on overweight and obesity. http://www.who.
int/mediacentre/factsheets/fs311/en/.
2. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G:
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular
disease and death: 13 year follow up of participants in the study of men
born in 1913. Br Med J (Clin Res Ed) 1984, 288:1401–1404.
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M,
Anderson HR, Andrews KG, Aryee M, Lim SS, Vos T, Flaxman AD, Danaei G,
Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M,
Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S,
Baxter A, Bell ML, Blore JD, Blyth F, et al: A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990–2010: a systematic analysis for the
Global Burden of Disease Study 2010. Lancet 2012, 380:2224–2260.
4. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany
EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki
T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W,
Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J,
Cabral N, Nonato IC, Chang JC: Global, regional, and national prevalence
of overweight and obesity in children and adults during 1980–2013:
a systematic analysis for the Global Burden of Disease Study 2013.
Lancet 2014, e-publication ahead of print.
5. Scott A, Ejikeme CS, Clottey EN, Thomas JG: Obesity in sub-Saharan Africa:
development of an ecological theoretical framework. Health Promot Int
2013, 28:4–16.
6. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A,
Proietto J: Long-term persistence of hormonal adaptations to weight
loss. N Engl J Med 2011, 365:1597–1604.
7. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL: Long-term persistence of
adaptive thermogenesis in subjects who have maintained a reduced
body weight. Am J Clin Nutr 2008, 88:906–912.
8. Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for obesity and
overweight. Cochrane Database Syst Rev 2004, 3:CD004094.
9. Dixon JB, Zimmet P, Alberti KG, Rubino F: Bariatric surgery: an IDF
statement for obese Type 2 diabetes. Surg Obes Relat Dis 2011, 7:433–447.
10. Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat,
sibutramine, and rimonabant. Lancet 2007, 369:71–77.
11. Tseng YH, Cypess AM, Kahn CR: Cellular bioenergetics as a target for
obesity therapy. Nat Rev Drug Discov 2010, 9:465–482.
12. Wells JC: Thrift: a guide to thrifty genes, thrifty phenotypes and thrifty
norms. Int J Obes (Lond) 2009, 33:1331–1338.
13. Fawcett DW, Jones IC: The effects of hypophysectomy, adrenalectomy
and of thiouracil feeding on the cytology of brown adipose tissue.
Endocrinology 1949, 45:609–621. illust.
14. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen
M, Laine J, Savisto NJ, Enerback S, Nuutila P: Functional brown adipose
tissue in healthy adults. N Engl J Med 2009, 360:1518–1525.
15. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von
Schulthess GK: Brown adipose tissue: a factor to consider in symmetrical
tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol
Imaging 2002, 29:1393–1398.
16. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC,
Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR: Identification and
importance of brown adipose tissue in adult humans. N Engl J Med 2009,
360:1509–1517.
17. Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP: Emergence of brown
adipocytes in white fat in mice is under genetic control: effects on body
weight and adiposity. J Clin Invest 1998, 102:412–420.
18. Lean ME, James WP, Jennings G, Trayhurn P: Brown adipose tissue in
patients with phaeochromocytoma. Int J Obes (Lond) 1986, 10:219–227.
19. Lahesmaa M, Orava J, Schalin-Jantti C, Soinio M, Hannukainen JC, Noponen
T, Kirjavainen A, Iida H, Kudomi N, Enerback S, Virtanen KA, Nuutila P:
Hyperthyroidism increases brown fat metabolism in humans. J Clin
Endocrinol Metab 2014, 99:E28–E35.
20. Enerback S: Brown adipose tissue in humans. Int J Obes (Lond) 2010,
34(Suppl 1):S43–S46.
21. Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen
KA, Nuutila P, Schaart G, Huang K, Tu H, Van Marken Lichtenbelt WD, Hoeks
J, Enerbäck S, Schrauwen P, Spiegelman BM: Beige adipocytes are a
distinct type of thermogenic fat cell in mouse and human. Cell 2012,
150:366–376.
22. Whittle AJ, Lopez M, Vidal-Puig A: Using brown adipose tissue to treat
obesity - the central issue. Trends Mol Med 2011, 17:405–411.
23. van Marken Lichtenbelt WD, Schrauwen P: Implications of nonshivering
thermogenesis for energy balance regulation in humans. Am J Physiol
Regul Integr Comp Physiol 2011, 301:R285–R296.
24. Westerterp KR, Wilson SA, Rolland V: Diet induced thermogenesis
measured over 24 h in a respiration chamber: effect of diet composition.
Int J Obes Relat Metab Disord 1999, 23:287–292.
25. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T,
Nio-Kobayashi J, Iwanaga T, Miyagawa M, Kameya T, Nakada K, Kawai Y,
Tsujisaki M: High incidence of metabolically active brown adipose
tissue in healthy adult humans: effects of cold exposure and adiposity.
Diabetes 2009, 58:1526–1531.
26. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts
JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ: Cold-activated brown
adipose tissue in healthy men. N Engl J Med 2009, 360:1500–1508.
27. Nicholls DG, Locke RM: Thermogenic mechanisms in brown fat. Physiol
Rev 1984, 64:1–64.
28. Kozak LP: Brown fat and the myth of diet-induced thermogenesis. Cell Metab
2010, 11:263–267.
29. Ouellet V, Labbe SM, Blondin DP, Phoenix S, Guerin B, Haman F, Turcotte EE,
Richard D, Carpentier AC: Brown adipose tissue oxidative metabolism
contributes to energy expenditure during acute cold exposure in
humans. J Clin Invest 2012, 122:545–552.
30. Rothwell NJ, Stock MJ: Luxuskonsumption, diet-induced thermogenesis
and brown fat: the case in favour. Clin Sci (Lond) 1983, 64:19–23.
31. Yoneshiro T, Aita S, Matsushita M, Kameya T, Nakada K, Kawai Y, Saito M:
Brown adipose tissue, whole-body energy expenditure, and thermogenesis
in healthy adult men. Obesity (Silver Spring) 2011, 19:13–16.
32. Muzik O, Mangner TJ, Granneman JG: Assessment of oxidative metabolism
in brown fat using PET imaging. Front Endocrinol (Lausanne) 2012, 3:15.
33. Orava J, Nuutila P, Lidell ME, Oikonen V, Noponen T, Viljanen T, Scheinin M,
Taittonen M, Niemi T, Enerback S, Virtanen KA: Different metabolic
responses of human brown adipose tissue to activation by cold and
insulin. Cell Metab 2011, 14:272–279.
34. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG,
Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PL, Rinninger
F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J: Brown
adipose tissue activity controls triglyceride clearance. Nat Med 2011,
17:200–205.
35. Klitgaard HM, Dirks HB Jr, Garlick WR, Barker SB: Protein-bound iodine in
various tissues after injection of elemental iodine. Endocrinology 1952,
50:170–173.
36. Klieverik LP, Coomans CP, Endert E, Sauerwein HP, Havekes LM, Voshol PJ,
Rensen PC, Romijn JA, Kalsbeek A, Fliers E: Thyroid hormone effects on
whole-body energy homeostasis and tissue-specific fatty acid uptake
in vivo. Endocrinology 2009, 150:5639–5648.
37. Silva JE: Thermogenic mechanisms and their hormonal regulation. Physiol
Rev 2006, 86:435–464.
38. Jiang W, Miyamoto T, Kakizawa T, Sakuma T, Nishio S, Takeda T, Suzuki S,
Hashizume K: Expression of thyroid hormone receptor alpha in 3 T3-L1
Reddy et al. BMC Obesity 2014, 1:13 Page 9 of 12
http://www.biomedcentral.com/2052-9538/1/13
adipocytes; triiodothyronine increases the expression of lipogenic
enzyme and triglyceride accumulation. J Endocrinol 2004, 182:295–302.
39. Viguerie N, Millet L, Avizou S, Vidal H, Larrouy D, Langin D: Regulation of
human adipocyte gene expression by thyroid hormone. J Clin Endocrinol
Metab 2002, 87:630–634.
40. Sheehan TE, Kumar PA, Hood DA: Tissue-specific regulation of cytochrome
c oxidase subunit expression by thyroid hormone. Am J Physiol Endocrinol
Metab 2004, 286:E968–E974.
41. Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S, Gonzalez CR, Velagapudi
VR, Morgan DA, Schoenmakers E, Agassandian K, Lage R, Martínez de Morentin
PB, Tovar S, Nogueiras R, Carling D, Lelliott C, Gallego R, Oresic M, Chatterjee K,
Saha AK, Rahmouni K, Diéguez C, Vidal-Puig A: Hypothalamic AMPK and fatty
acid metabolism mediate thyroid regulation of energy balance. Nat Med
2010, 16:1001–1008.
42. Brent GA: The molecular basis of thyroid hormone action. N Engl J Med
1994, 331:847–853.
43. Ribeiro MO, Carvalho SD, Schultz JJ, Chiellini G, Scanlan TS, Bianco AC,
Brent GA: Thyroid hormone–sympathetic interaction and adaptive
thermogenesis are thyroid hormone receptor isoform–specific. J Clin
Invest 2001, 108:97–105.
44. Bianco AC, Silva JE: Cold exposure rapidly induces virtual saturation
of brown adipose tissue nuclear T3 receptors. Am J Physiol 1988,
255:E496–E503.
45. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong
G, Singh R, Shapses S, Malm J, Webb P, Baxter JD, Grover GJ: Anti-obesity,
anti-diabetic, and lipid lowering effects of the thyroid receptor beta
subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008,
111:262–267.
46. Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter
JD, Scanlan TS: Effects of the thyroid hormone receptor agonist GC-1 on
metabolic rate and cholesterol in rats and primates: selective actions
relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004, 145:1656–1661.
47. Amorim BS, Ueta CB, Freitas BC, Nassif RJ, Gouveia CH, Christoffolete MA,
Moriscot AS, Lancelloti CL, Llimona F, Barbeiro HV, de Souza HP, Catanozi S,
Passarelli M, Aoki MS, Bianco AC, Ribeiro MO: A TRbeta-selective agonist
confers resistance to diet-induced obesity. J Endocrinol 2009, 203:291–299.
48. Lee JY, Takahashi N, Yasubuchi M, Kim YI, Hashizaki H, Kim MJ, Sakamoto T,
Goto T, Kawada T: Triiodothyronine induces UCP1 expression and
mitochondrial biogenesis in human adipocytes. Am J Physiol Cell Physiol
2011, 302:463–472.
49. Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L,
Cochran C, Solomon J, Chen C, Gorden P: Thyroid hormone induced
brown adipose tissue and amelioration of diabetes in a patient with
extreme insulin resistance. J Clin Endocrinol Metab 2010, 95:256–262.
50. Simonsen L, Bulow J, Madsen J, Christensen NJ: Thermogenic response to
epinephrine in the forearm and abdominal subcutaneous adipose tissue.
Am J Physiol 1992, 263:E850–E855.
51. Simonsen L, Stallknecht B, Bulow J: Contribution of skeletal muscle and
adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes
Relat Metab Disord 1993, 17(3):S47–S51. discussion S68.
52. Ricquier D, Nechad M, Mory G: Ultrastructural and biochemical
characterization of human brown adipose tissue in pheochromocytoma.
J Clin Endocrinol Metab 1982, 54:803–807.
53. English JT, Patel SK, Flanagan MJ: Association of pheochromocytomas
with brown fat tumors. Radiology 1973, 107:279–281.
54. Melicow MM: Hibernating fat and pheochromocytoma. AMA Arch Pathol
1957, 63:367–372.
55. Bouillaud F, Ricquier D, Mory G, Thibault J: Increased level of mRNA for the
uncoupling protein in brown adipose tissue of rats during
thermogenesis induced by cold exposure or norepinephrine infusion.
J Biol Chem 1984, 259:11583–11586.
56. Hadi M, Chen CC, Whatley M, Pacak K, Carrasquillo JA: Brown fat imaging
with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG
SPECT: a study of patients being evaluated for pheochromocytoma.
J Nucl Med 2007, 48:1077–1083.
57. Wang Q, Zhang M, Ning G, Gu W, Su T, Xu M, Li B, Wang W:
Brown adipose tissue in humans is activated by elevated plasma
catecholamines levels and is inversely related to central obesity.
PLoS One 2011, 6:e21006.
58. Himms-Hagen J, Cui J, Danforth E Jr, Taatjes DJ, Lang SS, Waters BL, Claus
TH: Effect of CL-316,243, a thermogenic beta 3-agonist, on energy
balance and brown and white adipose tissues in rats. Am J Physiol 1994,
266:R1371–R1382.
59. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME, Himms-
Hagen J, Flier JS, Lowell BB: Targeted disruption of the beta 3-adrenergic
receptor gene. J Biol Chem 1995, 270:29483–29492.
60. Arch JR: The discovery of drugs for obesity, the metabolic effects of
leptin and variable receptor pharmacology: perspectives from beta3-
adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 2008,
378:225–240.
61. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH,
Astrup A: Effect of a 28-d treatment with L-796568, a novel beta(3)-
adrenergic receptor agonist, on energy expenditure and body composition
in obese men. Am J Clin Nutr 2002, 76:780–788.
62. van Baak MA, Hul GB, Toubro S, Astrup A, Gottesdiener KM, DeSmet M,
Saris WH: Acute effect of L-796568, a novel beta 3-adrenergic receptor
agonist, on energy expenditure in obese men. Clin Pharmacol Ther 2002,
71:272–279.
63. Joshi PV, Lele VR: Unexpected visitor on FDG PET/CT–brown adipose
tissue (BAT) in mesentery in a case of retroperitoneal extra-adrenal
pheochromocytoma: is the BAT activation secondary to catecholamine-
secreting pheochromocytoma? Clin Nucl Med 2012, 37:e119–e120.
64. Cheng W, Zhu Z, Jin X, Chen L, Zhuang H, Li F: Intense FDG activity in the
brown adipose tissue in omental and mesenteric regions in a patient
with malignant pheochromocytoma. Clin Nucl Med 2012, 37:514–515.
65. Feldman D: Evidence that brown adipose tissue is a glucocorticoid target
organ. Endocrinology 1978, 103:2091–2097.
66. Strack AM, Sebastian RJ, Schwartz MW, Dallman MF: Glucocorticoids and
insulin: reciprocal signals for energy balance. Am J Physiol 1995,
268:R142–R149.
67. Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE:
Glucocorticoids inhibit the transcriptional response of the uncoupling
protein-1 gene to adrenergic stimulation in a brown adipose cell line.
Mol Cell Endocrinol 2000, 165:7–15.
68. Garrel DR: Glucocorticoids and energy expenditure: relevance to the
regulation of energy balance in man. Nutrition 1997, 13:482–483.
69. Strack AM, Bradbury MJ, Dallman MF: Corticosterone decreases
nonshivering thermogenesis and increases lipid storage in brown
adipose tissue. Am J Physiol 1995, 268:R183–R191.
70. Feve B, Baude B, Krief S, Strosberg AD, Pairault J, Emorine LJ: Inhibition by
dexamethasone of beta 3-adrenergic receptor responsiveness in 3
T3-F442A adipocytes. Evidence for a transcriptional mechanism. J Biol
Chem 1992, 267:15909–15915.
71. Kiely J, Hadcock JR, Bahouth SW, Malbon CC: Glucocorticoids down-regulate
beta 1-adrenergic-receptor expression by suppressing transcription of the
receptor gene. Biochem J 1994, 302(Pt 2):397–403.
72. Vander Tuig JG, Ohshima K, Yoshida T, Romsos DR, Bray GA:
Adrenalectomy increases norepinephrine turnover in brown adipose
tissue of obese (ob/ob) mice. Life Sci 1984, 34:1423–1432.
73. Berthiaume M, Sell H, Lalonde J, Gelinas Y, Tchernof A, Richard D, Deshaies
Y: Am J Physiol Regul Integr Comp Physiol. Am J Physiol Regul Integr Comp
Physiol 2004, 287:R1116–R1123.
74. Ashizawa N, Takagi M, Seto S, Suzuki S, Yano K: Serum adiponectin and
leptin in a patient with Cushing's syndrome before and after
adrenalectomy. Intern Med 2007, 46:383–385.
75. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes
M: Hibernoma development in transgenic mice identifies brown adipose
tissue as a novel target of aldosterone action. J Clin Invest 1998,
101:1254–1260.
76. Penfornis P, Viengchareun S, Le Menuet D, Cluzeaud F, Zennaro MC,
Lombes M: The mineralocorticoid receptor mediates aldosterone-
induced differentiation of T37i cells into brown adipocytes. Am J Physiol
Endocrinol Metab 2000, 279:E386–E394.
77. Viengchareun S, Penfornis P, Zennaro MC, Lombes M: Mineralocorticoid
and glucocorticoid receptors inhibit UCP expression and function
in brown adipocytes. Am J Physiol Endocrinol Metab 2001,
280:E640–E649.
78. Kraus D, Jager J, Meier B, Fasshauer M, Klein J: Aldosterone inhibits uncoupling
protein-1, induces insulin resistance, and stimulates proinflammatory
adipokines in adipocytes. Horm Metab Res 2005, 37:455–459.
79. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein
J: The balance between gluco- and mineralo-corticoid action critically
Reddy et al. BMC Obesity 2014, 1:13 Page 10 of 12
http://www.biomedcentral.com/2052-9538/1/13
determines inflammatory adipocyte responses. J Endocrinol 2010,
204:153–164.
80. Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A, Rosano GM,
Caprio M: The role of the mineralocorticoid receptor in adipocyte
biology and fat metabolism. Mol Cell Endocrinol 2012, 350:281–288.
81. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M: Role of
mineralocorticoid receptor and renin-angiotensin-aldosterone system in
adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013,
137:99–106.
82. Al-Shoumer KA, Page B, Thomas E, Murphy M, Beshyah SA, Johnston DG:
Effects of four years' treatment with biosynthetic human growth
hormone (GH) on body composition in GH-deficient hypopituitary
adults. Eur J Endocrinol 1996, 135:559–567.
83. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark
RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC,
Robbins RJ, Schlechte J, Sharma M, Thorner MO, Vance ML: Growth
hormone (GH) replacement therapy in adult-onset gh deficiency:
effects on body composition in men and women in a double-blind,
randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004,
89:2048–2056.
84. Hioki C, Yoshida T, Kogure A, Takakura Y, Umekawa T, Yoshioka K, Shimatsu
A, Yoshikawa T: Effects of growth hormone (GH) on mRNA levels of
uncoupling proteins 1, 2, and 3 in brown and white adipose tissues and
skeletal muscle in obese mice. Horm Metab Res 2004, 36:607–613.
85. Lorenzo M, Valverde AM, Teruel T, Benito M: IGF-I is a mitogen involved in
differentiation-related gene expression in fetal rat brown adipocytes.
J Cell Biol 1993, 123:1567–1575.
86. Valverde AM, Benito M, Lorenzo M: Proliferation of fetal brown adipocyte
primary cultures: relationship with the genetic expression of glucose 6
phosphate dehydrogenase. Exp Cell Res 1991, 194:232–237.
87. Porras A, Alvarez AM, Valladares A, Benito M: TNF-alpha induces
apoptosis in rat fetal brown adipocytes in primary culture. FEBS Lett
1997, 416:324–328.
88. Guerra C, Benito M, Fernandez M: IGF-I induces the uncoupling protein
gene expression in fetal rat brown adipocyte primary cultures: role of
C/EBP transcription factors. Biochem Biophys Res Commun 1994, 201:813–819.
89. Duchamp C, Burton KA, Geloen A, Dauncey MJ: Transient upregulation of
IGF-I gene expression in brown adipose tissue of cold-exposed rats. Am J
Physiol 1997, 272:E453–E460.
90. Symonds ME, Mostyn A, Pearce S, Budge H, Stephenson T: Endocrine and
nutritional regulation of fetal adipose tissue development. J Endocrinol
2003, 179:293–299.
91. Viengchareun S, Servel N, Feve B, Freemark M, Lombes M, Binart N:
Prolactin receptor signaling is essential for perinatal brown adipocyte
function: a role for insulin-like growth factor-2. PLoS One 2008, 3:e1535.
92. Ben-Jonathan N, LaPensee CR, LaPensee EW: What can we learn from
rodents about prolactin in humans? Endocr Rev 2008, 29:1–41.
93. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R,
Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA: Bromocriptine: a novel
approach to the treatment of type 2 diabetes. Diabetes Care 2000,
23:1154–1161.
94. Krol E, Martin SA, Huhtaniemi IT, Douglas A, Speakman JR: Negative
correlation between milk production and brown adipose tissue gene
expression in lactating mice. J Exp Biol 2011, 214:4160–4170.
95. Julien Auffret SV, Adeline M, Bruno F, Marc L, Nadine B: Mice lacking
prolactin receptor resist high-fat diet–induced obesity by browning of
adipose tissue. Endocr Rev 2011, 32:p1–p787.
96. Rodriguez-Cuenca S, Monjo M, Frontera M, Gianotti M, Proenza AM, Roca P:
Sex steroid receptor expression profile in brown adipose tissue: effects
of hormonal status. Cell Physiol Biochem 2007, 20:877–886.
97. Gaspard U: Hyperinsulinaemia, a key factor of the metabolic syndrome in
postmenopausal women. Maturitas 2009, 62:362–365.
98. Nadal-Casellas A, Proenza AM, Llado I, Gianotti M: Effects of ovariectomy
and 17-beta estradiol replacement on rat brown adipose tissue
mitochondrial function. Steroids 2011, 76:1051–1056.
99. Rodriguez-Cuenca S, Monjo M, Gianotti M, Proenza AM, Roca P: Expression
of mitochondrial biogenesis-signaling factors in brown adipocytes is
influenced specifically by 17beta-estradiol, testosterone, and progesterone.
Am J Physiol Endocrinol Metab 2007, 292:E340–E346.
100. Monjo M, Rodriguez AM, Palou A, Roca P: Direct effects of testosterone,
17 beta-estradiol, and progesterone on adrenergic regulation in cultured
brown adipocytes: potential mechanism for gender-dependent
thermogenesis. Endocrinology 2003, 144:4923–4930.
101. Rodriguez AM, Monjo M, Roca P, Palou A: Opposite actions of testosterone
and progesterone on UCP1 mRNA expression in cultured brown
adipocytes. Cell Mol Life Sci 2002, 59:1714–1723.
102. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E,
Carpentier AC, Richard D: Outdoor temperature, age, sex, body mass
index, and diabetic status determine the prevalence, mass, and
glucose-uptake activity of 18 F-FDG-detected BAT in humans. J Clin
Endocrinol Metab 2011, 96:192–199.
103. Ryu JW, Kim MS, Kim CH, Song KH, Park JY, Lee JD, Kim JB, Lee KU: DHEA
administration increases brown fat uncoupling protein 1 levels in obese
OLETF rats. Biochem Biophys Res Commun 2003, 303:726–731.
104. Gilsanz V, Hu HH, Kajimura S: Relevance of brown adipose tissue in
infancy and adolescence. Pediatr Res 2013, 73:3–9.
105. Tseng YH, Kriauciunas KM, Kokkotou E, Kahn CR: Differential roles of insulin
receptor substrates in brown adipocyte differentiation. Mol Cell Biol 2004,
24:1918–1929.
106. Tanti JF, Gremeaux T, Brandenburg D, Van Obberghen E, Le Marchand-Brustel
Y: Brown adipose tissue in lean and obese mice. Insulin-receptor binding
and tyrosine kinase activity. Diabetes 1986, 35:1243–1248.
107. Shimizu Y, Kielar D, Minokoshi Y, Shimazu T: Noradrenaline increases
glucose transport into brown adipocytes in culture by a mechanism
different from that of insulin. Biochem J 1996, 314(Pt 2):485–490.
108. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW: Fat
feeding causes widespread in vivo insulin resistance, decreased
energy expenditure, and obesity in rats. Am J Physiol 1986,
251:E576–E583.
109. Shimizu Y, Nikami H, Tsukazaki K, Machado UF, Yano H, Seino Y, Saito M:
Increased expression of glucose transporter GLUT-4 in brown
adipose tissue of fasted rats after cold exposure. Am J Physiol 1993,
264:E890–E895.
110. Rothwell NJ, Stock MJ: A role for insulin in the diet-induced thermogenesis
of cafeteria-fed rats. Metabolism 1981, 30:673–678.
111. Shibata H, Perusse F, Bukowiecki LJ: The role of insulin in nonshivering
thermogenesis. Can J Physiol Pharmacol 1987, 65:152–158.
112. Gunawardana SC, Piston DW: Reversal of type 1 diabetes in mice by
brown adipose tissue transplant. Diabetes 2012, 61:674–682.
113. Markelic M, Velickovic K, Golic I, Otasevic V, Stancic A, Jankovic A, Vucetic M,
Buzadzic B, Korac B, Korac A: Endothelial cell apoptosis in brown adipose
tissue of rats induced by hyperinsulinaemia: the possible role of TNF-alpha.
Eur J Histochem 2011, 55:e34.
114. Rouru J, Cusin I, Zakrzewska KE, Jeanrenaud B, Rohner-Jeanrenaud F: Effects
of intravenously infused leptin on insulin sensitivity and on the expression
of uncoupling proteins in brown adipose tissue. Endocrinology 1999,
140:3688–3692.
115. Enriori PJ, Sinnayah P, Simonds SE, Garcia Rudaz C, Cowley MA: Leptin
action in the dorsomedial hypothalamus increases sympathetic tone to
brown adipose tissue in spite of systemic leptin resistance. J Neurosci
2011, 31:12189–12197.
116. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T,
Lubina JA, Patane J, Self B, Hunt P, McCamish M: Recombinant leptin for
weight loss in obese and lean adults: a randomized, controlled,
dose-escalation trial. Jama 1999, 282:1568–1575.
117. Koh KK, Park SM, Quon MJ: Leptin and cardiovascular disease: response to
therapeutic interventions. Circulation 2008, 117:3238–3249.
118. Qiao L, Yoo H, Bosco C, Lee B, Feng GS, Schaack J, Chi NW, Shao J:
Adiponectin reduces thermogenesis by inhibiting brown adipose tissue
activation in mice. Diabetologia 2014, 57:1027–1036.
119. Iacobellis G, Di Gioia C, Petramala L, Chiappetta C, Serra V, Zinnamosca L,
Marinelli C, Ciardi A, De Toma G, Letizia C: Brown fat expresses
adiponectin in humans. Int J Endocrinol 2013, 2013:126751.
120. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C,
Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le
Fur G: SR141716A, a potent and selective antagonist of the brain
cannabinoid receptor. FEBS Lett 1994, 350:240–244.
121. Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM,
Cani PD: The endocannabinoid system links gut microbiota to
adipogenesis. Mol Syst Biol 2010, 6:392.
122. Bajzer M, Olivieri M, Haas MK, Pfluger PT, Magrisso IJ, Foster MT, Tschop MH,
Krawczewski-Carhuatanta KA, Cota D, Obici S: Cannabinoid receptor 1
Reddy et al. BMC Obesity 2014, 1:13 Page 11 of 12
http://www.biomedcentral.com/2052-9538/1/13
(CB1) antagonism enhances glucose utilisation and activates brown
adipose tissue in diet-induced obese mice. Diabetologia 2011, 54:3121–3131.
123. Verty AN, Allen AM, Oldfield BJ: The effects of rimonabant on brown
adipose tissue in rat: implications for energy expenditure. Obesity (Silver
Spring) 2009, 17:254–261.
124. Perwitz N, Wenzel J, Wagner I, Buning J, Drenckhan M, Zarse K, Ristow M,
Lilienthal W, Lehnert H, Klein J: Cannabinoid type 1 receptor blockade
induces transdifferentiation towards a brown fat phenotype in white
adipocytes. Diabetes Obes Metab 2010, 12:158–166.
125. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA,
Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H,
Cinti S, Højlund K, Gygi SP, Spiegelman BM: A PGC1-alpha-dependent
myokine that drives brown-fat-like development of white fat and
thermogenesis. Nature 2012, 481:463–468.
126. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scime A, Devarakonda
S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR,
Spiegelman BM: PRDM16 controls a brown fat/skeletal muscle switch.
Nature 2008, 454:961–967.
127. Kajimura S, Seale P, Kubota K, Lunsford E, Frangioni JV, Gygi SP, Spiegelman
BM: Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta
transcriptional complex. Nature 2009, 460:1154–1158.
128. Cederberg A, Gronning LM, Ahren B, Tasken K, Carlsson P, Enerback S:
FOXC2 is a winged helix gene that counteracts obesity,
hypertriglyceridemia, and diet-induced insulin resistance. Cell 2001,
106:563–573.
129. Hallberg M, Morganstein DL, Kiskinis E, Shah K, Kralli A, Dilworth SM, White
R, Parker MG, Christian M: A functional interaction between RIP140 and
PGC-1alpha regulates the expression of the lipid droplet protein CIDEA.
Mol Cell Biol 2008, 28:6785–6795.
130. Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, Taniguchi CM, Tran
TT, Suzuki R, Espinoza DO, Yamamoto Y, Ahrens MJ, Dudley AT, Norris AW,
Kulkarni RN, Kahn CR: New role of bone morphogenetic protein 7 in brown
adipogenesis and energy expenditure. Nature 2008, 454:1000–1004.
131. Beenken A, Mohammadi M: The FGF family: biology, pathophysiology and
therapy. Nat Rev Drug Discov 2009, 8:235–253.
132. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J,
Straubhaar J, Czech MP, Corvera S: Mitochondrial remodeling in adipose
tissue associated with obesity and treatment with rosiglitazone. J Clin
Invest 2004, 114:1281–1289.
133. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi
N, Sarzani R, Collins S: Cardiac natriuretic peptides act via p38 MAPK to
induce the brown fat thermogenic program in mouse and human
adipocytes. J Clin Invest 2012, 122:1022–1036.
134. Crisan M, Casteilla L, Lehr L, Carmona M, Paoloni-Giacobino A, Yap S, Sun B,
Leger B, Logar A, Penicaud L, Schrauwen P, Cameron-Smith D, Russell AP,
Péault B, Giacobino JP: A reservoir of brown adipocyte progenitors in
human skeletal muscle. Stem Cells 2008, 26:2425–2433.
135. Elabd C, Chiellini C, Carmona M, Galitzky J, Cochet O, Petersen R, Penicaud
L, Kristiansen K, Bouloumie A, Casteilla L, Dani C, Ailhaud G, Amri EZ:
Human multipotent adipose-derived stem cells differentiate into
functional brown adipocytes. Stem Cells 2009, 27:2753–2760.
136. Stanford-RJ-WM KI, Ding AN, Kristy T, Hitchcox KM, Dae Young J, Yong Jin L,
Kim JK, Hirshman MF, Yu-Hua T, Goodyear LJ: Transplantation of Brown
Adipose Tissue Exerts Beneficial Effects on Glucose Homeostasis. San Diego:
American Diabetes Assocation, 71st Scientific Session; 2011.
137. David W, Piston SCG: Reversal of Type 1 Diabetes by Brown Adipose Tissue
Transplant. San Diego: American Diabetes Assocation, 71st Scientific Session;
2011.
doi:10.1186/s40608-014-0013-5
Cite this article as: Reddy et al.: Brown adipose tissue: endocrine
determinants of function and therapeutic manipulation as a novel
treatment strategy for obesity. BMC Obesity 2014 1:13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Reddy et al. BMC Obesity 2014, 1:13 Page 12 of 12
http://www.biomedcentral.com/2052-9538/1/13
Identification of Brown Adipose Tissue Using MR
Imaging in a Human Adult With Histological and
Immunohistochemical Confirmation
Narendra L. Reddy, Terence A. Jones, Sarah C. Wayte, Oludolapo Adesanya,
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Objective: Manipulation of human brown adipose tissue (BAT) represents a novel therapeutic
option for diabesity. Theaimofour studywas todevelopand test anovelmagnetic resonance (MR)
imaging-basedmethod to identifyhumanBAT,delineate it fromwhiteadipose tissue, andvalidate
it through immunohistochemistry.
Design: A 25-year old Caucasian female with hyperparathyroidism-jaw tumor syndrome under-
went parathyroidectomy. An 18fluoro-2-deoxyglucose positron emission tomography (PET)-com-
puted tomography (CT) scan performed after surgery ruled out malignancy but showed avid
uptake within the mediastinum, neck, supraclavicular fossae, and axillae, consistent with BAT.
Immunohistochemical staining using uncoupling protein-1 antibody was performed on one fat
sample obtained from the suprasternal area during parathyroidectomy. Subsequently, serial MR
scans were performed. Retrospectively, regions of interest (ROIs) were identified on MR corre-
sponding to areas of high uptake on PET-CT. Prospectively, ROIs were identified on MR based on
signal intensity and appearance and compared with PET-CT.
Results:Of 111 retrospectively identified ROIs from PET-CT, 93 (83.8%) showed corresponding low
MR signal: 25 of 25 mediastinum (100%), 29 of 31 neck (93.5%), 31 of 41 supraclavicular (75.6%),
and 8 of 14 axillae (57%). Prospectively, 47 of 54 ROIs identified on MR (87%) showed a corre-
sponding increased uptake on PET-CT. Serendipitously, the sample obtained at surgery corre-
sponded with high uptake and low signal on subsequent PET and MR, respectively, and immuno-
histochemistry confirmed BAT.
Conclusion:Weprovide the first report for the reliable use ofMR to identify BAT in a living human
adult, with histological/immunohistochemical confirmation. Our data demonstrate proof of con-
cept to support the development of MR as a safe, reproducible imaging modality for human BAT.
(J Clin Endocrinol Metab 99: E117–E121, 2014)
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Abbreviations: BAT, brown adipose tissue; BATretro, areas of presumed BAT on MR, iden-
tified retrospectively on the basis of having increased 18F-FDG uptake in corresponding
areas on PET-CT; BATprosp, areas of presumed BAT onMR, identified prospectively without
reference to PET-CT; CT, computed tomography; 18F-FDG, 18fluoro-2-deoxyglucose;
IDEAL, iterative decomposition of water and fat with echo asymmetry and least-squares
estimation; MR, magnetic resonance; PET, positron emission tomography; ROI, region of
interest; UCP1, uncoupling protein-1; WAT, white adipose tissue; WATretro, areas of pre-
sumedWAT onMR, identified retrospectively on the basis of differences in signal intensity.
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Recently, active brown adipose tissue (BAT) was iden-tified in human adults for the first time (1). The clin-
ical relevance is that BAT activation should promote
weight loss (2, 3) andmay account for 10%–20% increase
in energy expenditure (4, 5). BAT activity may also im-
prove glucolipid status (6, 7).
Most studies on human BAT have used 18fluoro-2-de-
oxyglucose (18F-FDG)-positron emission tomography
(PET) (1, 3). This technique is excellent for the assessment
of BAT activity. However, there are limitations that in-
clude signal variability resulting from changes in BAT ac-
tivity in response to environmental temperature (necessi-
tating careful control of environmental temperature).
Magnetic resonance (MR)-based images of human BAT
may overcome this problem and improve reproducibility.
MR would provide data on anatomy and BAT content
rather than activity that in turnwould provide insight into
the presence of BAT among the adult human population
and also could potentially be used in the assessment of
future therapies that manipulate BAT content. Further-
more, MR does not use ionizing radiation.
The rationale for exploring MR to identify human
adult BAT is based on the premise that BAT and white
adipose tissue (WAT) differ in their water to fat ratio (due
to differences in mitochondrial and triglyceride content)
(8).TheMRtechniqueof iterative decompositionofwater
and fat with echo asymmetry and least-squares estimation
(IDEAL MR) has been shown in rats to delineate BAT
fromWAT, with fat fraction ranges being 37%–70% and
90%–93%, respectively (9). However, this technique has
not been demonstrated to identify BAT conclusively in a
living human adult.
The aim of our study was to demonstrate proof of con-
cept that the identification of BAT in a living human adult
is possible using the technique of IDEAL MR.
Materials and Methods
The case
A25-year-old nonobeseCaucasian female (phenotype shown
in Supplemental Table 1)was diagnosedwith hyperparathyroid-
ism-jaw tumor syndrome (heterozygous mutation: T to C nu-
cleotide substitution in exon 2 ofCDC73 [c.191T!C], encoding
parafibromin) (10). There were no regular medications and no
other medical history of note. A right-sided mandibular lesion
(giant cell granuloma) was identified and resected. After a suc-
cessful enucleation of a 5-mm right inferior parathyroid ade-
noma, the serumPTH level was transiently elevated. Subsequent
18F-FDGPET-computed tomography (CT) scanwasnegative for
malignancy but revealed multiple areas of high 18FDG uptake
within suprasternal and mediastinal fat (Supplemental Figure
1A). Informed consent for study recruitment was obtained. Eth-
ical approval was obtained from the regional ethics committee.
Positron emission tomography scanning
The subject was fasted for 6 hours. A total of 375 MBq of
18F-FDG radiotracer was injected 1 hour prior to PET scan (GE
Discovery STE PET-CT scanner; General Electric Medical Sys-
tems). Two sets of emission data were obtained for 3 minutes in
each bed position; from skull base to midthigh (arms elevated);
and the head and neck protocol (without arm elevation). PET
images were reconstructed using CT data for attenuation
correction.
Magnetic resonance scanning
AbaselineMRscanusing 3-echo IDEAL sequence (11, 12) on
a 3T GE-HDxt scanner (General Electric Medical Systems) was
performed in the samemonth as the PET scan. Axial imageswith
5-mm slice thickness were obtained from upper cervical to
midthoracic level.TheT1-weighted IDEALsequenceparameters
were as follows: repetition time, 440 milliseconds; echo time,
10.8milliseconds; acquisitionmatrix size, 320"256; number of
excitations, 3; and field of view, 30 cm. This generated water-
only and fat-only (fat-IDEAL) images. The latter were used for
subsequent analyses. A second MR was performed 2 months
later using identical imaging parameters to determine temporal
variation in BAT distribution.
Retrospective image analysis
PET-CT and fat-IDEAL MR images were transposed and
coregistered using image fusion software Mirada XD 4.3
(Mirada Medical Ltd).
In the fused images, BATareas identifiedonPET (greater than
background levels of 18F-FDG uptake within adipose tissue)
were drawnon fat-IDEALMR images (Supplemental Figure 1C)
and will be referred to as BATretro. Radiotracer uptake in the
paravertebral regions was not assessed due to the difficulties of
accurately identifying these areas on MR. Image analysis was
then performed on the enhancedMR images possessingmapped
BATretro regions, using ImageJ 1.45s (National Institutes of
Health).
MR signals within BATretro areas were compared with those
from immediately adjacent adipose tissue (WATretro) to deter-
mine differences in signal intensity. The MR images were scru-
tinized with regard to adjacent image slices to ensure that any
perceived variation in MR signal did not represent partial vol-
ume artifact. Differences in signal intensity in BATretro and
WATretro areas were compared using the Wilcoxon matched-
pairs test (paired t test) using GraphPad Prism version 5.00
(GraphPad Software). One-way ANOVA was performed to
determine the variation of the BATretro to WATretro signal
ratios according to the anatomical location.
Prospective image analysis
Two radiologists independently drew BAT areas on un-
mapped fat-IDEALMR images (BATprosp) based on differences
in signal intensity observed between BATretro andWATretro dur-
ing retrospective analyses 4 months after the retrospective anal-
ysis (to reduce any recall bias). The regions of interest (ROIs)
were restricted to adipose tissue within the upper mediastinum,
base of neck, and supraclavicular fossae.
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Histology and immunohistochemistry
The single fat sample obtained during parathyroidectomyun-
derwent histological and immunohistochemical analysis (no
other samples were taken). The Vectastain Elite ABC kit (Vector
Laboratories; PK-6101) and rabbit antiuncoupling protein-1
(UCP1; 1:500, U6382; Sigma) were used according to the man-
ufacturer’s protocol.
Results
Retrospective image analyses
One hundred eleven ROIs of 18F-FDG uptake on PET
were identified, which were consistent with BAT (Figure
1AandSupplemental Figure1A): uppermediastinum(n!
25); supraclavicular fossae (n ! 41); neck (n ! 31);
and axillae (n ! 14) (Table 1). These ROIs of increased
18F-FDG uptake had a total cumulative surface area of
9031mm2, ofwhich themajority oc-
curred within the mediastinum and
supraclavicular regions. Visual com-
parison of the MR signal within
these BATretro areas and adjacent
WATretro revealed consistently lower
signal intensity and were often de-
lineated by a discrete margin, as
shown in Figure 1B and Supple-
mental Figure 1B.
Overall, 93 of the 111 BATretro
ROIs (83.8%) had a lower MR sig-
nal than adjacent WATretro, al-
though this did vary according to an-
atomical site (Table 1). Twenty-five
of 25 of the BATretro ROIs in the up-
per mediastinum (100%) had a
lower MR signal than adjacent adi-
pose tissue, 29 of 31 in the neck
(93.5%), 31 of 41 in the supraclavic-
ular fossae (75.6%), and 8 of 14 in
the axillae (57%). A significant dif-
ference was found between MR sig-
nal within BATretro and WATretro
ROIs (Table 1) using Wilcoxon
matched-pairs test in all but the axillary region. The signal
intensity varied considerably along the B0 axis (cranio-
caudal direction), with a 10-fold difference in signal in-
tensity between cranial (neck) images and caudal (medi-
astinal) images (Supplemental Figure 2). This was due to
the signal variation from the receiver coil because the dis-
tance between the receiver coil and the body was greater
in the cervical region than themediastinum.However, the
BATretro to WATretro signal ratio remained constant with
slice position (Supplemental Figure 3). There was varia-
tion in the BATretro to WATretro signal ratio according to
the anatomical region (Table 1 and Supplemental Figure
4), with a significantly lower signal ratio (P" .0001, one
wayANOVA)within themediastinumandneck (ie, lower
BAT signal with respect to WAT) than in the supraclavic-
Figure 1. A, 18F-FDG uptake within the suprasternal notch on PET-CT (arrow). B, fat-IDEAL MR
at the same level showing corresponding low signal in the suprasternal notch. Hematoxylin-eosin
staining (C) and UCP1 immunostaining (D) provide confirmation of BAT obtained from this area.
Table 1. For Each Anatomical Region, the Number of BATretro ROIs With Low and Normal Signal Intensity on MR,
the Variation in BATretro and WATretro MR Signal Intensity, and BAT-WAT Signal Ratio Are Tabulated
Anatomical
Regions
BATretro ROIs
With Lower MR
Signal Than
Adjacent Fat, n
BATretro ROIs
With Similar MR
Signal to
Adjacent Fat, n
Total
ROI, n
Mean BATretro
MR Signal
Mean WATretro
MR Signal Significance
Signal BAT to
WAT Ratio
All regions 93 18 111 485 (#229) 549 (#260) P " .0001 0.89 # 0.12
Mediastinum 25 0 25 586 (#145) 750 (#197) P " .0001 0.79 # 0.11
Supraclavicular 31 10 41 541 (#68) 594 (#90) P " .0001 0.92 # 0.12
Neck 29 2 31 196 (#116) 219 (#125) P " .0001 0.89 # 0.09
Axillae 8 6 14 783 (#189) 788 (#184) P ! .76 0.99 # 0.08
The BATretro ROIs were retrospectively drawn on MR from areas of corresponding high
18F-FDG uptake on the PET-CT images.
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ular fossae and axillae. The repeat IDEAL MR scan
(Supplemental Figure 5) demonstrated little change in the
distribution of low signal regions (Supplemental Figure 1B).
Prospective image analyses
Fifty-four ROIs were prospectively identified on un-
mappedMRby two investigators (T.A.J. andO.A.) on the
basis of having discrete areas of low signal intensity with
respect to adjacent adipose tissue and were presumed to
represent BAT (BATprosp). The total cumulative surface
area of these BATprosp ROIs was 6207 mm
2, compared
with 5661 mm2 in the mediastinum and supraclavicular
fossae in BATretro ROIs (the majority of ROIs occurring
within centrally located regions due to favorable signal to
noise ratio). The surface area of 54 BATprosp ROIs com-
prised 2.4% of the total surface area of adipose tissue
examined (257,181mm2).ComparisonbetweenBATprosp
ROIsandPET-CTscans showed that47of54ROIs (87%)
coincided with areas of 18F-FDG uptake. Cohen’s kappa
coefficient of interrater agreement was 0.61.
Histology and immunohistochemistry
Hematoxylin-eosin staining of the fat tissue obtained
from the suprasternal area (white arrowhead, Figure
1B) demonstrated smaller multilocular cells with mul-
tiple small lipid droplets (yellow arrowhead, Figure
1C), consistent with BAT in contrast to larger uniloc-
ular droplets inWAT (white arrowhead, Figure 1C) (8).
BAT was unequivocally confirmed on immunostaining
with antiserum against rabbit UCP1 (Figure 1D), a
unique marker for BAT (13). Although the fat sample
was collected prior to imaging, there was morphologi-
cal and immunohistochemical correlation between the
suprasternal ROIs corresponding to BAT in PET and
MR images, confirming the presence of BAT.
Discussion
We report the first proof of concept of MR in the identi-
fication of BAT in a living human adult, with immuno-
histochemical and histological confirmation. Using MR,
we demonstrated unequivocal differences in signal inten-
sities between BAT and adjacent WAT.
BAT was identified using MR in mice (14, 15) and in
human postmortem studies (16), including a 3-month-old
infant [with lower fat fraction for BAT (41.9%!6.25%) vs
WAT ("90%)] (17). Presumed BATwas identified in a pre-
mature 13-day-old live neonate based on MR (18). In con-
trast to previous studies though, we demonstrate the first
conclusive identificationofBATusingMRina livinghuman
adult.
We show data on one human adult, and future studies
should validate this technique, including obese adults. Al-
though retrospective and prospective analyses were sep-
arated by 4 months, there may have still been some recall
bias, and this could be better controlled for in subsequent
validations. The anatomical variation inMRsignal results
from differences in signal to noise ratio between centrally
and more laterally located tissues. Furthermore, small ar-
eas of BAT (such as in paravertebral regions)were difficult
to identify. These factors may limit the usefulness of MR
as an accurate quantifier of BAT in human adults. Finally,
we had immunohistochemistry from only one sample. Fu-
ture validations should assess multiple samples of BAT
and WAT.
It seems unlikely that MR signals from adipose tissue
are abnormal in hyperparathyroidism-jaw tumor syn-
drome because immunohistochemistry showed character-
istic features of BAT (3). Furthermore, although (mini-
mally invasive) surgery preceded the imaging, we believe
that this is unlikely to have affected the MR signal from
this region, given that there was little surgical damage to
tissues, and the appearance and signal from BAT in this
region was similar to that in other centrally located BAT
areas. The potential bias from transposing areas of 18F-
FDG uptake on PET-CT onto MR images was limited by
scans being performed with the patient adopting a similar
position (arms down) as per standard protocols.
In summary, we provide proof of concept of an MR-
based novel method for demonstrating BAT with clear
delineation from adjacent WAT, in a living human adult.
Future studies should focus on developing and validating
IDEAL MR imaging as a clinical and research tool, in-
cluding obese adults, for use in future assessments and
quantification of human BAT.
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Summary
Objective Meal duration may influence cardiometabolic health.
The aim of this study was to explore postprandial effects of meal
duration on human metabolism and appetite.
Design Postprandial comparisons following a standard meal
eaten slowly over 40 min (‘D40’) and the same meal eaten quickly
over 10 min (‘D10’) on a different day. Each participant therefore
acted as their own control, thereby limiting confounding factors.
Patients Obese premenopausal Caucasian women (n = 10) with
confirmed normoglycaemia were recruited from an obesity clinic
at UHCW, Coventry UK. Subjects underwent whole-body calo-
rimetry (8-h) on two separate days.
Measurements Following standard lunch (D40 vs D10), 4-h
postprandial analysis included thermic effect of food (TEF) and
bloods taken at predefined times (including baseline fasting). Ana-
lytes included lipid profile, adiponectin, insulin, glucose, ghrelin,
leptin, endotoxin, gut and pancreatic hormones. Appetite was
measured using visual-analogue scales and ad libitum food intake
at subsequent meal. Paired sample t-tests [including area under
the curve (AUC)] were used to compare D40 and D10 trials.
Results Postprandial TEF (over 240-min) was significantly
greater for D40 than D10 [mean (SEM): 80!9 kcal (3!8) vs 29!9
kcal (3!4); 10!6% vs 3!9%, respectively, P = 0!006; AUC 71!7
kcal.h vs 22!4 kcal.h, respectively, P = 0!02]. Postprandial plasma
NEFA was significantly lower, and adiponectin levels were signif-
icantly higher for D40 than D10 [AUC (SEM): NEFA 627
lmol.h/l (56) vs 769 lmol.h/l (60), respectively, P = 0!02;
adiponectin 33!4 lg.h/ml (3!9) vs 27!3 lg.h/ml (3!8), respec-
tively, P = 0!04]. Other postprandial analytes and appetite mea-
sures were equivalent.
Conclusions In obese women, eating slowly associates with
enhanced TEF, elevated serum adiponectin and suppressed NEFA.
(Received 13 September 2014; returned for revision 12 October
2014; finally revised 23 October 2014; accepted 31 October 2014)
Introduction
The global obesity epidemic shows no signs of abating.1 Obesity
and its associated problems including type 2 diabetes mellitus
(T2D) constitute the biggest threat to global health and healthcare
economies.2 Novel strategies implemented in multifaceted ways
are required: development of novel pharmacological therapies;
redesign of our obesogenic living spaces; policies to improve our
diet particularly for our children; and cultural change.
Diet, a major determinant of fat mass, is an obvious target for
obesity prevention and management.3 Although macronutrient
composition 4 and food viscosity 5 are important considerations,
other eating-related behaviours such as meal duration merit
investigation. Faster eating has been shown to associate with
increased energy intake during single meals,6–8 and higher BMI,9–
11 thereby potentially influencing body weight. Although meal
duration may influence metabolism and appetite (and therefore
body weight) via effects on adipokines and gut and pancreatic
neuro-endocrine signals,12 this remains speculative.10,11,13,14
A clear understanding of how meal duration influences human
metabolism [including thermic effect of food (TEF)] and appetite
would provide invaluable insight into obesity pathogenesis and
potential strategies for prevention and management of obesity
through modification of eating-related behaviour. We define TEF
as overall energy expenditure in the 4-h postprandial period fol-
lowing a meal, incorporating obligatory energy requirements of
food digestion, absorption, metabolism and storage, and faculta-
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tive energy expenditure (EE), mediated at least in part by the
sympathetic nervous system.4 The aim of this study was to
explore in obese, normoglycaemic women the postprandial
effects of meal duration on metabolism [including TEF and
excursions of glucose, insulin, endotoxin and nonesterified fatty
acids (NEFA)] and appetite (including excursions of appetite-
related hormones such as ghrelin).
Methods and procedures
Subjects
All subjects (n = 10) were recruited from the Obesity clinic at
the Warwickshire Institute for the Study of Diabetes, Endocrinol-
ogy and Metabolism (WISDEM) centre at the University Hospi-
tals Coventry and Warwickshire (UHCW). All subjects were
obese (BMI > 30 kg/m2) premenopausal (based on menstrual
history and absence of clinical features suggestive of peri- or
postmenopausal status), white, Caucasian women, with normo-
glycaemia (based on fasting and postprandial plasma glucose
measurements, and no past history of dysglycaemia). All subjects
were nonsmokers, and none had any other medical problems
including weight-related conditions such as polycystic ovary syn-
drome, Cushing’s syndrome, obstructive sleep apnoea or other
adverse metabolic sequelae. Exclusion criteria included prior ba-
riatric surgery, weight-loss medication or actual weight-loss of
>2!5 kg up to 3 months prior to recruitment. All subjects had
received standard lifestyle advice from a specialist dietician prior
to inclusion in the study as part of their clinical care. All clinical
investigations were conducted in accordance with the guidelines
in the Declaration of Helsinki. All subjects provided fully
informed written consent, and a local Research Ethics Committee
in the United Kingdom approved the study.
Anthropometry, calorimetry and meal duration
Following informed consent, each subject was invited to
undergo metabolic studies on two separate days at the Human
Metabolism Research Unit (HMRU), a University of Warwick
and UHCW NHS Trust facility. HMRU houses two whole-body
calorimeters (WBCs) (2 m 9 3 m 9 2!5 m), each hermetically
sealed to the outside environment and replicating free-living
environments. Double-doored hatches allow food to be delivered
into and waste out of each WBC. Accurate minute-by-minute
measurements of CO2 and O2 from air entering and leaving the
WBCs enable EE (including TEF) to be calculated in real time
using Weir’s formula: EE (kcal) = [3!941 9 O2 consumed
(L)] + [1!106 9 CO2 produced (L)].15 Thermoneutral tempera-
ture (24 °C) and relative humidity (57%) were kept constant.
The two WBC metabolic studies were executed within 2 weeks
of each other. Subjects were instructed to avoid caffeine inges-
tion and strenous physical activity for 24-h preceding each visit,
and to adhere to their normal diet and physical activity sched-
ules. Subjects were fasted for 12 h prior to commencement of
each metabolic study. On each study day morning, the subject
arrived at HMRU in a fasted state. Prior to metabolic studies,
waist circumference, BMI and body composition (body fat mass
and fat percentage) was measured, the latter with a BodPod
using air displacement plethysmography (Cosmed Inc, USA).16
Baseline fasting blood tests were taken. Subjects then entered
WBC at 0900 h and lay still on the bed for 120 min, to allow
for equilibration and estimation of resting EE. During postpran-
dial periods, subjects had minimal activity or ambulation.
For each study day, standard lunch was provided at 1200 h. The
same standardized lunch (designed and prepared by a specialist
weight-management dietician) was served for all the metabolic
studies. The standard lunch (ham sandwich, yoghurt, banana, bis-
cuit and orange juice drink) contained a total of 763 kcal; 50%
carbohydrate, 18% protein and 32% fat. On their first metabolic
assessment day, each subject was served standard lunch, with calo-
ric content of the meal divided equally into eight separate food
boxes, the food contents of each box eaten over 5 min for a total
meal duration of 40 min (the lunch being completed by 1240 h).
This trial is referred to as ‘D40’. For the second metabolic assess-
ment (on a different day), an identical protocol was followed
except that the duration of the standard lunch was 10 min rather
than 40 min. For this assessment, the caloric content of the stan-
dard meal was divided into two halves, with the food contents of
each box being eaten over 5 min for a total meal duration of
10 min (the lunch being completed by 1210 h). This trial is
referred to as ‘D10’. Subjects were provided with timers and were
monitored by study investigators to ensure compliance with eating
rate. Subjects were instructed to vary chewing speed accordingly.
Postprandial phase
During the 4-h postprandial phase, subjects were requested to
remain seated in the WBC with minimal activity and to refrain
from ingestion of food or drink. Blood tests were taken at pre-
defined time-points (at baseline, 30-, 60-, 90-, 120-, 180- and
240-min intervals). The timing of the postprandial blood tests
was determined by the end-point of the standard meal (to avoid
taking any bloods during the D40 meal), that is time ‘0’ was
defined by the end of the meal for D40 at 1240 h and for D10
at 1210 h. Blood was taken from an arm placed through a hatch
of the WBC, a plastic cover used to avoid any air exchange with
the WBC. All samples were spun in a centrifuge immediately,
and serum samples frozen at "80 °C. Appetite was assessed just
prior to each blood test through use of visual analogue scale
(VAS). At 1700 h, subjects were invited to leave the WBC and
offered an ad libitum standard buffet meal, consisting of cold
foods (sandwiches, chocolate bars, fruit, sausage rolls and
drinks). The carloric content and macronutrient composition of
the ad libitum food ingested was calculated. TEF was calculated
using validated methods reported in literature, and also
expressed in percentage of energy intake [(Postprandial EE-
Baseline EE)/Amount of calories ingested].17
Biochemical evaluation
Fasting baseline serum samples were analysed for lipid profile
(total cholesterol, LDL cholesterol, HDL cholesterol and triglyce-
© 2015 John Wiley & Sons Ltd
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rides), HbA1C, glucose, 0900 h cortisol, insulin-like growth fac-
tor 1 (IGF1), thyroid-stimulating hormone (TSH), free T4, tes-
tosterone, sex hormone-binding globulin (SHBG) and 25-
hydroxycholecalciferol. Postprandial and prelunch blood samples
(D40 and D10) were analysed for ghrelin, leptin, PYY, GLP-1,
adiponectin, cortisol, insulin, glucose, total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, endotoxin and NEFA.
4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride (Pefab-
loc SC) and dipeptidyl peptidase-IV inhibitor were added to
chilled EDTA tubes for measurements of pancreatic and gut
hormones. Serum insulin was measured with a chemilumines-
cent assay (DPC immulite 2500 machine), and plasma glucose
with a hexokinase assay (ADVIA 2400 analyser). Serum testos-
terone and SHBG were measured with chemiluminescent assays
(Immulite 2000 analyser). Serum ghrelin (total) was measured
with a radioimmunoassay (LINCO Research, St. Charles, MO,
USA) with lower limit of detection 100 pg/ml. (intra-assay coef-
ficient of variation for all assays used <7%). Serum endotoxin
was analysed using a commercially available QCL-1000 LAL
Endpoint Assay (Lonza Inc., Allendale, NJ, USA) and validated
as previously described.18
Statistical analyses and power calculations
Statistical analyses were conducted in SPSS (version 21 Windows;
SPSS Inc., Chicago, IL, USA) and Microsoft Excel. Paired sample
t-tests were used for comparisons of 4-h postprandial ‘area under
the curve’ (AUC) metabolic and biochemical data between D40
and D10. Each subject acted as their own control thereby limiting
confounding. We had >80% power to detect a between meal dura-
tion difference exceeding 50% of a standard deviation (SD) for
plasma glucose from D40 to D10 (alpha = 0!05). A P-value < 0!05
was considered significant. Data are shown as mean and SEM
unless otherwise stated. AUC was calculated using the validated
trapezoid method in Excel.
Results
Baseline anthropometric, clinical and biochemical data
Baseline anthropometric, clinical and fasting biochemical data
are shown in Table 1. Mean age was 41!8 years (SD 6!7). Mean
BMI was 42!1 kg/m2 (SD 4!6). Mean body fat percentage was
50!7% (SD 7!4). By definition, all subjects had normal fasting
glucose and HbA1C and were biochemically euthyroid and
normoandrogenaemic.
Postprandial biochemical data
Postprandial biochemical data are shown in Table 2. For each
analyte, AUC (SEM) data from the 4-h postprandial period are
shown. Plasma NEFA in the postprandial period was signifi-
cantly lower for D40 than D10 [AUC (SEM): NEFA 627
lmol.h/l (56) vs 769 lmol.h/l (60), respectively, P = 0!02]. Post-
prandial adiponectin was significantly higher for D40 than D10
[Adiponectin AUC (SEM) 33!4 lg.h/ml (3!9) vs 27!3 lg.h/ml
(3!8), respectively, P = 0!04]. Postprandial insulin, ghrelin and
glucose levels (and all other analytes) were statistically equivalent
between D40 and D10 (Table 2).
TEF
TEF was significantly greater in D40 than D10 [TEF mean over
240-min postprandial period (SEM): 80!9 kcal (3!8) vs 29!9 kcal
(3!4), respectively, P = 0!006, Table 3; TEF AUC 71!7 kcal.h vs
22!4 kcal.h, respectively, P = 0!02, Fig. 1]. As a proportion of
energy intake during the meal, TEF was significantly greater in
D40 than D10 (10!6% vs 3!9%, respectively, P = 0!006).
Postprandial appetite (Visual Analogue Scale and ad
libitum evening buffet)
Postprandial data on appetite (VAS) and evening buffet con-
sumption are shown in Table 3. Appetite was greatest premeal
and was most suppressed in the early postprandial phase
Table 1. Baseline anthropometric, clinical and biochemical (fasting) data
for subjects (n = 10) taken prior to entry into WBC at first metabolic
study
Variable Mean SD
Age (years) 41!8 6!7
Weight (kg) 116!5 16!2
BMI (kg/m2) 42!1 4!6
Waist circumference (m) 1!20 0!09
Hip circumference (m) 1!35 0!13
Waist: hip ratio 0!90 0!1
Fat mass (kg) 59!5 14!5
Lean mass (kg) 57!0 8!7
Fat % 50!7 7!4
Glucose (mmol/l) 4!7 0!6
Total Cholesterol (mmol/l) 5!0 0!9
LDL Cholesterol (mmol/l) 3!2 0!8
HDL Cholesterol (mmol/l) 1!3 0!1
Triglycerides (mmol/l) 1!2 0!3
Haemoglobin A1C (%) 5!6 0!3
9am Cortisol (gmol/l) 356 165
IGF1 (gmol/ml) 20!7 5!8
TSH (mIU/l) 2!4 1!1
Free T4 (pmol/l) 15!2 1!6
Testosterone (gmol/l) 0!8 0!6
SHBG (gmol/l) 54!4 31!5
25-hydroxycholecalciferol (gmol/l) 36 18
BMI, body mass index; kg, kilogram; SHBG, sex hormone-binding glob-
ulin; TSH, thyroid-stimulating hormone; IGF1, insulin-like growth fac-
tor-1; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD,
standard deviation.
To convert glucose mmol/l to mg/dl, divide by 0!0555; to convert trigly-
ceride mmol/l to mg/dl, divide by 0!0113; to convert cholesterol mmol/l
to mg/dl, divide by 0!0259; to convert cortisol nmol/l to microgram/dl,
divide by 27·59; to convert testosterone gmol/l to ng/dl, divide by
0!0347; to convert 25-hydroxycholecalciferol gmol/l to gg/ml, divide by
2!496; to convert SHBG gmol/l to lg/ml, divide by 8!896; to convert
IGF1 gmol/l to gg/ml, divide by 0!131; to convert free T4 pmol/l to gg/
dl, divide by 12!871.
© 2015 John Wiley & Sons Ltd
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(0–90 min). Comparisons between appetite VAS for D40 and
D10 were equivalent throughout (Table 3). For the early evening
ad libitum buffet following the standard lunch, total calories
ingested and macroconstituent food fractions for D40 and D10
were equivalent [mean (SD) total calories ingested 482Kcal
(274) vs 448 kcal (243), respectively, P = NS].
Discussion
We demonstrate objectively that duration of a standard meal
influences TEF, postprandial NEFA suppression and adiponectin
levels in obese women. To our knowledge, our study is the first
to report on effects of meal duration in the free-living environ-
ment of a WBC.
Given beneficial metabolic effects of adiponectin,19 eating
slowly may improve insulin sensitivity through adiponectin
effects, although this remains speculative. This hypothesis is,
however, consistent with evidence from the literature that shows
acute effects of changes in adiponectin levels on insulin sensitiv-
ity (through effects on AMP kinase, GLUT4 transporters, fatty
acid oxidation and gluconeogenesis).20 The differences in NEFA
suppression between the D40 and D10 trials may be explained,
at least in part by differences in adiponectin, mediated via possi-
ble effects on insulin sensitivity and peripheral lipoprotein lipase
activity.21 We hypothesize that the relatively higher levels of
adiponectin for D40 compared with D10 may facilitate enhanced
action of insulin on NEFA suppression through enhanced
peripheral lipoprotein lipase activity: this may be an explanation
Table 2. Postprandial biochemical data of study subjects following each standard meal (D10 vs D40) (n = 10)
Analyte D40 AUC (SEM) D10 AUC (SEM) D40 Mean (SEM) D10 Mean (SEM)
Glucose (mmol/l) 23!8 (0!7) 25!2 (0!9) 6!0 (0!4) 6!4 (0!3)
Insulin (pmol/l) 2416 (301) 2853 (537) 615 (143) 693 (130)
NEFA (lmol/l) 627* (56) 769* (60) 191* (50) 242* (69)
Ghrelin (pg/ml) 305 (77) 226 (43) 78* (5!3) 54* (5!7)
Leptin (gg/ml) 74 291 (15 718) 69 645 (19 352) 17 837 (1194) 17 154 (693)
GLP1 (pg/ml) 274 (29) 292 (34) 67 (3!3) 72 (3!2)
PYY (pg/ml) 503 (34) 535 (37) 127 (6!4) 132 (6!2)
Adiponectin (lg/ml) 33!4* (3!9) 27!3* (3!8) 8!4 (1!3) 6!9 (0!4)
Cortisol (gmol/l) 1575 (93) 1424 (241) 438 (64) 387 (45)
Total Cholesterol (mmol/l) 18!8 (1!1) 18!9 (0!8) 4!7 (0!01) 4!7 (0!03)
LDL Cholesterol (mmol/l) 11!8 (1!0) 12!0 (0!8) 3!0 (0!02) 3!0 (0!04)
HDL Cholesterol (mmol/l) 4!1 (0!2) 4!1 (0!1) 1!03 (0!01) 1!03 (0!01)
Triglycerides (mmol/l) 5!7 (1!3) 5!7 (1!3) 1!4 (0!06) 1!4 (0!05)
Endotoxin (EU/ml) 23!2 (3!5) 23!4 (3!5) 5!9 (0!4) 6!0 (0!4)
*Significant difference (P < 0!05) between D10 and D40 values.
AUC, area under the curve; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; NEFA, noneste-
rified fatty acids; GLP1, glucagon-like peptide 1; PYY, peptide YY; For the AUC data, the units are multiplied by time (hours). To convert insulin from
pmol/l to lIU/ml divide by 7!175.
To convert glucose mmol/l to mg/dl, divide by 0!0555; to convert triglyceride mmol/l to mg/dl, divide by 0!0113.
To convert cholesterol mmol/l to mg/dl, divide by 0!0259; to convert cortisol gmol/l to lg/dl, divide by 27!59.
Table 3. Data showing measures of appetite (visual analogue scales) in the postprandial phase, consumption of ad libitum evening meal data and
energy expenditure in the postprandial phase (n = 10)
D40 Mean (SD) D10 Mean (SD)
Premeal (SL) appetite VAS 7!5 (2!6) 7!4 (2!4)
Early postprandial appetite VAS (0–90 mins) 1!6 (1!1) 1!7 (0!9)
Late postprandial appetite VAS (120–240 mins) 3!2 (2!2) 3!3 (2!1)
Postbuffet VAS 2!6 (3!0) 4!1 (3!1)
Buffet total calories ingested (kcal) 482 (274) 448 (243)
Buffet total protein ingested (g) 24 (7!6) 21 (9!0)
Buffet total CHO ingested (g) 45 (29!6) 41 (24!1)
Buffet total fat ingested (g) 23 (17!6) 23 (16!4)
Resting metabolic rate (kcal/h) 37!4 (2!5) 38!6 (3!7)
Total TEF for 240 min (kcal) 80!9* (3!8) 29!9* (3!4)
*significant difference (P < 0!05) between D10 and D40 values.
SL, standard lunch; VAS, visual analogue scale (0 = no hunger and fully satiated; 10 = extremely hungry); g, grams; CHO, carbohydrate; kcal, kilocalo-
ries; mins, minutes; SD, standard deviation; D10, data for the 10-min standard lunch study; D40, data for the 40-min standard lunch study; EE, energy
expenditure; TEF, thermic effect of food.
© 2015 John Wiley & Sons Ltd
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for differences in NEFA suppression between D40 and D10
despite equivalent postprandial insulin levels. Speculatively,
improved postprandial NEFA suppression associated with eating
slowly may, over time result in improved ectopic fat deposition.
Consistent with this hypothesis is a report of an association
between short meal duration and T2D.22 The equivalence of
endotoxin data (a biomarker for metabolic inflammation)
between trials may simply be a reflection that although subjects
were obese, they were also young and healthy. Also, the standard
meal was balanced with avoidance of a high fat or high carbohy-
drate load that would usually be required to provoke an endo-
toxin response.23
Ingestion of food results in increased oxygen consumption
and body temperature primarily from digestive processes
accounting for TEF.24 Between D40 and D10 trials, a mean dif-
ference in TEF of 51Kcal per 763Kcal standard lunchtime meal
was observed during the 4-h postprandial period. Assuming that
a similar standard lunch with equivalent caloric and macronutri-
ent content were ingested each day over an entire year, the
extrapolated difference in TEF between eating this meal each day
slowly over 40 min vs quickly over 10 min would be in excess
of 18 600 kcal. Assuming that 3500 kcal is equivalent to 395 g
of fat,25 this energy difference equates to a difference in body
weight of 2!1 kg/year.
Our data are consistent with objective data from Hamada and
colleagues that demonstrated correlation between meal duration
and postprandial energy expenditure in healthy normal-weight
subjects.26 It was hypothesized that number of chews and
splanchnic blood flow (both of which correlated with meal dura-
tion) may have contributed towards observed differences in
postprandial expenditure.26 Most other reported studies on meal
duration have relied upon subjective self-reported measures of
eating behaviours in cross-sectional designs. In one study on
young people, the validity of a self-questionnaire about eating
rate was supported, with self-reports being related to objective
measurements of number of chews and duration of chewing.27
Using subjective measures of eating behaviours, speed of eating
and BMI have been reported to be positively correlated in some
studies.10,11,13 In one of the largest studies to date on a Japanese
cohort (n = 7275), prevalence of obesity, blood pressure, lipid
levels and glycaemic control all correlated with self-reported
speed of eating.28 Whilst it is tempting to speculate that slow-
eaters have favourable body weight through beneficial effects on
TEF, this remains speculative and causality cannot be inferred
from the observational studies outlined here.
The effects of slow eating rate on food intake and appetite are
incompletely understood. Data are conflicting, with one study
reporting that eating slowly (with long meal duration) associates
with increased food ingestion 29 (possibly resulting from
prolonged elevation of postprandial plasma ghrelin levels 30),
and another showing anorexic effects of eating slowly.31 In one
study by Scisco and colleagues, implementation of a slow eating
rate through use of a ‘bite-rate counter’ device was shown to
reduce caloric intake.32 Conversely, in a study on subjects with
Prader–Willi syndrome, a faster rate of eating was more effective
than slow eating at stimulating anorexigenic gut peptides
(including PYY release) and promoting satiety, a pattern that
was not evident in age-matched subjects with simple obesity.33
We showed no differences in appetite or ad libitum meal inges-
tion in relation to speed of eating a standard meal. One explana-
tion is that all subjects in our study were obese women with
similar postprandial profiles of ghrelin, PYY and GLP1 between
meal duration trials. PYY and ghrelin response to food was
shown in one study to be blunted in obese female adolescents.34
Our data are in contrast to those from another study that showed
elevations of PYY and GLP1 in response to eating slowly.31 The
differences in anorexigenic gut peptide response to speed of food
ingestion between our study and other reports in the literature
may be due to differences in inclusion criteria between studies:
we only studied obese women who were also healthy, despite
>50% body fat, representing a unique metabolic scenario.
Our study is limited by a relatively small number of subjects,
therefore with potential for type 1 errors in the analyses for the
exploratory outcome measures of adiponectin and NEFA, with
AUC differences for these measures that were just significant
between meal duration trials. However, the number of subjects
included in our study was comparable to that of other reported
studies in this field. Although our sample size was calculated
from a priori calculations based on changes in postprandial
plasma glucose levels, we showed no differences in postprandial
glucose levels between the meal duration trials. We speculate this
may be due to the inclusion of healthy obese subjects, and the
relative sensitivities of glucose (compared with NEFA) to the
effects of insulin and adiponectin in the postprandial phase. A
further limitation of our study is the potential for phase of men-
strual cycle to have influenced TEF, demonstrated previously in
lean women.35 The design of our study precluded any assess-
ment of delayed metabolic and appetitive effects beyond the ini-
tial 4-h postprandial phase. We only included healthy obese
women. Future studies should include men, and subjects with a
range of BMI to explore the effects of meal duration in men vs
women and lean vs obese subjects. A further limitation of our
study was the lack of randomization to the order of the D40
and D10 trials. Finally, our measurement of expenditure was
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based on TEF, which reflects energy expenditure required to
digest food.24 Although the D40 group spent longer engaging in
eating activity for the standard meal, it is important to empha-
size that for both trials (D40 and D10), subjects consumed
exactly the same food (total calories and macronutrient con-
tent), and the postprandial period for each trial started once the
activity of eating had stopped, to avoid any confounding from
eating activity. During postprandial phases, subjects remained
inactive.
To summarize, we have shown preliminary evidence that dura-
tion of a standard meal influences TEF, postprandial NEFA sup-
pression and adiponectin levels in obese women. Eating a meal
slowly appears to confer beneficial metabolic effects in terms of
energy expenditure, metabolic profile and lipid handling. Future
studies are required to validate our findings, including prospec-
tive studies that focus on how these demonstrable acute
postprandial effects of meal duration translate into longer term
cardiometabolic effects, including body weight, ectopic fat depo-
sition and future development of T2D.
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You will first be asked to change into swimwear or close fitting underwear. There is a 
screen and couch provided and no one will be permitted to enter the room while testing 
takes place. 
 
You will be asked to stand on some weighing scales with your back towards the wall. It 
is very important that you stand very still for this measurement.   
  
You will then be asked to sit very still in the BodPod for approximately five minutes in 
total while measurements are being taken.   
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At the end of the test you are free to get dressed and leave the room. 
 
What do I need to wear? 
• Please bring close fitting swimsuit or underwear. 
• A cap will be provided to cover your hair 
 
How safe is the Bodpod? 
The BodPod equipment is very safe and used only by those with appropriate training. 
 
The operator will open and close the door several times during the procedure. Please 
do not try to help. Keep your hands on your lap and away from the door at all 
times. 
 
There is an emergency button if you want the door to open at any time. 
 
The BodPod is very quiet, however, when the door is closed a ‘popping’ sound can be 
heard after approximately 30 seconds. 
 
 
 
We hope this information will help to prepare you for your visit to the BodPod at the 
Human Metabolism Research Unit. If you have any further questions, please do not 
hesitate to contact the staff at the Unit on 024 7696 5621 
 
Comments  
If you have any comments on your visit to the HMRU BodPod then please let your 
researcher or HMRU staff know. We would like to use your experience to help future 
users of the Unit. 
 
We look forward to meeting you. 
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The Trust has access to interpreting and translation services. If you need this 
information in another language or format please contact 024 7696 5621 and we will do 
our best to meet your needs. 
 
 
The Trust operates a smoke free policy. 
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Patient Information 
 
   
Welcome to the Human Metabolism 
Research Unit (HMRU) 
 
Information Guide 
 
You have been asked by your researcher to attend University 
Hospital’s Human Metabolism Research Unit. Please read this 
information carefully before your visit. 
 
What is the Human Metabolism Research Unit (HMRU) 
The Human Metabolism Research Unit (HMRU) is a dedicated research unit run by 
University Hospitals Coventry and Warwickshire NHS Trust (UHCW) in partnership with 
Warwick Medical School. It includes a unique two room Whole Body Calorimeter. 
HMRU is located on the ground floor of University Hospital, outside Ward 2 
 
What facilities are there during my stay? 
The Whole Body Calorimeter has two bedsit rooms, a shower room and monitoring 
area.  On arrival you will be given an outline of the timetable for your stay. You will 
have a tour with full instructions about your room and its facilities. 
 
Each room has a desk, chair, fold down bed, toilet, sink, telephone and an internet 
connected computer/television. An exercise step is provided for light exercise or as 
directed by your researcher. There is an intercom to speak to the resident in the 
second room as well as the staff. 
There are three windows; one with an outside view, one to the neighbouring room and 
one in the door. 
There are three two-way hatches which are air locked. These are used for passing 
food, urine samples and taking blood tests. Only one side of the hatch can be opened 
at a time. 
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What do I need to bring with me? 
• Reading materials if desired, such as book, newspaper etc 
• Nightwear and toiletries - no aerosols please 
• Usual medication, if any 
• Towel and change of clothing if you wish to shower at the end of your stay 
• Outdoor clothing and extra belongings can be stored in a secure locker  
• Do not bring any food or drinks – these will be provided 
 
 
You have been asked by your researcher to stay on the unit for a set time, usually 
between 8 and 36 hours. During this time you will be required to stay in your room 
with the door closed. This enables very accurate measurements to be taken from the 
surrounding air.  
 
Fresh air is constantly circulating and temperature and humidity is regulated. Please 
inform the staff if you are too warm or cold. 
 
There is a fire alarm in your room. You will be given instructions as to what to do in an 
emergency. 
 
You may, of course, leave at any time if you no longer wish to participate. Simply open 
the door, it is never locked. 
 
Are there any special preparations required? 
• Please do not exercise for 24 hours  
• Arrive by public transport or car, do not walk any distance to the Unit 
• While in the HMRU you will not be able to drink caffeinated drinks (for example, tea 
or coffee), alcohol and fizzy drinks – you may want to gradually reduce your intake 
of these before this if necessary.  
• Do not eat or drink anything except water for 12 hours before arrival. 
 
Comments  
If you have any comments, positive or negative, about your stay in the HMRU, please 
let your researcher or HMRU staff know. We would like to use your experience to help 
future users of the Unit. 
 
We look forward to meeting you. 
 
We hope this information will help to prepare you for your visit to the Human 
Metabolism Research Unit. If you have any further questions, please do not hesitate to 
contact the staff at the Unit on 024 7696 5621 
 
The Trust has access to interpreting and translation services. If you need this 
information in another language or format please contact 024 7696 5621 and we will do 
our best to meet your needs. 
 
 
The Trust operates a smoke free policy. 
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Oral presentation in 73rd Scientific Sessions American Diabetes Association               
 
22nd June 2013, Chicago, United States of America !!!
!!!
 
Prizes  
 
2nd prize for poster presentation – Certificate and cash reward 
‘MR imaging of human BAT’ 
13th December 2012, The Royal Society, London 
Joint meeting of The Physiological Society and The Academy of Medical Sciences  
 
 
1st prize for oral presentation – Certificate and cash reward 
‘Metabolic significance of Brown fat in humans’ 
8th February 2013, National Exhibition Centre, Birmingham 
Midlands Endocrine Club 
 !

